IL-36 gamma promotes anti-tumor immunity through therapeutic induction of tumor-associated tertiary lymphoid structures by Weinstein, Aliyah M
 
 
IL-36 GAMMA PROMOTES ANTI-TUMOR IMMUNITY THROUGH THERAPEUTIC 
INDUCTION OF TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURES 
 
 
 
 
 
 
 
by 
 
Aliyah Miel Weinstein 
 
B.A., Rutgers, the State University of New Jersey, 2012 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of the 
 
School of Medicine in partial fulfillment 
 
of the requirements for the degree of 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2018 
 ii 
 
 
 
UNIVERSITY OF PITTSBURGH 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
Aliyah Miel Weinstein 
 
It was defended on 
 
March 16, 2018 
 
and approved by 
 
Lisa H. Butterfield, PhD, Professor, Department of Medicine 
 
Binfeng Lu, PhD, Associate Professor, Department of Immunology 
 
Adrian E. Morelli, MD, PhD, Associate Professor, Departments of Surgery and 
Immunology 
 
Donna Beer Stolz, PhD, Associate Professor, Department of Cell Biology 
 
Dissertation Advisor: Walter J. Storkus, PhD, Professor, Department of Dermatology 
 iii 
 
Copyright © by Aliyah Miel Weinstein 
2018
IL-36 GAMMA PROMOTES ANTI-TUMOR IMMUNITY THROUGH THERAPEUTIC 
INDUCTION OF TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURES
 
Aliyah Miel Weinstein, PhD 
 
University of Pittsburgh, 2018 
 
 
The last decade has advanced our understanding of the composition of the tumor-
immune microenvironment and its role as a potential target for therapeutic intervention. 
Recently, tertiary lymphoid structures have been observed to develop in the tumor 
microenvironment and serve as a positive prognostic marker in many types of solid 
tumors. The major signals that control tertiary lymphoid organogenesis are the same as 
those that direct the development of secondary lymphoid organs. Tertiary lymphoid 
structures are classically characterized by high endothelial venules, which serve to 
recruit T cells, dendritic cells, and B cells to sites of persistent inflammation and locally 
prime T cells against tumor-derived antigens. Our group has long been interested in 
understanding whether tertiary lymphoid structures can be therapeutically induced to 
form within the tumor microenvironment and induce a protective anti-tumor immune 
response. In previous studies, we characterized dendritic cells engineered to 
overexpress the Type-1 transactivator Tbet (i.e. DC.Tbet) and showed that they are 
able to delay tumor progression following intratumoral injection in a murine model of 
sarcoma. In this work, I show that the effector molecule responsible for the therapeutic 
efficacy of DC.Tbet is IL-36γ. Dendritic cells engineered to ectopically overexpress IL-
36γ and injected intratumorally into the murine MC38 model of colorectal carcinoma can 
direct the same magnitude of immune response as DC.Tbet therapy, even in the 
absence of Tbet expression by the injected cells. IL-36γ drives intratumoral expression 
of lymphotoxins and chemokines that direct tertiary lymphoid organogenesis, and 
promotes an intratumoral Type-1 immune response in conjunction with delayed tumor 
progression. Finally, I evaluated the expression pattern of IL-36γ in human colorectal 
 v 
cancer. I show that within the immune compartment, expression of IL-36γ by M1 
macrophages is positively correlated with a high CD4+ central memory T cell infiltrate 
into those tumors; and that IL-36γ expression on the tumor vasculature is associated 
with an increased density of B cells within tumor-associated tertiary lymphoid structures. 
Together, these data support IL-36γ as a novel mediator of anti-tumor immunity and its 
further investigation as a therapeutic agent to enhance protective Type-1 immune 
responses in the tumor microenvironment. 
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  1.0 INTRODUCTION
 
 
 
 
1.1 IMMUNE RESPONSES IN THE TUMOR MICROENVIRONMENT 
 
 
 
In their 2011 article, Hanahan and Weinberg updated the "hallmarks of cancer" to 
include "avoiding immune destruction." Indeed, it has become recognized over the past 
decade that the immune system plays a crucial role in tumor development and 
progression. Early in the formation of a tumor during the elimination and equilibrium 
phases, the immune system keeps a developing tumor at bay through the cooperation 
of innate and adaptive immune cells in recognizing tumor antigens, secreting Type-1-
polarizing cytokines, and destroying the malignant cells. Subsequently, in the escape 
phase, the tumor evades immune system control by producing immunosuppressive 
molecules and downregulating intrinsic antigen presentation, thus preventing its 
recognition by immune cells (1). 
  
 2 
Our understanding of how to at least partially reverse immune ignorance to evolving 
tumors has progressed in recent years. Most notably, inhibitors to PD-1 and PD-L1 
negate negative signaling between tumor cells or tolerogenic myeloid cells and effector 
NK or T cells, and CTLA-4 blockade reverses T cell inhibition mediated through CD80 
or CD86 molecules expressed on antigen presenting cells. While studies into the long-
term efficacy of these therapies remains ongoing, early results indicate that their 
effectiveness may persist even after treatment is stopped, giving patients a chance at 
long-term survival without continued maintenance on treatment protocols. In light of 
these data, a major question still remains as to whether it is possible to not only induce 
broad-scale reversal of immunosuppression within the tumor microenvironment (TME), 
but to tailor the intratumoral immune response to be most effective at eliminating the 
tumor. 
 
 
 
1.1.2 Tbet has a multitude of roles in the immune response, including the 
promotion of Type-1 immunity 
 
Studies indicate that Type-1 immune responses, characterized by the expression of 
Tbet, IL-12p70, and IFNγ, are most effective at recognizing and destroying tumor cells 
(2). Tbet (i.e. TBX21) is a T-box family transcription factor expressed by a variety of 
innate and adaptive immune cells, including CD4+ and CD8+ T cells, NK cells, B cells, 
and dendritic cells (DC) (3,4). In particular, Tbet is best known as the master regulator 
of Type 1 immunity, though its role differs depending on the immune cell type in which it 
is expressed. Tbet is necessary for the transcription of the canonical Type-1 cytokine 
IFNG in CD4+ effector T cells (5) via a mechanism involving the suppression GATA-3 
and downstream IL-4 and IL-5 expression to prevent skewing towards a Type-2 
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phenotype (6,7) as well as the downmodulation of Type-17-like responses (8). Forced 
overexpression of Tbet into polarized Th2 (CD4+) or Tc2 (CD8+) T cells converts these 
cells to a Type-1 phenotype, and they begin to express IFNγ (5,7) while suppressing 
secretion of IL-4 and IL-5 (5). Conversely, CD4+ effector T cells generated from Tbet-/- 
mice express extremely low levels of IFNγ, but high levels of IL-4 and IL-5 compared to 
CD4+ T cells generated from WT mice (5). In CD8+ T cells, Tbet controls the transition 
from a naïve to effector phenotype after exposure to cognate antigen (9). Tbet is also 
important for promoting the infiltration of CD8+ T cells into the tumor versus lymph node 
following adoptive T cell therapy, where it also cooperates with Eomes to promote the 
development of effector and central memory T cells that protect the host against tumor 
re-challenge (10). 
Tbet plays a similar role in DC to that it plays in CD4+ T cells, as it is required for the 
expression of IFNγ (but not other pro-inflammatory cytokines such as IL-12p40, IL-
12p70, TNF, and IL-1). Indeed, Type-1 polarized DC (DC1) express similar levels of 
Tbet as do Th1 cells (4). Tbet is required for IFNγ expression by DC following 
stimulation with IL-12p70 and/or IL-18, as Tbet-/- DC, but not their WT counterparts, fail 
to transcribe or secrete IFNγ following stimulation with these cytokines (4). Upon 
stimulation with IFNγ, DC can upregulate expression of Tbet, an effect that is not 
replicated when DC are stimulated with other classical activators such as LPS, TNF, or 
IL-1. Expression of Tbet by DC is also necessary for their ability to activate Th1 cells, as 
shown following OVA stimulation in an in vivo model (4) and downstream of TLR9 
stimulation by CpG ODN in an in vivo model of Listeria monocytogenes infection (11); in 
both systems, protection is lost if DC lack expression of Tbet. There have also been 
reported roles for Tbet in B cells: Tbet appears to be required for the class switching of 
autoantibodies to IgG, independent of its role in T cells in both in mouse models of 
lupus pathogenesis (12) and an OVA vaccine model targeting melanoma (13). Intrinsic 
expression of Tbet by B cells appears to be predominantly found in the memory and 
plasmablast subsets (14), and is required for the migration of antibody-forming and 
germinal center B cells towards CXCL10, which is produced in high levels at sites of 
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inflammation (13). Tbet is also known to be expressed by human cytotoxic CD56dim NK 
cells, iNKT cells, and some Eomes+ gamma-delta T cells (14). 
 
1.1.3 DCs in cancer 
 
1.1.3.1 Endogenous DCs Conventional DC can be naturally found within some types of 
human cancers, where they serve as a positive prognostic biomarker. In lung cancer, a 
high density of (mature) DC-LAMP+ DC, which are found exclusively within tertiary 
lymphoid structures (TLS), was found to be the best predictor of extended overall and 
disease-free survival (15). The density of DC-LAMP+ DC in patients with non-small cell 
lung cancer (NSCLC) was also positively correlated with the density of Tbet+ CD4+ T 
cells, an effect not observed when considering the Tbet+ CD8+ T cell compartment (16). 
In breast cancer patients, the presence of DC-LAMP+ DC in tumors was similarly linked 
to increased overall and disease-free survival. Notably, DC represent the primary 
source of the TLS-inducing cytokine lymphotoxin beta (LTβ) in the TME over tumor 
cells, NK cells, T cells, and B cells. The density of DC-LAMP+ DC correlated with 
expression of the chemokines CCL19, CCL21, and CXCL13, all of which can 
independently promote the migration of T cells, B cells, and DC into tissue, and which 
are correlated with the density of T cells, B cells, and PNAd+ HEV in the TME of breast 
cancer (17). A similar relationship between mature DC and TLS occurs in the setting of 
melanoma, where the densities of DC-LAMP+ DC and high endothelial venules (HEV) 
are strongly correlated with one another, with DC observed to localize around HEV (18). 
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1.1.3.2 DC-based immunotherapies Because of their role as the primary antigen 
presenting cell in inducing Type-1 immune responses, DC are frequently the basis of 
immunotherapies designed to treat or prevent cancer. Such therapies include DC-based 
vaccines, in which autologous DC are pulsed with tumor-derived peptides, including 
those derived from the tumor cells themselves (19–21) or from components of the TME, 
such as the tumor vasculature (22–24). These DC-based vaccines are generated in 
vitro by maturing autologous DC to increase expression of T cell stimulatory molecules, 
including CD80, CD86, and MHCII (19,21) and then loading these cells with target 
antigen for presentation of T cell epitopes in MHC complexes expressed on the DC 
surface. Injection of DC primed against tumor antigens activates a rapid Type-1 immune 
response that often leads to delayed tumor growth or tumor regression in murine 
models (19–24). Interestingly, the efficacy of these DC-based immunotherapies appears 
to require that they be conditioned under Type-1 conditions in order for the treatment to 
promote the expansion of tumor-specific CD8+ CTL versus T cells unable to exert 
effector function against target tumor cells (25). Vaccine-induced epitope spreading in 
the T cell repertoire, or therapeutic T cells invoked by the vaccine but reactive against 
tumor antigens not present in the vaccine, as a consequence of evolving rounds of 
antigen cross-priming, can also be observed (20,22) and may serve as a useful as a 
prognostic biomarker to identify patients most likely to respond well to treatment (26). 
Unfortunately, it has also been noted that tumors can escape from the therapeutically-
induced immune response and continue to progress following DC-based vaccination. 
This supports the importance of generating poly-specific immune responses reactive 
against multiple tumor antigens to sustain therapeutic benefit and preclude the 
progression of antigen-escape variants. 
Other DC-based immunotherapies are not antigen-specific, and instead are designed to 
bestow enhanced antigen presenting capability to these cells via stimulation with 
activating or Type-1-polarizing cytokines or engineering to force overexpression of 
immunostimulatory chemokines, cytokines, or transcription factors by these cells. Our 
lab has previously investigated whether DC engineered using an adenoviral vector to 
overexpress either IL-12p70 (DC.IL12) or Tbet (DC.Tbet) are able to delay tumor 
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progression in a mouse model. Results from the CMS4 (BALB/c) sarcoma model 
indicate that DC.IL12 or DC.Tbet treatments are able to delay tumor progression, while 
treatment with DC.Tbet/IL12 (i.e., cells engineered to overexpress both IL-12p70 and 
Tbet) leads to tumor regression and increased overall survival. Each of these 
treatments enhances CD8+ T cell reactivity to tumor cell- and tumor-associated stromal 
cell-derived antigens (27). Treatment with DC.Tbet has also been shown to delay tumor 
progression in the MCA205 (C57BL/6) sarcoma model, via a mechanism dependent on 
the local recruitment of CD8+ T cells and NK cells following treatment, but not the 
migration of injected DC to secondary lymph nodes (28). In the CMS4 as well as B16 
models, the observed effect of DC.Tbet, DC.IL12, or DC.Tbet/IL12 treatments were 
enhanced by the loading of DC with tumor peptides prior to injection (27). 
 
1.1.3.3 Perspectives on DC-based Immunotherapy DC-based vaccination strategies 
have shown minimal success both in the pre-clinical and clinical settings, and an 
additional disadvantage to peptide-based vaccines is that the same vaccine can not 
necessarily be applied across multiple tumor types, nor to different patients with the 
same type of tumor due to variations in tumor antigen expression and HLA haplotypes 
(29). The question remains as to how DC can best be employed to induce a protective 
immunity across a range of tumor types, regardless of the antigen expression profiles 
by heterogeneous populations of tumor cells. 
 
 
 
1.2 THERAPEUTIC LYMPHOID ORGANOGENESIS IN THE TUMOR 
MICROENVIROMENT 
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1.2.1 Abstract 
The inflammatory status of the tumor microenvironment (TME) has been heavily 
investigated in recent years. Chemokine and cytokine signaling pathways such 
as CCR7, CXCR5, lymphotoxin, and IL-36, which are involved in the 
generation of secondary lymphoid organs (SLO) and effector immune responses, are 
now recognized as having value both as prognostic factors and as 
immunomodulatory therapeutics in the context of cancer. Furthermore, when 
produced in the TME, these mediators have been shown to promote the recruitment 
of immune cells, including T cells, B cells, DCs, and other specialized immune cell 
subsets such as follicular DCs and T follicular helper (Tfh) cells, in association with 
the formation of tertiary lymphoid structures (TLS) within or adjacent to sites of 
disease. Although TLS are composed of a heterogeneous collection of immune 
cell types, whose composition differs based on cancer subtype, the qualitative 
presence of TLS has been shown to represent a biomarker of good prognosis for 
cancer patients. A comprehensive understanding of the role each of the driver 
pathways plays within the TME may support the rational design of future 
immunotherapies to selectively promote/bolster TLS formation and function, leading 
to improved clinical outcomes across the vast range of solid cancer types. 
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1.2.2 Introduction 
 
In recent years, a growing body of literature has established important roles for 
inflammatory immune cells in the etiology of a wide variety of diseases, including 
infectious virus-associated diseases, autoimmune diseases such as psoriasis and 
arthritis, and cancer. More recently, work in this field has expanded in an attempt to 
elucidate critical signaling pathways involved in initiating and fine-tuning inflammatory 
immune cell activity within affected tissue sites. It has become clear that an array of 
chemokines (e.g. CXCL13, CCL19, CCL21, and members of the TNF family) and 
cytokines (e.g. IL-36R and LTβR agonists) play important roles in the recruitment, 
activation, and function of immune cells within inflamed/diseased tissue 
microenvironments. The orchestration of these factors culminates in the development of 
organized networks of innate and adaptive immune cells within the TME, that have 
commonly been referred to as TLS. Here, we will attempt to provide a better 
understanding of these pathways to provide a foundation for the design of next-
generation immunotherapies that will allow for the selective targeting of inflammatory 
pathways at the appropriate time and location during disease evolution to prevent, 
deter, or eradicate cancer in vivo. 
 
1.2.3 Development of TLS in Chronically-Diseased Tissues 
 
Our understanding of the dynamics of how immune cells infiltrate and persist as an 
operational unit within the TME has evolved considerably over the past decade, and 
now encompasses a paradigm in which TLS develop at the periphery of or within tumor 
lesions to limit disease progression and/or as a consequence of effective treatment 
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intervention. TLS are distinct from primary and secondary lymphoid organs as they do 
not form during embryonic development and instead can originate in any non-lymphoid 
tissue that has been subject to prolonged/chronic inflammation (30). TLS express 
chemokines including CCL19, CCL21, and CXCL13 that recruit naive and effector CD4+ 
and CD8+ and memory CD4+ T cells, B cells, and NK cells to sites of inflammation (31). 
The primary cell populations found within TLS are DCs, B cells, and naive and memory 
T cells (32). For example, lymphocytic aggregates and an upregulation of associated 
chemokines have been observed in the affected tissues of individuals with chronic 
inflammatory diseases such as Sjögren syndrome, rheumatoid arthritis, multiple 
sclerosis, myasthenia gravis and Hashimoto’s thyroiditis (33), as well as cancer (15,34–
36). 
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1.2.3.1 TLS: Organizational structure Interestingly, it has been observed that there is 
not a uniform distribution of TLS within inflammatory peripheral tissue 
microenvironments. For instance, in the setting of oral squamous cell carcinoma, 
approximately one third of tumors presenting with TLS were missed when only one 
section of the tumor was evaluated by pathologists (37). In Merkel cell carcinoma, most 
tumor-infiltrating CD8+ T cells and TLS were located at the tumor periphery, with the 
presence of TLS correlating with an increased CD8+-to-CD4+ T cell ratio at the margin, 
but not in the center, of the tumor mass (38). Similarly, in breast cancer, TLS are 
sometimes observed proximal to the stroma, and within an individual lymphoid 
structure, the number of lymphocytes decreased as a function of proximity to the center 
of the tumor, with the most actively proliferating lymphocytes localized to a small area 
adjacent to the stroma (39). In other models of breast cancer, TIL are observed in the 
tumor stroma, but not embedded within the tumor tissue itself (40). In metastatic 
colorectal cancer, B cell infiltrates were localized to the outer edges of the tumor lesion 
(41). These data suggest that the TME is architecturally heterogeneous with regard to 
the presence and localization of TIL/TLS, and that diverse signals likely contribute to 
determining the anatomic locations in which TLS are “seeded”. In this regard, studies 
have shown that the same signals controlling lymphocyte recruitment to sites of 
inflammation may play drastically different roles under normoxic (characteristic of the 
tumor outer cortex/margin) versus hypoxic (characteristic of the tumor core) conditions. 
For example, signaling via the CCL21/CCR7 axis has been shown to promote 
angiogenesis in inflammatory microenvironments (42), and new blood vessel formation 
is one mechanism that facilitates tumor growth and metastasis. In ovarian cancer, 
hypoxia induced an increase in intrinsic CCR7 expression by tumor cells, with CCL21 
signaling in the hypoxic TME contributing to an upregulation of N-cadherin and the 
matrix metalloproteinase MMP-9, which are known to promote cell migration and 
invasiveness (43). In patients with non-small cell lung cancer (NSCLC), a similar effect 
has been observed, as expression of MMP-1 and ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 (ADAMTS2) in PBMCs was correlated with poor clinical 
outcome (44). 
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The organizational structure of TLS in tumors can vary substantially. While classical 
lymphoid structures are comprised of a B cell follicle (i.e. a germinal center) intertwined 
with a network of follicular DC, intratumoral B cell infiltrates have been observed in 
which the B cells are heterogeneously “sprinkled” throughout the tissue instead of being 
localized within focused aggregates. This has been observed in human oral squamous 
cell carcinoma (37) and breast cancer (40) tissues, and in tissue sections of murine 
MCA205 fibrosarcomas (36), in association with more beneficial disease outcomes. 
Thus, the establishment of higher order structure in TLS in or near tumors in vivo may 
not be a critical factor to the development of effective anti-tumor immune response. It 
may only be required that the infiltrating effector cells and antigen (cross)-presenting 
cells interact productively within the TME. 
 
1.2.4 TLS in cancer: Clinical Correlates of Disease Progression and Response to 
Treatment 
 
In the cancer setting, the presence of TLS in the TME correlates with increased 
disease-free survival in patients, with similar results obtained in murine tumor models 
(see Table 1.1). These structures allow for the activation, expansion and differentiation 
of tumor antigen-specific B and T cells within the tumor itself, leading to a more effective 
anti-tumor immune response even in the absence of therapeutic intervention (31,45). In 
melanoma, a 12-gene signature has been characterized that predicts both the presence 
of TLS within a tumor and increased survival. This signature includes genes that encode 
for CCL19, CCL21, and CXCL13, as well as CCL4, CXCL9, and CXCL10 (46). In 
patients with oral squamous cell carcinoma, the presence of TLS is associated with a 
decrease in tumor-associated death (37). In Merkel cell carcinoma, the presence of TLS 
correlated with significantly increased recurrence-free survival compared with patients 
whose tumors did not contain TLS (38). In lung cancer, TLS arise spontaneously and 
confer a beneficial phenotype to patients (45). In these patients, both the density of 
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mature (DC-LAMP+) DC (15) and follicular DC (47) can be used as markers for 
increased survival. Tumors containing fewer mature DC demonstrate a corresponding 
decrease in Type 1-polarized CD4+ T cells (15), suggesting that TLS within the TME are 
crucial locations for generating effective Type-1 anti-tumor immune responses and that 
a diminished ability to prime a Type-1 response allows for tumor growth. Supporting this 
contention, in lung cancer, the presence of mature DC within TLS was a better predictor 
of patient survival than the presence of CD8+ T cells in TLS, with high densities of 
mature DC also correlating with increased expression of genes related to Type-1 
effector cell polarization and cytotoxicity in the TME (48,49), and patients with 
intratumoral TLS have an increased likelihood of survival compared to those who do not 
(15,47). In primary HER2+ breast cancer, infiltration of lymphocytes corresponded to a 
decrease in the recurrence rate of tumors and a more favorable patient outcome. This 
was marked by an increase in intratumoral levels of chemokines associated with the 
development of lymphoid structures - including CCR7, CCL19, CXCL9, CXCL10, 
CXCL13, and LIGHT - and levels of genes associated with lymphocytes- such as 
ZAP70, CD8, CD28, and Lck (50). 
In patients with metastatic colorectal cancer, an increased number of discrete TLS 
within the TME correlates with an increase in overall survival and a decrease in disease 
recurrence compared with patients presenting with less immune cell infiltrates; these 
groups can be stratified based on the presence of TLS or the level of CD45+ or CD20+ 
tumor-infiltrating cells (41), indicating that interactions between B cells and other 
lymphocyte populations play a role in mediating anti-tumor immunity. B cell infiltration 
also corresponded with a more favorable prognosis in breast cancer. The number of B 
cells found within the TME correlated with an increase in cancer specific survival and 
disease free survival in patients (40). B cells in the TME undergo antigen-driven 
proliferation, somatic hypermutation, and affinity maturation within the tumor, and these 
cells co-localize with T cells, follicular DC, and plasma cells into structures resembling 
tertiary lymphoid structures (51). In a subsequent study of breast cancer patients, an 
additional marker of overall survival related to the presence of TLS was determined to 
be the presence of T follicular helper cells, a subset of CD4+ T cells that produces 
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CXCL13 and recruits B cells to sites of inflammation (39). In this study, the presence of 
CXCL13 was also positively correlated with IFNγ expression, suggesting that T follicular 
helper cells play a role in initiating Type 1 immune responses. B cells have 
independently been shown to be required for the generation of anti-tumor CTL 
responses, especially in melanoma. Depletion of B cells before inoculation of B16 
melanoma into mice led to an increase in primary tumor burden and in number of lung 
metastases, indicating that B cells are important for the initial immune response 
generated against a tumor. The increase in tumor growth was concurrent with a 
decrease in IFNγ- and TNFα-secreting T cells in the TME as well as a decrease in the 
number of T cells found in the periphery and in the tumor draining lymph node (52). Of 
note, it was also observed that the T cells present within tumors with high numbers of 
tumor infiltrating lymphocytes were more likely to be T follicular helper cells or Type 1-
polarized CD4+ cells (39). These data support the idea that orchestrated interactions 
between immune cell subtypes within the tumor are critical to the generation of 
protective anti-tumor immune responses. 
Interestingly, some tumors that arise in highly inflammatory microenvironments benefit 
from the infiltration of regulatory T cells (Tregs) as opposed to effector immune cells into 
the TME. In particular, in the cases of head and neck cancer and colorectal cancer, the 
presence of intratumoral Treg has been reported to convey good clinical prognosis 
(53,54).  
Furthermore, the presence and magnitude of tumor infiltrating lymphocytes (TIL) in the 
TME has been strongly associated with the effectiveness of a range of chemo- and 
immuno-therapeutic agents. Many immunotherapeutic strategies currently being 
investigated in clinical trials involve immune checkpoint blockade, including the use of 
antibodies capable of inhibiting signaling through CTLA-4 or PD-1 into T cells. 
Interestingly, it appears that these therapies may work, at least in part, via increasing 
the ability of newly-arrived CD8+ TIL to be primed and then mature into protective anti-
tumor T effector cells. Priming of CD8+ T cells in the tumor draining lymph nodes or the 
trafficking of circulating T effector cells into the TME appear less important to clinical 
outcome than the priming of resident TIL after blockade of CTLA-4, PD-L1, or IDO (55). 
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Similarly, the presence of T follicular helper cells in breast cancer TME predicts for 
superior responsiveness to pre-operative chemotherapy (39). More broadly, the 
presence of TLS or CXCL9 expression in the TME of patients with breast cancer is a 
statistically significant predictor of a higher incidence of complete response to 
neoadjuvant chemotherapy (56). 
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Table 1.1. Presence and Prognostic Significance of TLSs in Cancer 
 
Cancer subtype Location of TLS Inflammatory infiltrates Anti-inflammatory infiltrates 
Predictive outcome of 
TIL/TLS presence References 
Bladder 
carcinoma 
proximal to tumor 
cell nests 
CD3+ T cells, including CTL; 
CD20+ B cells; follicular DC; 
mature CD208+ DC 
N/A 
increased anti-tumor immune 
response; no correlation with 
invasion, metastasis, or poor 
prognosis 
(57,58) 
Breast cancer 
proximal to/within 
tumor stroma; 
peritumoral 
lymphocytes; B cells; T cells; 
follicular DC; plasma cells; T 
follicular helper cells 
N/A 
decreased disease recurrence; 
increased response to 
chemotherapy 
(39,40,50,56,59) 
Colorectal 
carcinoma tumor periphery 
B cells; Type 1-polarized 
memory T cells; CD8+ T cells; 
CD45RO+ T cells; follicular 
DC 
Tregs 
inflammatory cells: equivocal 
(either disease progression 
and recurrence, or anti-tumor 
immune response and low-
risk, early-stage disease); 
Tregs: improved survival 
(31,53,54,60,61) 
Gastric cancer invasive margin; tumor core 
B cells; Bcl6+ germinal center 
B cells; CD4+, including Th1, 
T cells; CD8+ T cells; follicular 
DC 
FoxP3+ Tregs increased overall survival; relapse-free survival (62,63) 
Head and neck 
cancer 
tumor stroma; 
tumor periphery; 
intratumorally 
macrophages; CD4+ T cells; 
CD8+ T cells FoxP3
+ Tregs 
effector T cells: increased 
overall survival; Tregs: 
decreased local recurrence 
(53,64) 
Hepatocellular 
carcinoma liver parenchyma 
T cells; B cells; neutrophils; 
NK cells; macrophages; 
follicular DC 
Tregs Increased recurrence; decreased overall survival (65) 
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Lung cancer 
(NSCLC) tumor stroma 
mature DC; follicular DC; 
CD62L+ and naive CD4+ and 
CD8+ T cells; B cells; follicular 
DC 
N/A increased survival (15,45,47–49) 
Melanoma peritumoral stroma; intratumorally B cells; T cells; CD86
+ DC N/A increased survival (46,52) 
Merkel cell 
carcinoma tumor periphery CD8
+ T cells; B cells; APC N/A increased recurrence-free survival (38) 
Metastatic 
colorectal cancer tumor periphery CD45
+ T cells; CD20+ B cells N/A increased overall survival; decreased disease recurrence (41) 
Oral squamous 
cell carcinoma peritumoral stroma B cells; follicular DC N/A increased survival (37) 
Pancreatic 
cancer 
Intratumoral; 
peritumoral 
Th1 and Th17 cells; CD8+ T 
cells; B cells; DC; follicular 
DC 
low infiltrate of 
Tregs and M2 
macrophages 
increased overall and disease-
free survival (66–68) 
Renal cell 
carcinoma peritumoral mature DC; CD3
+ T cells N/A 
increased disease-free 
survival; increased overall 
survival 
(69) 
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1.2.5 Cues for TLS Development  
 
While the precise sequence of signals that serve to control TLS development has yet to 
be completely elucidated, especially in the context of the TME, certain signaling 
pathways classically known to recruit immune cells into inflammatory tissue 
microenvironments appear to be involved. 
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1.2.5.1 The requirement for lymphotoxin signaling in the evolution of TLS in the 
TME Lymphotoxin (LT)-α/-β signaling through the LTβR is required for the 
establishment and maintenance of lymphoid structures. LTα and LTβ are members of 
the TNF family and share common receptors and signaling pathways with other 
members of their family. The lymphotoxin ligands are expressed predominantly by 
immune cell subsets, while the receptors are found on epithelial cell populations. The 
receptor-ligand interactions promote the organization of immune cells and stromal cells 
within lymphoid structures (70). The LTα/LTβ subunits exert their biologic function by 
forming three distinct trimeric molecules, each with different receptor specificity. The 
homotrimer of lymphotoxin alpha, LTα3, is a secreted protein that signals through 
TNFR1, TNFR2, and HVEM (70,71). Two membrane bound heterotrimers can also form 
from the lymphotoxin subunits: LTα1β2 and LTα2β1, with LTα1β2 being the predominant 
form. LTα1β2 signals through the lymphotoxin beta receptor (LTβR), while LTα2β1 is able 
to bind TNFR1 and TNFR2 but does not have a clear biologic role in signaling through 
these receptors (70). The receptors TNFR1 and TNFR2 have broad expression 
throughout the body. The lymphotoxin beta receptor is expressed by stromal cells, 
epithelial cells, monocytes, and DC. HVEM is expressed by T cells, DC, macrophages, 
and epithelial cells (Table 1.2 and ref. (72)). Specifically, signaling through the LTβR is 
required for HEV differentiation and for the formation of organized SLO. Blockade of 
signaling through the LTβR results in decreased lymphocyte migration into lymph nodes 
in a model of collagen-induced arthritis, and this appears due to impaired expression of 
adhesion molecules PNAd and MAdCAM on HEV (73). A similar decrease in 
lymphocyte trafficking is observed in Peyer’s patches in the absence of LTβR-mediated 
signaling (74). In the spleen, signaling through the LTβR is required for the segregation 
of B cells and T cells into distinct zones, and for the generation of follicular DC and the 
formation of B cell follicles (75). LTβR-associated signaling also plays a key role in TLS 
formation. In mice that constitutively express both LTα and LTβ in the pancreas, the T 
and B cell chemokines CCL19, CCL21 and CXCL13 were more predominantly 
expressed, L-selectin+ (aka CD62L+; binds PNAd and MAdCAM) cells were more 
abundant, and T and B cell zones within the immune infiltrate were more pronounced 
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than in mice only expressing LTα (76). In the TME, PNAd and L-selectin expression is 
exclusively found within TLS and not elsewhere in the stroma or the tumor tissue, and 
the two co-localize with each other (45). L-selectin is important for the trafficking of 
naïve (77,78) of central memory T cells (79), in conjunction with CCL19 and CCL21 
gradients that signal through CCR7 on these cells (31,79). Lymphotoxin-α/-β induce the 
production of CCL19, CCL21, and CXCL13 (80). Specifically, lymphotoxin-α is required 
for CCL19, CCL21, and CXCL13 expression, while LTβ is most critically required for 
CXCL13, but less so CCL19 or CCL21, expression (81). This appears to be a result of 
the differential receptor binding ability of the lymphotoxins and the downstream 
signaling components being activated (70). Such pathways appear to involve a positive 
feedback loop in the spleen, where cells expressing the LTβR and CXCL13 recruit B 
cells, with activated B cells subsequently expressing LTα1β2, begetting further 
expression of CXCL13 by stromal cells (80). A similar biologic circuit has been shown to 
exist between LTα1β2 and CCL19 and CCL21 in both SLO and TLS (80,82). Blockade of 
signaling through the LTβR using a soluble decoy receptor blocks the recruitment of 
both B cells and CD8+ T cells into lymphoid organs (73). 
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Table 1.2. Lymphotoxin/LIGHT Receptors and Their Cell Expression Profiles. 
This table describes the receptor binding capabilities of the TNF family member ligands 
that play critical roles in tertiary lymphoid organogenesis. 
 
Ligands Receptor Function Receptor Expression References 
TNFα; LTα3; 
LTα2β1 
TNFR1 Signaling Widespread (70,72,83) 
TNFα; LTα3; 
LTα2β1 
TNFR2 Signaling Widespread (70,72,83) 
LTα1β2; LIGHT LTβR Signaling Stromal cells; epithelial cells; monocytes; DC (71,72,83) 
LIGHT; LTα3 HVEM Signaling T cells; DC; macrophages; NK cells; epithelial cells (72,83) 
LIGHT DcR3 Decoy Secreted (84) 
 
 
Surprisingly, tumor and stromal cells may also express and respond to signaling 
through the LTβR. Induction of this signaling pathway by the natural ligand LTα1β2 or by 
cross-linking with LTβR-Ig can induce the secretion of the pro-inflammatory mediators 
IL-8 and CCL5 by both melanoma (A375) and fibroblast (WI38VA13) cell lines in vitro 
(85). The effect of LTβR signaling on non-immune cell subsets is predicted to have an 
additional role in promoting anti-tumor immunity besides its role in the formation of TLS. 
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1.2.5.2 EnLIGHTening Protective Immunity in TLS Both stromal and immune cell 
populations respond to LIGHT (also known as TNFSF-14). LIGHT, expressed by T 
cells, immature DC, and macrophages (72), is related to the lymphotoxins and is able to 
signal through several receptors of the TNF superfamily, including the LTβR on stromal 
cells and HVEM (also known as TNFRSF-14; ref (71)) on T cells. In regard to the 
generation of an immune response, LIGHT is required for CD8+ but not CD4+ T cell 
proliferation and differentiation (86). Mice lacking LIGHT were shown to have impaired 
CD8+ T cell responses to bacterial infection (86), indicating a requirement for LIGHT in 
the generation of productive Type 1 immune responses. Furthermore, LIGHT is able to 
synergize with IFNγ to enhance the production of CXCL9, CXCL10, and CXCL11, which 
serve to recruit and polarize CXCR3+ Type-1 immune cells (87). 
In the context of tumor immunology, expression of LIGHT appears to have a broadly 
beneficial role in reducing tumor burden and improving survival. In breast cancer 
patients, LIGHT expression correlates with the generation of TLS in the TME. 
Expression of LIGHT mRNA was 5 times greater in the newly-formed structures than in 
normal lymph nodes isolated from the same patient (88), suggesting that LIGHT may be 
a driver in the formation of TLS in the cancer setting. Ectopic introduction of LIGHT into 
the TME has been shown to promote the development of anti-tumor immunity in 
numerous models of cancer. Forced expression of LIGHT in a fibrosarcoma model 
(Ag104Ld) resulted in increased signaling through the LTβR on stromal cells in the TME, 
leading to upregulated expression of CCL21 and MAdCAM-1 by these cells. Treated 
tumors also exhibited increased CD8+ T cell infiltration that ultimately led to the rejection 
of established disease (89,90). A similar result was observed in established murine 
melanoma (B16) and colon (MC38) cancers (90). Intratumoral vaccination with a 
recombinant adenovirus encoding the cDNA for LIGHT (Ad.LIGHT) is able to incite anti-
tumor immune responses against B cell lymphoma (91), cervical cancer (92), and 
breast cancer (90). In the B cell lymphoma model, treatment with Ad.LIGHT induces 
expression of CCL21 and recruitment of T cells into the TME, increases overall survival 
from primary tumor challenge, and protects treated mice against normally lethal tumor 
re-challenge (91). When applied in combination with a HPV16-VRP vaccine in cervical 
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cancer models, Ad.LIGHT is able to increase circulating levels of anti-tumor T cells, 
promote CD8+ T cell infiltration into the TME, regulate tumor growth, and increase 
overall survival, when compared with vaccines alone (92). Ad.LIGHT injected into 
established murine 4T1 breast cancers results in diminished lung metastasis after 
surgical removal of the primary tumor (90). Together, these results suggest that 
Ad.LIGHT is able to initiate a systemic, tumor antigen-specific immune response that is 
protective. Work evaluating treatment with mesenchymal stem cells engineered to 
overexpress LIGHT (MSC-L) has also shown an inhibition tumor growth following 
treatment in both gastric (93) and breast (94) cancer models. In the breast cancer 
model, the efficacy of MSC-L was dependent on the ability of lymphocytes to be 
recruited into the TME via LTβR-dependent signaling events (94). Interestingly, another 
study evaluating LIGHT/HVEM signaling determined that advanced stage gastric cancer 
patients expressed significantly lower levels of HVEM on the surface of their leukocytes, 
and higher serum levels of soluble HVEM shed from leukocytes when compared to 
healthy controls (95). Prior studies reported the presence of robust levels of soluble 
HVEM in the serum of patients with autoimmune diseases such as psoriasis, dermatitis, 
and arthritis (96), suggesting that soluble HVEM may represent a marker of ongoing 
chronic inflammatory conditions. In addition, low levels of HVEM have been shown to 
drive the generation of dominant Type-2-polarized immune responses in patients with 
cutaneous T cell lymphoma, in association with disease progression (87). Low levels of 
LIGHT production in metastatic colorectal cancer lesions has been linked to a 
decreased number of intratumoral T cells compared to normal tissue (97). This 
immunosuppression could be reversed by introducing LIGHT into the system as an 
interventional strategy. In support of this possibility, forced expression of LIGHT in the 
mouse TRAMP-C2 model of prostate cancer overcomes Treg-mediated 
immunosuppression and synergizes with a biologic vaccination strategy (PSCA TriVax) 
to activate DC and recruit effector T cells into the TME (98). In particular, synergy 
between LIGHT and PSCA TriVax suggest that LIGHT plays a role in the generation of 
autoimmune responses, which in the context of cancer may promote a reduction in 
tumor burden. HVEM, the receptor for LIGHT, is also able to bind BTLA, a molecule 
found on T effector cells that enhances their ability to be suppressed by Tregs (99). 
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Thus, in the immunosuppressive TME, LIGHT may compete with BTLA for binding of 
HVEM, thereby limiting the ability of Tregs to suppress immune effector cells (99). 
Furthermore, LIGHT has the capacity to bind to decoy receptor 3 (DcR3), a soluble 
receptor that is expressed by many tumors, including those located in the esophagus, 
stomach, colorectal, pancreatic, lung, brain, renal, ovarian, blood, hepatocellular, and 
oral cavity (100). DcR3 is related to two other decoy receptors of the TNF family that 
bind but do not induce signaling upon binding their ligand. Since DcR3 sequesters 
LIGHT, an additional avenue of translational research aims to engineer a mutant LIGHT 
that is unable to bind DcR3 but retains its ability to signal through HVEM and LTβR to 
induce more potent anti-tumor immune responses. Of note, LIGHT that is unable to bind 
DcR3 is better able to induce the apoptotic death of tumor cells (101), with its effects on 
immune cell subsets to be determined. LIGHT does appear to have detrimental effects 
in tumors that arise due to chronic inflammation. In livers infected with hepatitis or with 
virally-induced hepatocellular carcinoma, levels of LTA, LTB, LIGHT and LTβR are 
increased, and chronic hepatitis in this model can be alleviated by treatment with LTβR-
Ig, which serves as a sink for LTβR ligands (102). 
LIGHT has also been shown to play a role in NK cell involvement in anti-tumor 
immunity. NK cells constitutively express HVEM, and forced expression of LIGHT in the 
TME mediates recruitment of NK cells to the tumor from the periphery and activation of 
these cells, including secretion of IFN-γ. Strikingly, this study observed a requirement for 
both activated NK cells and IFNγ in inducing an anti-tumor CTL response at later time 
points: peak NK cell infiltration was observed at 10 days post-tumor inoculation, while 
peak CD8+ T cell levels occurred 22 days post tumor inoculation. This unique role for 
NK cells in CD8+ T cell activation is not observed in SLO such as the spleen (103). NK 
cells have also been shown to induce the maturation of DC using a similar pathway: 
upon recognition of target cells, NK cells upregulate their cell surface expression of 
LIGHT, and LIGHT-expressing NK cells were able to induce upregulation of CD86 on 
the surface of autologous DC in a cytokine-independent manner (104). Thus in addition 
to playing a role in the recruitment of lymphocytes to the TME, LIGHT appears to also 
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have a direct role in priming anti-tumor immune responses, pointing to LIGHT as a 
potential therapeutic agent to be explored in the clinic. 
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1.2.5.3 The Importance of CCR7 Agonists for TLS Evolution in the TME CCL19 (i.e. 
EBV-induced molecule 1 ligand chemokine/ELC or MIP-3β) and CCL21 (i.e. secondary 
lymphoid chemokine/SLC) are constitutively expressed by stromal cells and serve to 
recruit CCR7+ cells to sites of inflammation (105). Within the immune repertoire, CCR7 
is expressed on naive and memory T cells, B cells, DC, and NK cells (31,106,107). In a 
mouse model involving the forced expression of CCL19, CCL21a, or CCL21b in 
peripheral tissues, each single chemokine was sufficient to induce immune cell 
infiltration into the pancreas (82,108), but not into the skin or the central nervous system 
(108,109). CCL19/CCL21-induced infiltrated tissue contained HEV and organized 
networks of stromal cells (82), consistent with the TLS paradigm. Some cancers have 
evolved mechanisms to antagonize the host-protective effects of CCR7-mediated 
immune cell chemotaxis. HPV-induced cervical cancer manipulates its local 
microenvironment by secreting IL-6, which inhibits NFκB and CCR7 expression by 
mature DC and instead upregulates the pro-tumorigenic MMP-9 metalloproteinase. 
Such effects are reversible as a consequence of treatment with neutralizing anti-IL-6 
antibodies (110). However, CCR7 has also been reported to have detrimental effects in 
certain cancers. In hepatocellular carcinoma, signaling by both CCL19 and CCL21 
promoted the proliferation and invasion of tumor cells, while CCRL1/CCX-CKR, a 
naturally occurring receptor sink for the CCR7 ligands, was able to mitigate these 
effects (111). CCRL1 is unable to induce intrinsic intracellular signaling pathways, but it 
mediates the internalization and degradation of CCL19 and disallows its agonism of 
CCR7 (112). Melanoma cells have been shown to express CCL19 and CCR7, and 
expression of CCR7 correlates with metastasis, especially to the liver (113). Thus in 
certain cases, it appears that tumor cells have established mechanisms to use the 
body’s natural chemokine gradients to benefit their own survival. While in many 
instances their roles are considered as parallel or redundant, expression of CCL19 and 
CCL21 in different organs may be under the control of different signaling pathways. For 
example, blockade of signaling through the LTβR causes a decrease in CCL19, but not 
CCL21, levels in lymph nodes (73). These results suggest that signaling pathways 
involving these chemokines include both shared and differential components and that 
these differences may be organ-dependent. 
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Chemotaxis of naive B cells towards a CCL21 gradient is mediated in part by Type-1 
IFNα. Specifically, IFN-α is able to diminish the ligand-induced receptor internalization 
of CCR7 in the presence of CCL21, allowing for B cells in pro-inflammatory 
microenvironments to traffic more efficiently during the generation of antigen-specific 
humoral immune responses (107). In mice, three isoforms of CCL21 exist. CCL21a 
differs from CCL21b and CCL21c based on the presence of a serine instead of a 
leucine at position 65, whereas the exon sequences of CCL21b and CCL21c are 
identical and may represent splice variants (114). Humans express just one isoform of 
this protein, which contains a leucine at position 65 but performs the same functions as 
all three mouse isoforms. The tissue distribution of CCL21 varies between mouse and 
humans as well: in humans, CCL21 expression is found predominantly in lymphoid 
tissues including the lymph nodes, spleen, and appendix, while in mice, CCL21 is more 
broadly expressed and is found at the highest levels in spleen and lung (115). Within 
lymphoid structures, CCL21 is expressed by stromal cells and endothelial cells, 
especially those that make up HEV (106), and allow for the recruitment of CCR7-
expressing immune cells towards a gradient. In a normal skin microenvironment, 
subcutaneous injection of CCL21 led to the recruitment of lymphocytic infiltrates into the 
skin at the site of injection 4 days later. CCL21 injection also led to an increased T cell 
(and DC) recruitment to the draining lymph node, and this recruitment also peaked 4 
days post-injection (116). In melanomas treated with DC engineered to ectopically 
express CCL21 (i.e. DC.CCL21), TLS developed at the site of DC delivery, and 
expression of IFNγ by CD4+ and CD8+ T cells was observed, concurrent with a 
reduction in tumor burden in treated patients (36,117). In this situation, priming of anti-
tumor effector T cells takes place within the TLS, as DC.CCL21 do not migrate to the 
tumor draining lymph node. Instead, naive T cells are recruited to the TME from the 
peripheral circulation, and begin to express CD25 (IL-2Rα) within 24 hours of arrival 
(117). Interestingly, some tumors intrinsically express CCL21, in association with an 
immunosuppressed TME. This may be the result of CCL21 recruitment of CCR7+ Tregs 
that can mitigate the clinical benefits of inflammatory immune effector cells (118). In the 
setting of melanoma, tumor cell secretion of CCL21 promotes tumor immune escape 
through the production of TGF-β and the recruitment of Tregs and myeloid derived 
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suppressor cells (MDSC; ref. (119)). A similar result has been observed in a pancreatic 
islet beta cell tumor model, in which forced overexpression of CCL21 in the tumor cells 
led to enhanced tumor progression and significantly higher numbers of Tregs found 
within the TME (120). This latter result was dependent on host tissue expression of 
CCR7. CCL21-CCR7 signaling has also been reported to have a pro-angiogenic effect. 
In a model of rheumatoid arthritis, a CCL21 gradient caused migration of CCR7+ micro-
vascular endothelial cells. CCL21 also leads to the secretion of pro-angiogenic factors, 
such as VEGF, Ang-1, and IL-8, by fibroblasts and macrophages. Neutralization of 
CCL21 or blockade of CCR7 abrogated micro-vascular endothelial cell migration in vivo 
(42). Thus in the context of cancer, the pro-angiogenic capability of CCL21 signaling 
may mediate tumor progression, as de novo blood vessel formation is required for 
tumor growth and metastasis. 
CCL19 is expressed by stromal cells in lymphoid organs, as well as by mature DC 
(121). Like CCL21, the transcription of CCL19 is regulated by two NFκB binding sites 
and one interferon-stimulated response element in its promoter region. The inhibition of 
NFκB activation partially down-regulates transcription of IFNγ and CXCL10 by DC (122). 
However, CCL19 also stimulates the proliferation and metastasis of breast cancer cells, 
which can only be alleviated by interfering with CCR7 receptivity on tumor cells (123). 
Increased levels of CCL19 and CCR7 are also known to be expressed by prostate 
cancer tissues, and signaling by CCL19 through CCR7 expressed on prostate cancer 
cells induces cell proliferation (124). CCR7 is expressed by gastric cancer cells, with 
higher levels of CCR7 expression associated with lymph node metastasis, higher stage 
tumor, and poor overall survival. Treatment of human gastric cancer cells with CCL19 
induced the expression of MMP-9 and decreased levels of E-cadherin, consistent with a 
shift towards a pro-metastatic phenotype (125). In ovarian cancer, CCR7+ tumor status 
was correlated with advanced disease stage and with lymph node metastasis, and 
these clinical parameters were linked to increased expression of MMP-9 and N-cadherin 
(43) that were subsequently determined to be dependent upon CCL19 signaling (125). 
DC are also recruited to lymphoid organs and activated via CCR7 ligand gradients. After 
the acquisition of antigen in its local microenvironment and the provision of activation 
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(danger or maturation) signals, DC upregulate CCR7 on their surface and become 
competent to migrate in response to secondary lymph node chemokines, CCL19 or 
CCL21 (116,126). The ability of DC to migrate in response to a CCR7 ligand gradient 
was found to be partially dependent on MMP-9 expression by the DC (126). In addition 
to recruiting DC to sites of inflammation, CCL21 boosts the T cell-priming function of 
DC. Human DC treated with recombinant CCL21 and subsequently peptide pulsed and 
co-cultured with CD8+ T cells were better able to stimulate IFNγ release from the T cells 
than peptide-pulsed DC that were not treated with CCL21. The T cells also expressed 
slightly elevated levels of perforin, granzyme B, and FasL. Interestingly, this benefit of 
CCL21 treatment required CXCL10 signaling during the T cell priming phase (127). 
Interestingly, however, in a murine model of metastatic melanoma, the intratumoral 
presence of elevated levels of CCL21 at the time of adoptive T cell therapy resulted in 
increased survival, proliferation, and effector function of transferred T cells and led to 
prolonged survival of CCR7+ T cell-treated mice compared to mice treated with 
transferred T cells alone (128). In a lung cancer model, injection of recombinant CCR7 
into tumors led to complete tumor regression concurrent with trafficking of CD4+ and 
CD8+ T cells to the tumor and to the tumor draining lymph node (129). This effect was 
dependent upon T cell recruitment (129) and the recruiting cytokines/chemokines 
CXCL9, CXCL10, and IFNγ (130). In the LoVo model of human colorectal cancer, 
treatment with recombinant CCL19 suppressed tumor growth in vivo concurrent with 
increased serum levels of IL-12 and IFNγ via a T cell-independent mechanism that 
involved DC and NK cells (131). Furthermore, results from non-tumor models support a 
beneficial role for CCL21 in generating protective Type 1 immune responses. CCL21 
can co-stimulate effector CD4+ and CD8+ T cells, induce T cell proliferation, and induce 
a Type 1 polarized immune response characterized by secretion of IFNγ and not IL-4 or 
IL-5 (132). When taken together, these results suggest a dual function for CCR7 and its 
ligands CCL19 and CCL21 in anti-tumor immunity, as CCR7 signaling may promote the 
formation of TLS and the recruitment and survival of immune effector cells in an 
inflammatory microenvironment, or the recruitment of suppressive immune cells such as 
Tregs and MDSCs and the secretion of regulatory cytokines, depending on context. The 
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precise signals involved with determining the pro- versus anti-tumor impact of CCR7 
and its ligands have not yet been elucidated. 
 
1.2.5.4 The Importance of CXCR5 agonists in TLS evolution  
CXCL13, also known as BLC, is critical for the formation of SLO and TLS. Its receptor, 
CXCR5 is expressed on the surface of B cells, and these cells migrate towards 
gradients of CXCL13 expressed by follicular DC or stromal cells in lymphoid organs 
(106). Mice deficient in either CXCL13 or CXCR5 lack structured lymphoid organs 
including lymph nodes, Peyer’s patches and spleen, which appears to be due to a lack 
of follicular DC networks that are required for the organization of recruited B cells into 
follicles/germinal centers (80). CXCL13 is under the transcriptional control of LTβR-
mediated signaling in all SLO (73), and signaling by CXCL13 through CXCR5 leads to 
increased cell surface expression of LTα1β2 (80). The CCR7 ligands CCL19 and CCL21 
also promote elevated expression of LTα1β2 on the surface of B cells, though to a lesser 
extent than does CXCL13 (80). In response to infection, DC and CD4+ T cells are able 
to upregulate CXCR5, and this promotes the recruitment of B cells to sites of immune 
priming in lymphoid organs (133). Forced expression of CXCL13 in non-lymphoid 
organs leads to the formation of lymphoid-like structures and the recruitment of immune 
cells into affected tissue sites (134). Interestingly, CXCL13 expression within lymphoid 
organs appears to be required not only for B cell migration to lymphoid organs, but for 
antigen presentation to B cells at these sites as well (135). 
Like CCR7 ligand chemokines, CXCL13 appears to play multiple roles within the TME. 
Although CXCL13 is crucial for the recruitment of immune cells into sites of 
inflammation, it can also mediate the invasion and metastasis of many types of cancer. 
Colon cancer cell lines commonly express the CXCR5 receptor, and are able to 
proliferate and migrate in response to CXCL13 gradients in a CXCR5-dependent 
manner (136). The migratory capacity of these colon cancer cells appears to be 
mediated downstream of CXCR5 signaling by the matrix metalloproteinase MMP-13 
(136), consistent with results observed in human colon cancer patients (137). A similar 
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result has been observed in prostate cancer, as primary prostate cancer tissues and 
prostate cancer cell lines both express CXCR5. After treatment with CXCL13, prostate 
cancer cell lines upregulate MMP-1, MMP-2, and MMP-9, and are able to migrate 
towards a CXCL13 gradient in a CXCR5-dependent manner (138). In the Myc-CaP and 
TRAMP prostate cancer models in vivo, CXCL13 is upregulated by myofibroblasts in the 
tumor stroma downstream of TGF-β in response to hypoxia, and this promotes 
metastasis and the development of more aggressive, hormone-independent tumors 
(139). Many subtypes of human lung cancers also express CXCR5. Specifically, 
adenocarcinomas and squamous cell carcinomas, but not healthy lung tissues, express 
CXCR5 (140). Furthermore, patients with lung adenocarcinomas or squamous cell 
carcinomas present with increased serum levels of CXCL13 when compared to healthy 
patients, and CXCR5-expressing lung cancer cell lines are able to migrate towards a 
CXCL13 gradient in vivo (140). Some breast cancer patients have been shown to 
express elevated levels of CXCL13 in both the TME and systemically in the peripheral 
blood (141). In particular, patients with metastatic breast cancer present with 
significantly higher serum levels of CXCL13 when compared to normal controls and to 
patients whose tumors were resected, suggesting that CXCL13 may be a potential 
biomarker capable of detecting early metastatic disease in these patients (141). Both 
CXCR5 and CXCL13 have also been shown to be expressed by patients with infiltrating 
ductal carcinoma, and their co-expression correlates with lymph node metastasis and 
an up-regulation in expression of MMP-9 in these patients, supporting a role for the 
CXCR5-CXCL13 axis in promoting epithelial to mesenchymal transition of breast cancer 
cells (142). 
Speaking to the prognostic value of CXCL13 expression, in colorectal cancer, both 
CXCR5 and CXCL13 may be upregulated in malignant compared to normal tissues, and 
patients with higher expression of CXCR5 and CXCL13 present with a lower 5-year 
overall survival and lower 5-year progression free survival when compared to disease 
stage-matched patients whose tumors were negative for CXCR5 and CXCL13 (143). In 
a clinical trial for HER2-positive breast cancer, the presence of CXCL13 on tumor 
infiltrating lymphocytes was associated with a lower occurrence of complete response to 
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treatment (144). However, other groups have reported a beneficial role for CXCL13 and 
CXCR5 in breast cancer. In particular, there was a positive correlation observed 
between high intratumoral CXCL13 or CXCR5 expression and increased disease free 
survival in high risk HER2-positive, estrogen receptor-low breast cancer patients (145). 
In hormone receptor-positive invasive ductal carcinoma, patients with grade I non-triple 
negative breast cancer presented with higher intratumoral levels of CXCL13 compared 
to patients with higher grade (grade II/III) or triple negative tumors (146). Interestingly, 
interferon regulatory factor 5 (IRF5), a regulator of CXCL13, is present in some but not 
all breast cancers, and media conditioned in vitro by IRF5-positive tumors is able to 
recruit B- and T-cells while IRF5-negative tumor conditioned media is not (146), 
suggesting that these tumors may secrete CXCL13 in vivo, generating a gradient to 
recruit lymphocytes into the TME. Thus in the cancer setting, increased 
CXCL13/CXCR5 expression- especially in patients with metastatic disease- may in fact 
represent a mechanism by which protective immune responses are actively recruited 
into disease sites. 
Overall, work evaluating the role of chemokine signaling in the context of tumor 
progression suggests that chemokine/chemokine receptor expression may not be 
entirely beneficial or entirely harmful to the patient. Instead, chemokine expression may 
coordinately mediate immune cell recruitment into the TME and promote the metastasis 
of tumor cells, as many forms of tumor/tumor cell lines have been shown to express 
chemokines or chemokine receptors. Thus in the context of generating novel 
therapeutics to cancer, it will be important to balance the positive and the negative 
effects of enhancing or inhibiting signaling through these pathways. Specifically, it may 
be useful to stratify patients based on expression of chemokines/chemokine receptors 
to optimize the benefits of targeted (immuno)therapies. 
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1.2.6 Therapeutic Manipulation of TLS in Cancer Patients: Establishing a 
Paradigm for Anti-Tumor Efficacy 
 
Our own work in murine models suggests that forced overexpression of cDNA encoding 
the Type 1 transactivator Tbet within the TME is therapeutic in the cancer setting. In 
particular, we have shown that DC engineered to (over)express Tbet (i.e. DC.Tbet) 
inhibit the growth of CMS4 (BALB/c) and MCA205 (C57BL/6) sarcomas in vivo after 
intratumoral injection, leading to the prolonged overall survival of treated tumor-bearing 
mice (27,28). This result is dependent upon the presence of host lymphocytes and NK 
cells, as RAG1-/- mice and mice depleted of either CD8+ T cells or NK cells were not 
protected from tumor growth by treatment with DC.Tbet (28). As T cells and NK cells 
must be able to traffic to the site of the tumor, it stands to reason that early chemokine 
signaling plays a key role in the mechanism by which intratumoral delivery of DC.Tbet 
leads to the recruitment of Type 1-polarized immune cells into the TME. In support of 
this hypothesis, DC.Tbet (but not control DC) cells express increased transcript levels 
for numerous chemokines, including CCL1, CCL4, CCL8, CCL12, CCL17, CCL25, 
CCL28, and CXCL12 (28). Furthermore, DC.Tbet treatment leads to an upregulation of 
CXCL9 and CXCL10 in the TME as late as 21 days post tumor inoculation (27). As a 
set, these chemokines are attractants for T cells, B cells, and NK cells as well as for DC 
and monocytes. These results provide a framework by which DC.Tbet promotes a rapid 
(hours) and sustained (days to weeks) chemokine response to actively recruit and retain 
immune cells in TLS within the effectively treated TME. 
 
1.2.7 Conclusions and Future Directions for Clinical Translation 
 
Chemokine expression within the TME and the development of TLS can often, but not 
always, represent a positive prognostic marker in patients with solid tumors. Due to the 
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differential requirements for effector and regulatory immune cell subsets within the TME 
of a diverse array of cancer types (see Table 1.1), immunotherapies designed to 
promote the recruitment of immune cells into the TME, or those targeting chemokine 
pathways, must still be evaluated on an empirical “case-by-case” basis. Examples of 
controversial effects of TLS include the positive effect of TLS presence in metastatic, 
but not primary, colorectal carcinoma, or the benefit of both Treg and effector T cell 
infiltration in head and neck cancer (53,64), which traditionally arises as a result of 
prolonged inflammation at the site of disease. Future avenues of research must 
elucidate whether the presence or absence of certain chemokines, cytokines, or cell 
populations within the TLS can predict a patient’s ability to mount a successful anti-
tumor immune response secondary to treatment. Although trends in the prognostic 
value of TLS are seen within cancer subtypes, it is likely that a better method of 
stratifying patients for immunotherapy will be to evaluate the specific immune cell 
infiltrates and chemokines expressed at the time of diagnosis, in hopes of determining 
whether the enhancement or suppression of the immune response therapeutically is the 
best course of treatment. 
Therapeutic agents targeting TLS-relevant chemokine pathways have thus far been 
evaluated in mouse tumor models, with forced expression of LIGHT or CCL21 both 
mediating beneficial therapeutic outcomes against a variety of solid tumors. Further 
analyses of the pathways involved in beneficial immune responses within the TME have 
identified additional immunomodulatory agents that may prove to be clinically important 
targets of immunotherapy. 
In summary, recent advances in our understanding of chemokine and cytokine 
pathways and their role in the generation of lymphoid organs have allowed for a greater 
appreciation of the dynamic crosstalk between immune cell types that occurs within TLS 
that form in or proximal to the TME. This paradigm provides a set of biologic endpoints 
that should be achieved in order to render improved clinical benefit as a consequence of 
(immuno)therapeutic intervention in cancer patients. Specifically, intratumoral delivery 
or promotion of TLS-facilitating factors, applied as single agents via viral vectors or 
transduced cells (e.g. DC) or direct injection of recombinant proteins into accessible 
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tumor lesions, may allow for the preferential manipulation of protective-over-regulatory 
TIL within tumor-associated TLS. Under such conditions, TLS-primed/expanded anti-
tumor immune effector cells may confer systemic clinical benefits (i.e. locoregional 
treatment of a single lesion may beget circulating immune-mediated regulation of 
disseminated disease) with minimal anticipated off-target toxicities. 
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1.3.1 Abstract 
 
Peripheral node addressin (PNAd) marks HEV, which are crucial for the recruitment of 
lymphocytes into lymphoid organs in non-mucosal tissue sites. PNAd is a sulfated and 
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fucosylated glycoprotein recognized by the prototypic monoclonal antibody MECA-79. 
PNAd is the ligand for L-selectin, which is expressed on the surface of naïve and central 
memory T cells, where it mediates leukocyte rolling on vascular endothelial surfaces. 
Although PNAd was first identified in the HEV of peripheral lymph nodes, recent work 
suggests a critical role for PNAd in the context of chronic inflammatory diseases, where 
it can be used as a marker for the formation of tertiary lymphoid structures (TLS). TLS 
form in tissues affected by sustained inflammation, such as the tumor microenvironment 
(TME), where they function as local sites of adaptive immune cell priming. This allows 
for specific B- and T-cell responses to be initiated or reactivated in inflamed tissues 
without dependency on SLO. Recent studies of cancer in mice and humans have 
identified PNAd as a biomarker of improved disease prognosis. Blockade of PNAd or its 
ligand, L-selectin (aka CD62L or LECAM-1), can abrogate protective anti-tumor 
immunity in murine models. Here, we examine the pathways regulating PNAd 
biosynthesis by the endothelial cells integral to HEV and the formation and maintenance 
of lymphoid structures throughout the body, particularly in the setting of cancer. 
 
1.3.2 Pathways regulating PNAd expression 
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1.3.2.1 Signaling through the lymphotoxin beta receptor is required for HEV 
differentiation Lymphotoxin beta receptor (LTβR) signaling drives expression of 
adhesion molecules and chemokines involved in the recruitment of circulating 
lymphocytes into lymphoid organs, including CCL21, CXCL13, MAdCAM-1, and PNAd 
(76). Specifically, expression of LTβR on endothelial cells in peripheral lymph nodes is 
required for their development into HEV, with high endothelial cells functioning as 
lymphoid tissue organizer cells (LTo). Endothelial cell-specific deletion of LTβR leads to 
a reduction in: i.) MECA-79 staining, ii.) CCL19, CCL21 and GlyCAM-1 expression, and 
iii.) the ability to assume cuboidal morphology, by endothelial cells in peripheral 
lymphoid organs (Figure 1.1A and ref. (147)). In vivo work using bone marrow chimeric 
mice deficient in LTα in their hematopoietic compartment also implicates a role for 
LTβR-mediated signaling in the maintenance of HEV, as these mice exhibit profoundly 
reduced lymph node cellularity (148). 
LTα1β2 and LIGHT can bind and signal through the LTβR, while a related ligand, LTα3, 
can signal through TNFRI, TNFRII, and HVEM. All three ligands can be produced by 
CD11c+ DC (148). However, each ligand appears to have a distinct role in regulating 
PNAd expression. In SLO, LIGHT appears to have little impact on PNAd expression 
(73). Using a transgenic model of lymphotoxin overexpression in the pancreas, it was 
observed that LTα and LTβ play distinct roles in the formation of TLS. LTα1β2 controls 
luminal PNAd expression, while LTα3 controls abluminal PNAd expression (76). These 
differences in ligand function appear to relate to their impact on the level of GlcNAc6ST 
expression by endothelial cells. GlcNAc6ST-2 expression was reduced if only LTα but 
not LTβ was present, with HEV in LTβ-/- animals (that retained GlcNAc6ST-2) 
expressing PNAd (76). LTα-/- animals were deficient in GlcNAc6ST-2 expression on 
HEV, although they retained PNAd expression (149). Blockade of LTβR signaling also 
decreases transcription of GlcNAc6ST-2 in lymph nodes by 10-fold, with GlcNAc6ST-1, 
FucT-VII and FucT-IV levels also coordinately reduced, thereby limiting post-
translational modification of PNAd and inhibiting its ability to be recognized by L-selectin 
(73). 
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Lymphocytes are also able to secrete lymphotoxin ligands (73,147). Interestingly, the 
requirement for T or B cells themselves in HEV activation in SLO is equivocal. Reports 
suggest that neither cell type is required for HEV differentiation (73), although it has also 
been observed that Rag-/- mice exhibit decreased expression of GlcNAc6ST-2 
compared to WT mice (150).  
 
1.3.2.2 Post-translational modifications are required for L-selectin recognition of 
PNAd Members of the PNAd family of addressins include GlyCAM-1, CD34, sgp200, 
podocalyxin, endomucin, and nepmucin: however, not all PNAd ligands appear to be 
required for lymphocyte trafficking (151,152). For example, lymphocyte trafficking to 
peripheral lymph nodes remains unaltered in CD34-/- (153) or GlyCAM1-/- (154) mice, 
suggesting redundancy in the functional roles of PNAd family members. In order for 
PNAd to be recognized by MECA-79 as well as its receptor, L-selectin, a series of post-
translational modifications must first occur (Figure 1.1). Specifically, while PNAd 
undergoes sulfation and glycosylation (155), it is sulfation of the 6 sialyl Lewis X motif 
that renders these molecules recognizable by the MECA-79 antibody (156). 
Fucosylation of the Core 2 branched O-glycan serves as the recognition site of PNAd by 
L-selectin (Figure 1.1B) (157,158). 
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Figure 1.1. PNAd biosynthesis. 
(A) (1) LTβR is expressed on blood vessel endothelial cells. Membrane-bound LTα1β2 
or secreted LTα3 secreted from cDC can signal through this receptor. (2) LTβR-
mediated signaling promotes a physical change in vascular endothelial cells from a flat 
to cuboidal morphology. This signaling cascade also leads to the expression of PNAd 
on the surface of vascular endothelial cells, promoting HEV status. (3) LTβR signaling 
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further induces HEV secreted chemokines, including CCL19, CCL21, and CXCL13. (4) 
Chemokines form gradients and “decorate” the blood vessel wall, initiating the 
recruitment of CCR7+ T cells or CXCR5+ B lymphocytes from the peripheral blood 
circulation into chronically inflamed tissues. (5) L-selectin on the surface of T cells is 
able to bind PNAd on the surface of HEV. These cells are then able to adhere to the 
vessel wall and extravasate into the tissue. (B) PNAd is synthesized from a Core 1 O-
glycan. The extended Core 1 O-glycan serves as the MECA-79 recognition motif. The 
fucosylated Core 2 O-glycans are able to be recognized by L-selectin. Sulfation of the 
extended Core 1 and Core 2 O-glycans at the sixth position is mediated by GlcNAc6ST-
1 and -2; α3 fucosylation is added by FucT-IV and -VII. 
 
 
1.3.2.2.1 Sulfation GlcNAc6ST-1 and GlcNAc6ST-2 are members of the GalNAc6ST-6-
O-sulfotransferase subfamily of glycosyl sulfotransferases that are critical to the transfer 
of sulfate groups to galactose or GlcNAc at the 6 position, with this sulfation of 
carbohydrate motifs on PNAd required for it to be presented at the cell surface and to 
be recognized by the MECA-79 antibody and by its natural ligand, L-selectin (159). 
Though related, GlcNAc6ST-1 and GlcNAc6ST-2 have different roles in the sulfation of 
PNAd. Using mice deficient in either single sulfotransferase, it was shown that 
GlcNAc6ST-2 controls luminal expression of PNAd while GlcNAc6ST-1 controls 
expression of PNAd on the abluminal vascular surface (160,161). 
GlcNAc6ST-2 is expressed by mature, but not immature, HEV. Using a Cre-
recombinase model, Kawashima and colleagues observed that expression of 
GlcNAc6ST-2 is activated in HEV cells recognized by the MECA-79 antibody (i.e., 
expressing PNAd) but not in cells reactive only with the MECA-367 antibody 
(recognizing MAdCAM-1) (162). This is consistent with observations that GlNAc6ST-1 
and -2 have little impact on cellular expression of MAdCAM-1, a canonical marker of 
immature HEV in SLO within non-mucosal tissue sites (163).  
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1.3.2.2.2 Glycosylation A family of alpha(1,3)fucosyltransferases control the 
fucosulation of E-, P-, and L-selectin ligands (164). In particular, FucT-VII and FucT-IV 
play distinct roles in the generation of L-selectin ligands on the surface of HEV. FucT-IV 
is required for the expression of L-selectin ligands on the surface of HEV, whereas the 
primary role of FucT-VII appears to be in its contribution to enhancing GlyCAM-1-
mediated tethering of rolling lymphocytes. The specific role of FucT-VII temporally 
follows glycosylation and sulfation of the glycoprotein and is involved in capping the 
molecule to produce the preferred ligand recognized by L-selectin. Double knockout of 
both FucT-VII and FucT-IV in mice reduced lymphocyte recruitment to SLO by over 
80% when compared to FucT-VII-/- mice. (165). 
 
1.3.3 Markers of high endothelial venules 
 
Two sets of adhesion molecules dominantly modulate lymphocyte recruitment to 
SLO/TLS depending upon which site in the body the cells are trafficking to: recruitment 
to peripheral lymph nodes is dependent upon the L-selectin/PNAd interaction, while 
recruitment to mucosal sites requires the α4β7 integrin/MAdCAM-1 interaction (166). The 
same high endothelial cells that express PNAd or MAdCAM-1 also express CCL21, a 
CCR7 ligand. Supporting the importance of PNAd- and CCL21-expressing HEV for the 
recruitment of lymphocytes, the majority of lymphocytes in HEV-expressing tissues are 
spatially located within approximately 20 microns of HEV (167). CCL21 preferentially 
recruits CCR7+ CD4+ L-selectin+ (naïve) T cells, which can interact with PNAd on the 
cells of the HEV. CCL21, like PNAd, is under the control of intrinsic LTβR-mediated 
signaling during HEV development (but not in mature lymphoid tissues) (73,76). 
 
1.3.4 Immune Cell Recruitment by HEV 
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PNAd binds L-selectin expressed on the surface of lymphocytes. This interaction is 
required for the recruitment of lymphocytes into SLO (168). Post-translational 
modifications of PNAd family members are critical for this interaction. For example, B 
cell recruitment to peripheral lymph nodes is dependent on sulfation of PNAd (163). The 
velocity of T and B cell rolling is also dependent upon sulfation of L-selectin ligands on 
lymph node endothelial cells, with adherence of lymphocytes to the vessel wall 
decreased in GlcNAc6ST-deficient animals (163). This may also be controlled by the 
presence of DC within SLO, as the velocity of lymphocyte rolling in CD11c-DTR mice 
was significantly increased, and the percentage of lymphocytes able to adhere to the 
vessel wall was decreased, in these mice after treatment with diphtheria toxin to delete 
DC. The HEV of DC-depleted mice regained expression of MAdCAM-1, and after 
reconstitution with adoptively-transferred CD11c+ DC, these HEV recovered classical 
cuboidal morphology, suggesting that DC-produced factor(s) is/are required for the 
maturation of HEV (148). 
The CCR7-CCL21 axis is also important for lymphocyte recruitment into lymphoid 
organs. Mice deficient in CCR7 have impaired migration of B and T cells, as well as DC, 
to SLO including lymph nodes and Peyer’s patches. This limits primary immune 
responses against infectious agents (169). Expression of CCL21 by high endothelial 
cells is controlled by a pathway unique to these cells versus high endothelial cells 
expressing alternate addressins. Specifically, heparan sulfate, a glycosaminoglycan 
primarily found on the surface of vascular endothelial cells, is required for CCL21 
expression on HEV (170). Using an Ext1-flox/flox mouse crossed with a GlcNAc6ST-2-
cre transgenic mouse to delete a glycosyltransferase necessary for the synthesis of 
heparan sulfate in PNAd-expressing cells, expression of CCL21 on the surface of HEV 
was abrogated (167). 
 
1.3.5 Tertiary Lymphoid Organs 
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Although the pioneering work identifying PNAd and the pathways controlling its 
expression were initially studied in the context of SLO, recent literature supports an 
important role for PNAd in TLS (aka ectopic lymphoid structures) that develop in 
peripheral tissue sites impacted by chronic inflammation. Overall, TLS have varying 
degrees of similarity to SLO. Classical TLS closely resemble SLO in their cellular 
composition, with TLS containing a network of follicular DCs and germinal centers in 
which B cells reside, proliferate and differentiate (Figure 1.2A). Non-classical TLS also 
contain some degree of B cell infiltration, but they do not exhibit an follicular DC 
“framework” (37), with only diffuse, sparse B cell distributions being observed (Figure 
1.2B) (36,40). 
The L-selectin-PNAd interaction controls lymphocyte recruitment to TLSs. In particular, 
PNAd upregulation in affected tissues is observed in the settings of allergic contact 
dermatitis, lymphoid hyperplasia, and a variety of types of skin lesions and cutaneous 
lymphomas; i.e. diseases characterized by robust lymphocytic infiltrates into peripheral 
tissues (171). The CCR7 signaling axis also plays a role in TLS formation. Most 
importantly, CCR7-mediated signals are required for the clustering of DC in peripheral 
tissues. Interactions between DC and T cells proximal to blood vessels appears 
required for the acquisition of PNAd+ HEV in peripheral tissues (149). 
Notably, LTβR-mediated signaling controls the formation of HEV in peripheral tissues 
(34,149). Akin to the roles that lymphotoxin signaling plays in the control of PNAd 
expression in SLO, LTα3-dependent signaling has been reported to dominantly control 
PNAd expression on HEV within the TME in murine melanoma models (34), while in 
human breast cancer, LTβ (produced by DC-LAMP+ DC) appears to play a comparable 
dominant role (17). 
TLS have been observed in a variety of chronic inflammatory diseases, including 
arthritis (172), gastritis and ulcerative colitis (158,173), atherosclerosis (174), and 
cancer (31). As the development of TLS in chronic/autoimmune diseases has been well-
reviewed (33,175), we will now focus on the emerging field of TLS formation in solid 
tumors. 
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1.3.5.1 TLS in Cancer Cancer-associated TLS characteristically contain PNAd+ 
vessels, and are commonly localized to the outer margin (versus the core) of the tumor 
lesion (176). With the exception of reports for TLS predicting a worse prognosis in 
patients with renal cell carcinoma (RCC) (177) and some cases of colorectal cancer 
(178), the vast weight of the literature has correlated the presence of TLSs in human 
solid tumors with better clinical prognoses (32). Both classical and non-classical TLS 
have been reported within the TME (Figure 1.2). Of these 2 forms of TLS, however, the 
presence of classical TLS in tumors may provide a superior index for improved 
prognosis when compared to the presence of only non-classical TLS in the TME (37). 
These results suggest that systematic analysis of PNAd expression and TLS status in 
tumor biopsies may be a useful addition to current clinical criteria used to predict patient 
outcomes. 
 
 
 
Figure 1.2. Structure of classical and non-classical tertiary lymphoid structures. 
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 (A) Classical TLS contain a nucleated core of follicular DC and germinal center B cells 
(BGC), surrounded by an HEV-containing T cell zone. (B) Non-classical TLS do not 
contain follicular DC or BGC, but may contain sparse B cell, T cell, and DC infiltrates 
surrounding HEV.  
 
 
1.3.5.1.1 Lung Cancer In non-small cell lung cancer (NSCLC), PNAd+ vessels have 
been identified exclusively within TLS (45). In these tumors, the composition of cells 
within the TLS specifically correlates with patient prognosis. While T cells (all tumor-
infiltrating L-selectin+ T cells, comprised of both naïve and central memory CD4+ and 
CD8+ cells) are localized to TLS (45,48), overall T cell infiltrate and density appears to 
play a minor role in patient outcome when evaluated independently of other prognostic 
markers. Instead, the density and proximity of mature DC to TLS within the tumor may 
be most important, and patients with high DC-LAMP+ mDC infiltrates exhibit markedly 
extended overall survival (48). These findings are further supported by gene array data 
indicating that CXCR4, a gene associated with DC migration towards CXCL12 
gradients, is strongly correlated with increased overall survival in NSCLC patients (44). 
Unlike T cells, B cells do appear to play a significant protective role against lung cancer, 
and their presence can be used as a positive prognostic marker of overall survival. 
Interestingly, DC and B cell density in TLS can be used as a coordinate prognostic 
marker for patients with greatest overall survival. In NSCLC, B cells organize into 
germinal center-like structures containing CD21+ follicular DC. These B cells proliferate 
and differentiate in situ, leading to locoregional secretion of IgG and IgA antibodies 
reactive against tumor-associated antigens (47). 
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1.3.5.1.2 Skin cancers TLS have been identified in both primary and metastatic 
melanoma, where they have been observed to contain PNAd+ vessels (179,180). TLS in 
primary melanomas can be either classical or non-classical TLS. In metastatic 
melanoma, these structures are primarily composed of CD3+ T cells and mature (DC-
LAMP+) DC proximal to PNAd+ HEV (181). Plasma B cells may also be present in such 
TLS, with these cells producing Th-dependent IgG and IgA antibodies specific for 
tumor-associated antigens (179,181). In primary cutaneous melanoma, the presence of 
intratumoral HEV has been correlated with robust lymphocytic infiltration and tumor 
regression. Furthermore, if the high endothelial cells making up HEV have a cuboidal 
morphology, indicative of functional HEV, a positive correlation with CCR7, CCL19, and 
CCL21 expression within the tumor has also been observed (182). 
The presence of TLS also portends better clinical outcome (recurrence free and overall 
survival) in the setting of Merkel cell carcinoma. These structures are also characterized 
by an increased CD8+/CD4+ T cell ratio at the tumor periphery and by a co-clustering of 
T and B cells within these anatomic sites (38). 
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1.3.5.1.3 Colon Cancer TLS in human colon cancer have been detected in both the 
colon crypt and at the invasive front of the tumor, as well as in the peritumoral region 
(61,183). They contain immune cell types typically observed in SLO, including B cells, 
CD21+ follicular DC, T cells, and mature DC marked by DC-LAMP+, with CD31+ 
vascular endothelial cells and LYVE-1+ lymphatic vessels also noted (61,183). T cells 
and mature DC represent positive prognostic markers in both primary (32) and 
metastatic (177) colorectal cancer. In such tumors, the B cells may not organize into 
germinal center-like structures (61,183). These TLS appear to function as local sites for 
the priming and expansion of both B and T cells, based on the expression of the Ki-67 
marker in de facto germinal centers in these diseased tissues (183). 
1.3.5.2 Therapeutic induction of TLS Recent work from our group suggests that 
intratumoral TLS can be induced therapeutically via adoptive transfer of gene-modified 
DC, leading to reduced tumor progression. Following intratumoral injection of Type 1-
polarized DC (DC engineered to overexpress Tbet, i.e. DC.Tbet) into established 
murine sarcomas or colon carcinomas, CD4+ and CD8+ T cell recruitment to the TME is 
observed within 2 days, with an upregulation of PNAd expression detected by 5 days 
after treatment. This suggests that PNAd-independent events control early T cell 
recruitment to the TME, and that T cell-dependent factors may consequently result in 
PNAd upregulation on tumor-associated VEC (28,36). Once established, PNAd+ vessels 
become surrounded by dense infiltrates of both CD11c+ DC and CD3+ T cells, with 
these non-classical TLS principally localized near the tumor periphery for at least two 
weeks following initial therapeutic intervention (36). The presence of DC in TLS is 
consistent with prior studies of SLO demonstrating that DC accumulation proximal to 
HEV is required for the subsequent optimal homing of lymphocytes into SLO (148). 
 
1.3.6 Future Perspectives 
Although there appears to be some variability in the cellular composition across tumor 
types, TLS in the TME contain PNAd+ HEV typically surrounded by dense B cell and/or 
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DC infiltrates. Importantly, the presence of intratumoral or peritumoral TLS has been 
almost universally linked with superior clinical prognosis in patients with solid forms of 
cancer. Though T cells are also present in intratumoral TLS, their presence has thus far 
proven equivocal as a prognostic biomarker (184). The spontaneous formation of TLS 
has been observed in a variety of human cancers, including those reviewed above as 
well as oral squamous cell carcinoma (37,185), gastric cancer (176,186), bladder 
cancer (57), breast cancer (40,51,56), and others (31,187,188). Thus, it may ultimately 
be best to employ PNAd as well as B cell and DC infiltration in the TME as biomarkers 
to stratify patients based on TLS status, i.e. to differentiate individuals that may respond 
better to treatment intervention, including immunotherapies (based on superior 
locoregional immune competency). Furthermore, because TLS may be induced 
therapeutically (at least in murine models), it is also intriguing to speculate on the 
possibility that protective TLS may be conditionally sponsored in patients receiving 
chemo- or immuno-therapies (189), and that such structures may be used to 
monitor/predict the patient’s outcome and prospective treatment management. 
1.4. THE IL-36 CYTOKINE SUBFAMILY IN IMMUNE-MEDIATED PATHOGENESIS 
This section is partially adapted from text originally published in Advances in 
Cancer Research (2015; vol. 128). doi: 10.1016/bs.acr.2015.04.003. Both authors 
contributed to the manuscript. 
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1.4.1 The IL-36 cytokines share unique characteristics with other IL-1 family 
cytokines 
 
The IL-36 family of cytokines is comprised by a recently identified IL-1 sub-family that 
supports the generation of pro-inflammatory immune responses. These cytokines share 
sequence similarities and three-dimensional structures with known IL-1 family members 
such as IL-1α and IL-1β, and were in fact assayed using genomics approaches to 
identify sequences homologous to IL-1 and IL-1Ra (190,191). The IL-36 subfamily 
consists of three agonists (IL-36α, IL-36-β and IL-36γ, previously referred to as IL-1F6, 8 
and 9, respectively), one full antagonist (IL-36Ra/IL-1F5), and one partial antagonist (IL-
38) that signal through a heterodimeric receptor consisting of IL-1Rrp2, a unique 
receptor, and IL-1RAcP, a co-receptor shared with the IL-1 and IL-33 receptors. Like all 
IL-1 family members, the IL-36 agonists and IL-1F5 require processing before they 
become fully active biologically. Indeed, specific truncation of the N-terminus of each of 
these proteins results in a 103-105 fold increase in biologic activity when compared to 
unprocessed, full-length protein (192,193). 
Similar to other IL-1 family members, the IL-36 family cytokines lack a signal sequence 
that directs classical secretion from the cell (191). Instead, both the cleavage and 
secretion of the IL-36 cytokines occurs through a pathway that is also involved in the 
secretion of IL-1β and IL-18, i.e. pyroptosis. This is a pro-inflammatory form of cell death 
that is distinct from apoptosis and requires the processing of the pro-forms of these 
cytokines by the non-canonical inflammasome, with the participation of caspase-1 
(194,195) and caspase-3/7 (195) for cytokine transcription and release from the cell, 
respectively. The IL-36 cytokines themselves are not involved in activating the cell 
death pathway, however; instead, recognition of pathogens or danger signals through 
Toll-like receptors and NOD-like receptors on antigen presenting cells activate caspase-
1, with the secondary release of these pro-inflammatory cytokines from producer cells 
undergoing pyroptosis propagating Type-1 immune responses (196). In immune cells, 
IL-36 expression is also induced downstream of IL-18 and Tbet (197); in epithelial cells, 
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IL-36 is classified as an alarmin and is induced by cathelicidins such as CRAMP/LL-37 
(198). 
An additional unique characteristic of IL-1 family cytokines is their ability to translocate 
to the nucleus, where they exert functions largely independent of their effects as 
secreted factors (199,200). We and others have observed that IL-36γ is able to enter the 
nucleus of DC (35) and epithelial cells (201), though the function of nuclear IL-36γ has 
yet to be described. This parallels the biology of several other IL-1 family members, as 
IL-1α (202,203), IL-1β (200,204,205), IL-33 (206,207), and IL-37b (208) can all enter the 
nucleus. Once in the nucleus, these cytokines can regulate transcription (202,207), for 
example through association with the heterochromatin as in the case of IL-33 (207). 
Interestingly, nuclear translocation of IL-1α appears to be partially dependent on 
receptor binding and the subsequent translocation of the bound complex to the nucleus 
(203); the prodomain of IL-1α is also able to translocate to the nucleus (209). 
 
1.4.2. IL-36R signaling 
 
A growing body of literature describes that the three IL-36R agonists, IL-36α, IL-36β, 
and IL-36γ, can be produced by different immune and non-immune cell types and/or 
under different physiologic conditions (210). Of particular interest to this work is IL-36γ; 
a summary of the immune cells capable of producing this cytokine is presented in Table 
1.3. Besides its expression by immune cells, high levels of IL-36γ are secreted by 
keratinocytes (195,198,211), other epithelial cell populations in the gut (201) and lung 
(212,213), and colonic myofibroblasts (214). Once released from producer cells, the IL-
36 cytokines have effects on IL-36R+ cell types throughout the body. Numerous immune 
cell subsets express IL-36R (Table 1.3); outside of the immune compartment, 
predominant IL-36R expression in humans occurs in the skin, while in mice, receptor 
expression is more broadly distributed throughout organs including the prostate, 
esophagus, uterus, seminal vesicle, and paw (192). Human and murine fibroblasts also 
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express IL-36R (201,215–217); reports of expression by intestinal epithelial cells appear 
equivocal in humans but have proven reproducible in mice (201,218). 
Despite speciation in the range of cell types expressing the IL-36 receptor (i.e. between 
mice and humans), IL-36 ligands appear to induce similar immune responses in both 
species. Downstream effectors of IL-36 signaling include NFκB, MAPK, ERK1/2, and 
Jnk. This leads to secretion of IL-6, IL-8 and GMCSF by IL-36-treated mouse and 
human transformed cell lines (192). Interestingly, in a mouse model of fibrosarcoma 
(MC57-SIY), NFκB signaling is required in both CD4+ and CD8+ T cells for priming of a 
Type 1 immune response (as measured by secretion of IFNγ and TNFα, and specific 
lysis of target cells) and control of tumor growth (219). This suggests a possible 
mechanism by which signaling through the IL-36 receptor via NFκB may promote anti-
tumor immunity. 
IL-36 induces the activation and maturation of human and mouse DC. In response to 
treatment with IL-36 agonists, murine DC upregulate CD80, CD86, and MHCII (220), 
and human DC upregulate CD83, CD86, and HLA-DR. Furthermore, IL-36 signaling 
leads to increased secretion of IL-1β and IL-6 by human DC (221) and IL-1β, IL-6, IL-
12p40, and IL-12p70 by murine DC (220), strong indications that IL-36 plays a critical 
role in promoting states of both acute and chronic inflammation.  
Naive murine CD4+ T cells constitutively express the IL-36 receptor and mature in 
response to IL-36 signaling. In particular, IL-36 (but not other IL-1 family members or IL-
12p70) specifically induces IL-2 secretion and the proliferation of naive CD4+ T cells 
(222). Treatment of CD4+ T cells with recombinant IL-36β in the presence of antigen 
leads to the secretion of pro-inflammatory cytokines/chemokines and the induction of a 
canonical Type-1 effector cell phenotype characterized by expression of Tbet and 
secretion of IFNγ (222). In the presence of IL-12p70, IL-36 can induce secretion of IFNγ 
by CD4+ T cells (222). However, the local cytokine milieu plays a role in conditioning the 
cellular response to IL-36R agonism. In the absence of IL-12p35, signaling through the 
IL-36 receptor instead leads to transcription of GATA3 and secretion of IL-4 in T cells 
(222). Notably, mice deficient in expression of IL-36R exhibit impaired IFNγ, IL-6, TNFα, 
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and nitrite responses to bacterial challenge (222), suggesting that IL-36 plays a crucial 
role in the initiation of adaptive immunity in vivo. It is worth noting that IL-36R 
expression is lost in mature Th1-, Th2-, and Th17-polarized CD4+ T cells (222). Indeed, 
IL-36R signaling appears to suppress polarization of naïve murine CD4+ T cells into the 
Th17 subset (218,222). 
Although expression of the IL-36R by human T cells appears to differ based on subtype 
and environmental condition (222–224), DC treated with rhIL-36 induce effects on the 
responding human T cell repertoire that appear similar to those induced directly on 
murine T cells by rmIL-36. For example, IL-36α-treated DC enhance allogeneic CD3+ T 
cell proliferation to a degree greater than mitogen-activated T cells (225), with human T 
cells expanded with IL-36-conditioned DC also secreting increased levels of IFNγ (225). 
Stimulation of naïve CD8 T cells in the presence of IL-12 plus either IL-36β or IL-36γ 
can stimulate IFNγ production by the T cells in the absence of TCR ligation (224). 
Indeed, human T cells primed in the presence of IL-36 are likely to be Type 1 polarized, 
since IL-36β treatment of DC leads to their secretion of IL-12 and IL-18, which then 
prompt the transcriptional activation of Tbet in responder T cells (225). IL-36R 
expression between human naïve, effector, and memory T cell subsets has not been 
sufficiently investigated; however, early data is emerging about the different subsets of 
Th17 cells. One study demonstrated that cytokine secretion by human memory Th17 
cells that have seen Candida albicans is inhibited by the addition of either IL-1F5 or IL-
38 into the culture (193), indirectly suggesting that these cells express IL-36R. Effector 
Th17 cells from the blood and lesional skin of psoriasis patients also appear capable of 
responding to IL-36 signaling (226). 
 
 
Table 1.3. IL-36R and IL-36γ expression in the immune system 
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The immune cell subsets expressing IL-36R and IL-36γ are summarized here. Green 
box, reported to express; yellow box, conflicting reports in the literature/subset-
dependent; red box, reported to not express; black box, no reports.  
 
 IL-36R IL-36γ 
Species Mouse Human Mouse Human 
DC (220,227) (221,225,228) (35,197,220,229) (197,215) 
macrophages (220,227) (228) (197,227,230,231) (197,215,230) 
monocytes  (221,228)  (215,232) 
pDC  (225,228)  (233) 
neutrophils (220,227) (221,234)  (227)  
NK cells (223) (228)   
CD4+ T cells (220,222,224,235
,236) 
(221,228,237,238) (220) (232,238,239) 
CD8+ T cells (220,223,224) (221,223,228,237,
240) 
(220) (232,238,239) 
γ/δ T cells (223) (241)   
B cells (220,227,236) (228,237)  (215) 
 
 
1.4.3 IL-36 as an Early Inflammatory Mediator of Lymphoid Organogenesis in 
Tissues, Including Cancer  
 
In the context of disease, IL-36 family cytokines have been implicated in the 
pathogenesis of several autoimmune diseases. Most notably, IL-36 signaling plays a 
major role in skin autoimmune diseases such as psoriasis and dermatitis. Pustular 
psoriasis may arise from DITRA (deficiency in the IL-36 receptor antagonist), a 
deficiency in IL-1F5 (242). A murine model of this disease is characterized by massive 
immune cell infiltrate into skin lesions of IL-1F5-deficient mice. This infiltrate consists of 
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CD45+ lymphocytes, neutrophils, and macrophages that are recruited into the diseased 
skin in an IL-36R-dependent manner (229). Mutations in IL-1F5 have also been 
observed in patients presenting with acute generalized exanthematous pustulosis 
(AGEP), a drug-induced side effect that presents with skin lesions containing robust 
lymphocytic infiltrates (243,244). It has been hypothesized that individuals with loss-of-
function mutations in IL-1F5 are more likely to develop lesional skin diseases. Similar 
immune infiltrates have been observed in patients presenting with pustular psoriasis, 
although in this disease setting, the dominant driver of pathogenesis appears to be 
locoregional overexpression of IL-36R agonist cytokines that leads to increased 
activation of MAPK and NFκB signaling in lesional skin (245). Supporting this, several 
studies evaluating human and murine models of psoriasis have observed 
overexpression of the IL-36 cytokines in diseased skin and reported that disease that is 
exacerbated in the absence of IL-1F5 expression (215,246). 
IL-36 signaling has more recently been reported to play opposing roles in the gut 
pathogeneses colitis and Crohn’s disease (215,235,247). In patients with Crohn’s 
disease, expression of IL-36α, IL-36γ, and IL-38 were positively correlated with each 
other, and in the cohort evaluated, 7/16 patients appeared to have elevated levels of IL-
36γ in affected bowel tissue (215). IL-36γ also appears to inhibit the development of 
peripheral CD4+ T regulatory cells in the gut, instead promoting Th9 cell expansion and 
subsequent colitis pathogenesis (235). In a murine model of dextran sodium sulfate 
(DSS)-induced colitis, one study indicated that signaling through the IL-36R was 
necessary for the resolution of intestinal damage, in a mechanism that appears to be 
dependent upon neutrophil recruitment to the site of damage to clear commensal 
bacteria (247); another showed that mice deficient in the IL-36R presented with less 
severe disease progression, including less weight loss, a lower disease activity index, 
and maintenance of normal colon pathology (218). While in both studies results 
indicated that IL-36R signaling was required for the infiltration of immune cells, including 
neutrophils, into the diseased tissue, in the latter study, this infiltrate was associated 
with inflammation and disease progression. Increased expression of IL36A and IL36G 
was also observed in the colon 6D following the onset of disease. In an investigation of 
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pediatric inflammatory bowel disease, however, no difference was observed in IL36G 
expression between normal mucosa, patients with ulcerative colitis, and patients with 
Crohn’s disease (IL36A expression was significantly increased; ref. (218)). Therefore, in 
the gut, it appears as though IL-36 signaling can play opposing roles depending on the 
particular cells involved in the etiology of each disease state. 
The role of IL-36R agonists in the pathogenesis of arthritis also remains contentious. 
Clinical reports suggest that patients with psoriatic arthritis and rheumatoid arthritis 
express elevated levels of IL-36α in their synovial lining when compared to patients with 
osteoarthritis, with IL-36α expression correlated with increased production of IL-6 and 
IL-8 in the affected joints (248). Expression of both the IL-36R and IL-36α is increased 
in the human TNF transgenic mouse model of inflammatory arthritis (hTNFtg), 
concurrent with lymphocytic infiltration into the joints; however, blockade of signaling 
through the IL-36 receptor using an antagonist antibody did not relieve inflammation 
(249). A similar result was observed in a collagen-induced arthritis (CIA) model (216). 
Thus, in arthritis, IL-36 is likely a contributing factor in disease pathogenesis, but not 
necessarily a dominant driver as it is in skin autoimmune conditions. 
Notably, IL-36 is a downstream target of Tbet (197), with a positive-feedback loop 
allowing for IL-36 to induce secondary transcription of Tbet as well (220). In human 
myeloid cells, silencing of Tbet by siRNA decreased expression of IL-36γ, and 
expression of IL-36γ by DC was also dependent upon IL-18/IL-18R signaling via MAPK- 
and NFκB-dependent pathways. Specifically, the promoter region of IL-36γ contains 
both Tbet and NFκB binding sites, with IL-18 signaling inducing Tbet binding to the IL-
36γ promoter (197). Tbet is also expressed in both human and murine DC, where it has 
been shown to be critical to DC1 functional polarization and the ability of these APC to 
activate Type-1 T cell responses in vivo (4). Interestingly, DC.Tbet generated from 
CCR7-/- hosts appeared most effective in preventing tumor growth, strongly suggesting 
that their preferred biology was manifest in the TME and not the TDLN (28). Indeed, the 
anti-tumor efficacy of i.t.-delivered DC.Tbet appears critically dependent upon TIL 
recruitment, activation, expansion and differentiation within the TME. In this context, IL-
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36 has been shown to bolster T cell proliferation and cytokine secretion, including 
secretion of IFNγ (220). Furthermore, CCL1 and CXCL10- chemokines observed to be 
upregulated by DC.Tbet cells- are known to be upregulated by wild-type DC after 
stimulation with IL-36R agonists (220). Thus we believe that IL-36 is a key early 
mediator of TLS development in inflamed tissues and that purposeful instigation of IL-36 
delivery or production in the TME (via administration of DC.Tbet or an equivalent 
modality) will have the potential to evolve both humoral and cellular immunity that is 
protective and/or therapeutic to the cancer-bearing host.  
Consistent with the observation that overexpression of IL-36 in tissues correlates with 
increased immune cell infiltration, results from our laboratory suggest that IL-36γ plays a 
role in the induction of chemokines that can rapidly recruit T and B cells into the 
inflammatory microenvironment of therapeutically-managed tumors. In contrast to 
concerns for pathologic autoimmunity resulting from such immune infiltrates in psoriasis, 
arthritis, and inflammatory bowel models, this is a highly-preferred biologic outcome in 
the context of cancer. We are currently evaluating the ability of IL-36γ to drive Type 1 
anti-tumor immune responses and TLS formation in vivo, when used as a single agent 
or in the context of combination immunotherapies. 
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2.0. TBET AND IL-36γ COOPERATE IN THERAPEUTIC DC-MEDIATED 
PROMOTION OF ECTOPIC LYMPHOID ORGANOGENESIS IN THE TME
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2.1 ABSTRACT 
 
We have previously reported that direct injection of DCs engineered to express the 
Type-1 transactivator Tbet (i.e. DC.Tbet) into murine tumors results in anti-tumor 
efficacy in association with the development of structures resembling tertiary lymphoid 
structures (TLS) in the TME (TME). These TLS contained robust infiltrates of B cells, 
DC, NK cells and T cells in proximity to PNAd+ blood vessels; however, they were 
considered incomplete, since the recruited B cells failed to organize into classic 
germinal center-like structures. We now report that anti-tumor efficacy and TLS-inducing 
capacity of DC.Tbet-based i.t. therapy is operational in peripheral lymph node-deficient 
LTA-/- mice, and that it is highly dependent upon a direct Tbet target gene product, IL-
36γ/IL-1F9. Intratumoral DC.Tbet fail to provide protection to tumor-bearing IL-36R-/- 
hosts, or to tumor-bearing wild-type recipient mice co-administered rmIL-1F5/IL-36RN, a 
natural IL-36R antagonist. Remarkably, the injection of tumors with DC engineered to 
secrete a bioactive form of mIL-36γ (DC.IL-36γ) also initiated therapeutic TLS and 
slowed tumor progression in vivo. Furthermore, DC.IL-36γ cells strongly upregulated 
their expression of Tbet, suggesting that Tbet and IL-36γ cooperate to reinforce each 
other’s expression in DC, rendering them competent to promote TLS formation in an 
“immunologically normalized”, therapeutic TME. 
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2.2 INTRODUCTION 
 
Preferred clinical endpoints for cancer immunotherapies include the activation and 
recruitment of Type-1 T effector cells into tumors, the sustained (poly)functionality of 
these T cell populations, and the coordinate reduction of operational antagonism 
mediated by regulatory cells (Treg and MDSC) and tumor cells in the 
immunosuppressive TME (TME) (250–255). Anti-tumor T cell (cross)priming is 
conventionally believed to occur in tumor-draining secondary lymph nodes (256–258); 
however, recent findings suggest that the induction of T effector cells from naïve 
precursors can occur in and around tumor lesions in vivo, within so-called TLS 
(36,45,48,53,183). The presence of TLS in a broad range of cancer types has been 
reported to represent a harbinger of improved clinical prognosis (e.g. extended OS, 
PFS, RFS), in association with the presence of robust populations of TIL 
(15,16,36,45,48,183,259,260). 
In contrast to tissue-draining SLO, TLS are not encapsulated and can be found 
embedded within almost any non-lymphoid tissue (261), typically under conditions of 
persistent inflammation, as seen in the settings of chronic infectious disease, 
autoimmunity, transplantation and cancer (261–264). A canonical feature of TLS is the 
presence of PNAd+ high-endothelial venules (HEV) (76,261), specialized vascular 
structures that allow for the preferential adhesion and recruitment of CD62L(L-selectin)+ 
naïve and central memory T cells and DCs into peripheral lymphoid sites (76,265). 
Notably, in a study of 225 primary melanomas, Martinet and colleagues reported that 
the density of HEVs correlated positively with the degree of tumor infiltration by naïve 
and Type-1-polarized T cells, as well as, DC-LAMP+ mature DC (18), with these 
recruited immune cell populations found to loosely cluster around HEV (179). 
Furthermore, B cells infiltrating primary melanomas were not organized into formal 
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germinal centers (GC) as is typical of SLO, suggesting a state of “incomplete” lymphoid 
organogenesis in the observed TLS (179). 
We have previously reported that DC engineered to express the Type-1 transactivator 
protein Tbet/TBX21 (i.e. DC.Tbet) exhibit Type-1 functional polarization (266), and that 
when delivered directly into tumor lesions in mice, these biologic products promote rapid 
(within hours) infiltration by lymphocytes and NK cells, and the development of TLS 
within days (28,36). We now show that the abilities of i.t.-delivered DC.Tbet to slow 
tumor growth and to promote TLS within the TME are highly IL-36γ-dependent, as this 
therapy fails to achieve either endpoint when applied in wild-type hosts that are co-
administered IL-36R antagonist IL-1F5 or when applied to tumor-bearing IL-36R-/- 
recipient mice. 
IL-36γ (aka IL-1F9) is a recently identified member of the IL-1 family that we now report 
to be profoundly upregulated in DC after infection with rAd.Tbet (but not control Ad), 
presumably due to the direct transcriptional action of Tbet on the IL-36γ promoter (197). 
Interestingly, we noted that DC engineered to express a secreted, bioactive form of mIL-
36γ (i.e. DC.IL-36γ) upregulate their expression of Tbet, suggesting a positive feedback 
loop formed between Tbet and IL-36γ. Like DC.Tbet, when delivered into the 
established TME, DC.IL-36γ also promoted the rapid development of TLS and slowed 
tumor growth. These results support the utility of Tbet- and IL-36γ-based therapeutics in 
the cancer setting and may provide clues for the roles of IL-36R agonist cytokines (i.e. 
IL-36α, IL-36β and IL-36γ) in disease-associated TLS formation in alternate chronic 
inflammatory states, such as autoimmune arthritis, diabetes and psoriasis 
(263,264,267,268), among others. 
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2.3 RESULTS 
 
2.3.1 DC.Tbet overexpress pro-inflammatory gene products, including IL-36γ. 
 
Day 5 cultured, bone-marrow derived DC from C57BL/6 mice were infected with 
rAd.mTbet to generate DC.Tbet. To investigate the effect of Tbet overexpression in DC, 
molecular profiling of DC.Tbet versus control DC.null was performed, leading to the 
identification of a range of differentially-expressed gene transcripts, including a number 
of pro-inflammatory cytokines and chemokines (Figure 2.1A). Notably, IL-36γ and IL-
12p40 were two of the most overexpressed gene transcripts in DC.Tbet when compared 
to control DC in both mice and humans (Figs. 2.1A, S2.1), whereas other transcripts 
such as CXCL9 and IL-1β were not consistently elevated in DC.Tbet in an 
evolutionarily-conserved manner (thus limiting their likely translational relevance). Both 
Tbet and IL-36γ protein expression could be detected in murine DC.Tbet by IFM (Figure 
2.1B), and DC.Tbet secreted higher levels of mIL-12p70 (Figure 2.1C) and mIL-36γ 
(Figure 2.1D) than control engineered DC. We then confirmed that injection of DC.Tbet 
cells into established s.c. MCA205 sarcomas on days 7 and 14 post-tumor inoculation 
resulted in slowed tumor growth when compared to i.t. therapy using PBS or control 
DC.ψ5 cells (Figure 2.1E). 
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Figure 2.1. Characterization of therapeutic DC.Tbet. 
Bone marrow-derived DC were generated in GMCSF + IL-4 cultures for 5-6 days, 
before being infected for 48h with rAd.mTbet or control rAd.EGFP or empty rAd.ψ5, or 
they were left untransduced, as indicated. In A, DC were treated, as indicated, with the 
addition of LPS + IFNγ for the second 24h of infection. Affymetrix gene array analyses 
were performed on DC.Tbet (A), with transcripts increased >5-fold compared to control 
DC reported. DC.Tbet generated from Tbet-ZsG (H-2b) reporter mice were then 
analyzed by IFM for intracellular expression of the Tbet reporter (green) and IL-
36γ (red), with DAPI staining of nuclei (B). DC.Tbet or control DC were cultured at 4 x 
105 cells/mL. After 48h of infection, supernatant was harvested and mIL-12p70 (C) or 
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mIL-36γ (D) production was analyzed by ELISA. **p < 0.05 for DC.Tbet versus control 
DC (t-test). In E, DC.Tbet, control DC.ψ5, or PBS were then injected intratumorally into 
mice bearing d7 established s.c. MCA205 sarcomas on days 7 and 14 post-tumor 
inoculation. Tumor size was measured over time. **p < 0.05 for DC.Tbet versus PBS or 
control DC.ψ5 treatment on days > 11 (ANOVA). Data are representative of those 
obtained in 2 independent experiments performed in each case. 
 
 
2.3.2 i.t. delivery of DC.Tbet results in rapid infiltration of lymphocytes and 
development of TLS in vivo. 
 
To investigate the longitudinal cellular and molecular changes occurring within the 
therapeutic TME, MCA205 sarcomas were harvested from tumor-bearing wild-type 
C57BL/6 mice or syngenic (H-2b) Tbet-ZsG reporter mice at various time points after i.t. 
delivery of DC.Tbet cells. Immunofluorescence microscopy analyses revealed early (by 
4-10h post-treatment) infiltration of treated tumors by T cells (both CD4+ and CD8+) that 
continued to increase in their abundance through 24h post-treatment (Figure 2.2A). 
Many of these TILs appeared to exhibit Type-1 functional polarization, based on their 
expression of the Tbet reporter in Tbet-ZsG recipient models (Figure 2.2A). In stark 
contrast, B cells (identified by their CD19+ or B220+ phenotypes) though present in the 
TME by 5 days following treatment with DC.Tbet, did not contribute significantly to TIL 
composition early or late (Figure 2.2A-C). Interestingly, although not evident at 4-24 
hours post-i.t. injection of DC.Tbet, PNAd+ vessels became readily detectable in 
MCA205 tumors beginning on day 5 after treatment and persisted until at least 5 days 
following the second treatment with DC.Tbet (i.e. d12 after first injection of DC.Tbet; 
Figure 2.2B, 2.2C). Immunofluorescence imaging also revealed strong local production 
of IL-36γ in MCA205 tumors beginning at 4h after i.t.-based DC.Tbet therapy, with 
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sustained intratumoral IL-36γ observed through 5 days following the second treatment 
with DC.Tbet (Figure 2.2D, 2.2E). Since PNAd+ HEV in peripheral tissues have been 
linked to the formation of TLS in chronically-inflamed tissues (171,257,261,262), we 
next analyzed whether injected DC.Tbet and/or the therapeutic TME expressed a 
transcript profile consistent with TLS formation. We observed that DC.Tbet at the time of 
injection into mice expressed higher levels of mRNA encoding CCL19, CCL21, LIGHT 
and LTA (but not CXCL13), when compared to control DC.ψ5 (Figure S2.2A). Notably, 
we found that each of these transcripts was differentially upregulated in the TME within 
4-10 days of DC.Tbet vs. control DC.ψ5 injection (Figure S2.2B), at least 
circumstantially implicating the involvement of additional DC.Tbet-conditioned tumor 
stromal cells (or tumor cells themselves) as principal pro-TLS transcript sources over 
time in vivo. 
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Figure 2.2. DC.Tbet injected i.t. promote the rapid infiltration of lymphocytes and the 
development of PNAd+ blood vessels in association with enhanced locoregional 
induction of IL-36γ. 
MCA205 tumor-bearing wild-type C57BL/6 mice or Tbet-ZsG reporter mice were 
treated by i.t. delivery of 1 x 106 DC.Tbet or DC.ψ5 7 days post-tumor inoculation. In A, 
tumors were harvested from Tbet-ZsG mice at 4h, 10h or 24h after treatment with 
DC.Tbet and tissue sections analyzed by IFM for CD4+ T cells, CD8+ T cells, CD19+ B 
cells, and PNAd+ HEV. In B and C, expression and localization of peripheral node 
addressin (PNAd), CD11c+ DC, CD3+ T cells, and B220+ B cells were analyzed in 
tumor sections 
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from Tbet reporter mice on days 5 (B) and 12 (C) post-treatment with DC.Tbet. In D, 
day 5 (post-DC.Tbet treatment) tumor sections from Tbet-ZsG mice were analyzed by 
IFM for co-expression of the Tbet reporter (green) and IL-36γ (red, using a specific 
polyclonal antibody). In E, IL-36γ protein levels were assayed by quantification of 
fluorescence from IFM, or transcript levels were assayed by real-time PCR in total 
tumor RNA isolated from wild-type C57BL6/J hosts, at the indicated time points 
following DC.Tbet or DC.ψ5 treatment. Data are representative of those obtained in 2-3 
independent experiments performed in each case. 
2.3.3 Therapeutic anti-tumor efficacy of i.t. DC.Tbet is not dependent on host LTA. 
Given evidence for the development of TLS in the TME of DC.Tbet-treated C57BL/6 
wild-type mice, we next examined whether SLO were necessary for the observed 
therapy benefits of this treatment strategy. MCA205 sarcomas were established in 
peripheral lymph node-deficient LTA-/- mice (269), and treated with i.t. delivered 
DC.Tbet or control DC.ψ5 as outlined in Figure 2.1D. We noted that the treatment of
MCA205 sarcomas with DC.Tbet was comparably efficacious in both LTA-/- and
C57BL/6 wild-type host animals (Figure 2.3A). Furthermore, based on the results of
repeat experiments involving the co-administration of depleting anti-CD4 or anti-CD8
antibodies, we conclude that therapeutic protection mediated by DC.Tbet in LTA-/- mice
is both CD4+ T cell- and CD8+ T cell-dependent (Figure 2.3B).
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Figure 2.3. I.t.-delivered DC.Tbet mediates anti-tumor efficacy in secondary lymph 
node-deficient LTA-/- mice that is both CD4+ and CD8+ T cell-dependent. 
In A, lymphotoxin-α (LTA)-/- mice bearing established day 7 MCA205 sarcomas were left 
untreated, or they were treated (D) on days 7 and 14 by i.t. injection of 106 DC.Tbet or 
control DC.ψ5 cells alone, with tumor size (mean +/- SD from 5 mice/group) then 
monitored over time. In B, this same model was left untreated, or treated on days 7 and 
14 with DC.ψ5 or DC.Tbet cells (+/- systemic i.p. administration of depleting anti-CD4 or 
anti-CD8 mAbs) and time-to-euthanasia (as an index of overall survival) reported over 
time. **p < 0.05 for DC.Tbet versus all other cohorts (ANOVA). Data are representative 
of those obtained in 2 independent experiments performed. 
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2.3.4 Ablation of IL-36R signaling abrogates the therapeutic anti-tumor efficacy of 
i.t. DC.Tbet. 
 
Although mouse and human DC.Tbet produce high levels of IL-36γ and IL-12 transcripts 
and protein (Figures 2.1 and S2.1), our previous work demonstrated that the 
therapeutic benefits of such treatments were maintained even if the injected DC.Tbet 
were generated from syngenic IL-12p35-/- or IL-12p40-/- mice (28). Subsequent 
mechanistic analyses were therefore focused on the study of DC.Tbet-associated IL-36γ 
and its receptor IL-36R. To determine whether the therapeutic benefits of i.t.-delivered 
DC.Tbet were IL-36R-dependent, wild-type C57BL/6 mice were treated on days 7 and 
14 after s.c. injection of MCA205 sarcomas, in the absence or presence of (i.t.) co-
delivered rmIL-1F5 (aka IL-36RA or IL-36RN), a natural IL-36R antagonist (192,211). As 
depicted in Figure 2.4, we observed that rmIL-1F5 co-delivery effectively blocked the 
ability of i.t. DC.Tbet to slow tumor growth (Figure 2.4A), to sponsor the development of 
PNAd+ HEV in the TME (Figure 2.4B), or to recruit/retain CD4+ and CD8+ TIL (Figure 
2.4C). 
To further confirm the importance of IL-36R on host (tumor stromal/immune) cells to the 
anti-tumor efficacy of i.t.-delivered DC.Tbet in an alternate tumor model, we established 
s.c. MC38 colon carcinomas in syngenic (H-2b) C57BL/6 wild-type or IL-36R-/- mice, 
before treating them i.t. on days 7 and 14 with DC.Tbet/EGFP or control DC.EGFP (i.e. 
rAd.EGFP was used to engineer both DC cohorts to mark these injected cells for 
subsequent tissue imaging studies). As shown in Figure 2.5A, consistent with data 
obtained in the MCA205 sarcoma model, treatment of established MC38 tumors with 
DC.Tbet/EGFP but not DC.EGFP resulted in significant slowing in tumor growth. Also 
consistent with data obtained in the MCA205 model, we noted that transcripts 
associated with PNAd+ HEV/TLS development and immune cell trafficking (particularly 
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LTA and CCL21) were increased in the TME of MC38-bearing mice treated i.t. with 
DC.Tbet/EGFP vs. control DC/EGFP (Figure S2.3). Although data from MCA205 
models in LTA-/- recipient animals argued against a major role for host LTA in the 
therapeutic efficacy of i.t.-delivered DC.Tbet (Figure 2.3), to determine the broader 
role(s) of LTβR agonist cytokines (from either the injected DC.Tbet cells or the host 
TME) on the anti-tumor action of DC.Tbet, we established s.c. MC38 tumors in C57BL/6 
mice, before treating them i.t. on days 7 and 14 with LTβR-Ig or an isotype control 
antibody in concert with control DC.EGFP or DC.Tbet/EGFP. As shown in Figure 2.5B, 
MC38 tumors in mice co-treated with LTβR-Ig and DC.Tbet/EGFP exhibited similar 
rates of slowed progression (through day 18 of the experiment) when compared to mice 
treated with DC.Tbet/EGFP plus an isotype control antibody. These data suggest that 
LTβR agonists do not play a pivotal role in DC.Tbet-associated anti-tumor efficacy.  
As was the case in our MCA205 tumor models, i.t. injections of DC.Tbet into established 
s.c. MC38 tumors in C57BL/6 mice led to the development of PNAd+ HEV surrounded 
by CD3+ T cell and CD11c+ DC infiltrates within 5 days of initiating treatment with 
DC.Tbet/EGFP, but not control DC.EGFP (Figure 2.5C). We also confirmed that the 
therapeutic benefit and TLS formation associated with i.t. delivery of DC.Tbet/EGFP into 
MC38 tumors was negated in IL-36R-/- recipient mice (Figure 2.5D, 2.5E), whereas TLS 
were readily apparent in H&E stains of DC.Tbet/EGFP-treated tumors in wild-type 
C57BL/6 recipient animals (Figure 2.5E). In MC38-bearing C57BL/6 wild-type hosts, 
TLS persisted within the TME for at least 6 days following the second injection of 
DC.Tbet/EGFP (Figure 2.5F), and these TLS contained injected EGFP+ DC located 
proximal to PNAd+ vessels (Figure 2.5G). Prior reports in the field have documented 
the proximity of lymphocytes to PNAd+ HEV in SLO and, critically, identified a role for 
PNAd in maintaining lymphocyte proximity to HEV (167). Consistent with previous 
observations for approximately 30-40% of lymphocytes residing within 20 µm of an HEV 
in SLO, we observed a similar distribution pattern in tumor-associated TLS after i.t. 
treatment with DC.Tbet/EGFP cells (Figure S2.4A-E). Specifically, we noted that 
31.99% of CD3+ T cells, 48.46% of B220+ B cells and 21.65% of CD11c+ DC within the 
TME treated with DC.Tbet were located within 20 µm of a PNAd+ vessel (Figure S2.4F). 
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However, as we also discerned in the MCA205 model, B cells in this therapeutic TME 
failed to organize into formal germinal-center like structures (Figure S2.4A). Tumors 
treated with DC.Tbet/EGFP also contained a higher frequency of CD3+ T cells versus 
tumors treated with control DC.EGFP (Figure S2.5A), with increased numbers of Tbet+ 
T cells within the TME after i.t. delivery of DC.Tbet/EGFP (Figure S2.5B). Interestingly, 
CD3+ TIL in DC.Tbet/EGFP-treated tumors contained a lower abundance of 
exhausted/anergic T cells as suggested by their decreased expression profiles for the 
PD-1, CTLA4 and TIM-3 checkpoint molecules, versus CD3+ TIL isolated from control 
treated mice (Figure S2.5C). 
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Figure 2.4. The anti-tumor efficacy and TLS promoting activity associated with i.t. 
DC.Tbet-based therapy is ablated by the IL-36R antagonist IL-1F5 in vivo. 
WT C57BL6/J mice bearing established day 7 MCA205 sarcomas were left untreated, 
or they were treated on days 7 and 14 by i.t. injection of 106 DC.Tbet or DC.ψ5 alone or 
with DC.Tbet plus co-injection (i.t.) of rmIL-1F5 (0.1 µg or 1 µg in 50 µl PBS) followed by 
(i.t.) injections of the respective doses of IL-1F5 alone in 50 µL PBS on days 8, 9, 15, 
and 16, with tumor growth (A) monitored over time (n = 5 mice/group). **p < 0.05 for 
DC.Tbet vs. all other cohorts (ANOVA) on days > 17. In B and C, tumors were 
harvested from the indicated treatment cohorts on day 25 post-tumor inoculation (i.e. 9 
days following the final injection of rmIL-1F5) and analyzed by IFM for the presence of 
PNAd+ vessels (B) and CD4+ T cells and CD8+ T cells (C). Data are representative of 3 
independent assays performed in each case. 
 
 
 71 
 
 
Figure 2.5. The anti-tumor efficacy and TLS promoting activity associated with i.t. 
DC.Tbet-based therapy is absent in the IL-36R-/- recipient mice. 
105 MC38 colon carcinoma cells were injected into the flanks of syngenic wild-type 
C57BL/6 (A) mice and allowed to establish. Tumor-bearing mice were randomized into 
groups of 5 animals/cohort on day 7 post-implantation, with all cohorts exhibiting 
comparable mean tumor size. These animals were then left untreated, or were treated 
on days 7 and 14 by i.t. injection of 106 control DC.EGFP or DC.Tbet/EGFP, with tumor 
growth subsequently monitored over time (n = 5 mice/group). **p < 0.05 for DC.Tbet vs. 
all other cohorts on days > 13 for C57BL/6 recipients. In B, the experiment from A was 
repeated, with the addition of co-treatment cohorts including LTβR-Ig (100 µg) or an 
isotype control antibody (100 µg), injected i.t. 3 hours prior to each injection of DC.Tbet. 
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*p < 0.05 for DC.Tbet + Iso-Ig vs. DC.EGFP on days > 11; **p < 0.05 for DC.Tbet + 
LTβR-Ig vs. DC.EGFP on days 11-18 (NS on day 20); ***p < 0.05 for DC.Tbet + Iso-Ig 
vs. DC.Tbet + LTβR-Ig on day 20. In C, tumors harvested 5 days following with 
DC.Tbet/EGFP or control DC.EGFP were cryosectioned and analyzed by IFM for the 
presence of PNAd+ HEV, CD3+ T cells, and CD11c+ DC (C). In D, 105 MC38 colon 
carcinoma cells were injected into the flanks of syngenic IL-36R-/- and allowed to 
establish and were treated as described in A. p = NS for DC.Tbet vs. control cohorts in 
IL-36R-/- mice at all time points (ANOVA). In E, day 18-21 tumors harvested from the 
indicated treatment cohorts were cryosectioned and then H&E stained as described in 
Materials and Methods. Robust TIL populations (C, E) were observed in cortical regions 
of MC38 tumors, only in DC.Tbet-treated C57BL/6 hosts. In F and G, DC.Tbet/EGFP-
treated tumors were harvested from wild-type C57BL6/J hosts at day 20 and analyzed 
by IFM for the presence of PNAd+ HEV, CD3+ T cells, and CD11c+ DC (F) or PNAd+ 
HEV, CD3+ T cells, and DC.Tbet/EGFP (G). Data are representative of those obtained 
in 3 independent experiments performed in each case. 
 
 
2.3.5 DC engineered to secrete bioactive rmIL-36γ (DC.IL-36γ) recapitulate the 
effects of i.t. DC.Tbet treatment in vivo. 
 
We next asked whether ectopic IL-36γ production by DC would allow these cells to 
phenocopy DC.Tbet in their ability to effectively treat established tumors after i.t. 
injection, in association with the promotion of “non-classical” TLS within the TME. We 
first designed and produced a recombinant adenoviral vector encoding a fusion protein 
consisting of the human CD8 signal sequence followed by a full agonist form of mIL-36γ 
chain (i.e. amino acid positions G13-S164 found in the processed, bioactive form of this 
cytokine) (192). This vector was then used to generate and characterize DC.IL-36γ 
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(Figure 2.6), before subsequently applying them as an i.t.-delivered cellular therapy 
(Figure 2.7). 
Predictably, DC.IL-36γ displayed a robust increase in mIL-36γ mRNA transcript (Figure 
2.6A) and protein (Figure 2.6B) levels when compared with control DC. Molecular 
profiling of DC.IL-36γ versus control DC was performed, leading to the identification of a 
panel of upregulated chemokines and cytokines (Figure 2.6C). Consistent with data 
from DC.Tbet cells, DC.IL-36γ at the time of injection expressed elevated levels of 
CCL21 and LTA, as well as LIGHT (Figure S2.6). Remarkably, DC.IL-36γ strongly 
upregulated their expression of Tbet when compared to control DC, although this level 
of elevated transcription (Figure 2.6D) and protein production (Figure 2.6E) did not 
quite reach that observed in DC.Tbet. IL-36γ was secreted from DC.IL-36γ (and 
DC.Tbet) but not control DC (Figure 2.6F), and the IL-36γ secreted by DC.IL-36γ was 
bioactive based on its ability to upregulate Tbet reporter expression in splenic T cells 
isolated from Tbet-ZsG mice (Figure 2.6G). When visualized by IFM, DC.IL-36γ cells 
were determined to co-express Tbet and IL-36γ (Figure 2.6H).  
We subsequently determined that i.t. delivery of DC.IL-36γ slows MC38 tumor growth in 
C57BL/6 wild-type hosts (Figure 2.7A) and promotes the development of TLS with 
MC38 tumors (Figure 2.7B) to a degree similar to that observed for DC.Tbet-based 
therapy (Figure 2.5). Euclidean distance analyses of fluorescence microscopy images 
revealed that 39.62% of CD3+ TIL, 60.09% of B220+ B cells and 37.32% of CD11c+ DC 
were located within 20 µm of PNAd+ vessels within the TME of animals treated with 
DC.IL-36γ (Figure S2.7). Transcripts associated with TLS formation, including LTA, 
LIGHT, CCL19, CCL21, and CXCL13, were coordinately upregulated within 1-5 days 
following DC.IL-36γ treatment. As expected, DC.IL-36γ-based therapy was ineffective in 
limiting tumor progression or in facilitating TLS formation in MC38 tumors established in 
IL-36R-/- recipient animals (Figure 2.7C, 2.7D). Given the coordinate upregulation of 
Tbet transcription and protein production in DC.IL-36γ (Figure 2.6D, 2.6E), we next 
analyzed whether DC.IL-36γ developed from Tbet-/- bone marrow remained effective as 
an anti-tumor agent in wild-type recipients. As shown in Figure 2.7E, DC.IL-36γ/EGFP 
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developed from wild-type or Tbet-/- bone marrow were equally efficacious as a therapy 
versus DC.EGFP when injected directly into MC38 tumors. Thus, DC expressing 
ectopic IL-36γ do not require intrinsic Tbet expression to mediate anti-MC38 benefit 
after i.t. delivery. 
 
 
 
 
Figure 2.6. DC.IL-36γ produce/secrete bioactive IL-36γ and upregulate intrinsic 
transcription of Tbet. 
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Real-time PCR (A) and Western blot analysis (B) for IL-36γ were performed on lysates 
of DC.IL-36γ/EGFP versus control DC.null or DC.EGFP to confirm transduction efficacy. 
In C, Affymetrix gene array analyses were performed as outlined in Materials and 
Methods, with transcripts increased >5-fold compared in DC.IL-36γ versus control 
DC.null reported. In D and E, real-time PCR (D) and Western blot analysis (E) for Tbet 
were performed on lysates of DC.IL-36γ/EGFP and/or DC.Tbet/EGFP and/or control 
DC.EGFP and/or control DC.null. In A and D, mean + SD data are reported; **p < 0.05 
(t-test). In F, DC were differentiated for 5 days in vitro, with CD11c+ cells then isolated 
and either transduced with rAd to express EGFP, mTbet, and/or mIL-36γ, or 
untransfected control DC were treated for 24h with the indicated TLR agonists or 
agonist anti-CD40 (FGK45) antibody. Cell-free supernatants were then analyzed by 
mIL-36γ ELISA. *p<0.05 for DC.Tbet and DC.IL-36γ vs. all other treatment groups 
(ANOVA). In G, cell-free supernatants were recovered from engineered DC and 
analyzed for bioactivity by addition to cultures of bulk splenocytes isolated from Tbet 
(ZsG) reporter mice; i.e. 106 splenocytes were cultured in 200 µL of basal media 
(negative control), media containing LPS + IFNγ (positive control) or cell-free media 
harvested from DC.null or DC.IL-36γ cells 48h after rAd infection. After overnight 
culture, splenocytes were analyzed by flow cytometry for upregulation of intracellular 
Tbet reporter expression. In H, DC.IL-36γ cells were analyzed by IFM as described in 
Figure 1B to detect coordinate expression of Tbet and IL-36γ protein. All data are 
representative of those obtained in 2-3 independent experiments performed in each 
case. 
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Figure 2.7. I.t. delivery of DC.IL-36γ is therapeutic and promotes TLS in wild-type, but 
not in IL-36R-/-hosts. 
105 MC38 colon carcinoma cells were established s.c. in the flanks of syngenic wild-
type C57BL/6 (A) mice. After randomization of the tumor-bearing animals on day 7 to 
cohorts (5 mice/group) exhibiting comparable mean tumor sizes, mice were treated by 
i.t. injection with 106 control DC.EGFP or DC.IL-36γ/EGFP on days 7 and 14, and tumor 
growth monitored over time. **p < 0.05 for DC.IL-36γ/EGFP vs. DC.EGFP on days > 11 
(ANOVA). After euthanasia on day 20 post-tumor inoculation, tumors were 
cryosectioned and analyzed by IFM for the presence of TLS based on the presence of 
PNAd+ HEV surrounded by CD3+ T cells, CD11c+ DC, and DC.IL-36γ/EGFP in the 
tumor cortex (B). In C, the experiment performed in A was repeated in IL-36R-/- host 
 77 
animals. NS for DC.IL-36γ/EGFP versus DC.EGFP at all time points (ANOVA). In D, 
MC38 tumor sections harvested on d18 (IL-36R-/- hosts) or d20 (WT C56BL/6J hosts) 
post-treatment with DC.IL-36γ/EGFP or control DC.EGFP were then H&E stained to 
identify TIL in the cortical regions of the tumors. In E, BMDC generated from wild-type 
or Tbet-/- mice were infected with control rAd.EGFP or rAd.mIL36γ/EGFP and injected 
i.t. into established MC38 tumors in wild-type C57BL/6 mice on days 7 and 14 and 
tumor growth (mean +/- SEM in mm2) was monitored over time. **p < 0.05 for WT or 
Tbet-/- DC.IL-36γ/EGFP vs. DC.EGFP on days >11; NS for WT versus Tbet-/- DC.IL-
36γ/EGFP at all time points (ANOVA). Data are representative of those obtained in 2-3 
independent experiments performed in each case. 
 
 
 
2.4 DISCUSSION 
 
A major novel finding in our report is that the therapeutic benefits of i.t. delivered 
DC.Tbet therapy are tied to the ability of these gene-modified cells to promote TLS 
formation in the cortical region of progressive tumors via a process that is strictly 
dependent on IL-36γ, an IL-1 family member cytokine associated with a range of chronic 
inflammatory diseases including psoriasis, arthritis, and diabetes, among others 
(263,264,267,268). Indeed, while development of TLS within tumors and slowed tumor 
growth resulted from the injection of DC.Tbet directly into established MCA205 sarcoma 
or MC38 colon carcinoma lesions in syngenic C57BL/6 mice, these processes failed to 
occur after DC.Tbet treatment of tumors in IL-36R-/- hosts or in wild-type mice that 
received co-injections of the IL-36R antagonist IL-1F5 (aka IL-36Ra/IL-36RN). 
Surprisingly, IL-36γ-dependent TLS formation in the TME did not appear to require 
significant participation by LTβR ligand cytokines based on the results of studies 
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integrating i.t. co-delivery of antagonist LTβR-Ig (Figure 2.5B) or the use of LTA-/- host 
animals (Figure 2.3). In this regard, recent results from Engelhard’s group suggest that 
induction of HEV and early stages of TLS development in i.p. B16.OVA melanomas are 
LTβR-independent, but LTα3/TNFR-dependent (34). Future studies using TNFR1/2-/- 
recipient animals will help in delineating the role of the LTα3/TNFR signaling axis in the 
antitumor efficacy of i.t.-delivered DC.Tbet (or DC.IL-36γ). 
The anti-tumor benefits mediated by i.t. delivery of DC.Tbet were associated with the 
rapid infiltration of tumors (within hours) by Tbet+ CD4+ and CD8+ T cells and by 
locoregional production of cytokines (LTA, LIGHT) and chemokines (CCL19, CCL21 >> 
CXCL13) classically linked to TLS formation (34,45,48,261,262). Tumor-infiltration by B 
cells and the development of PNAd+ HEV in the tumor cortex were subsequently 
observed by 5 days after treatment with DC.Tbet (but not with control DC). Notably, 
though present in the TME, B cells were not observed to coalesce into formal germinal 
centers in treated tumors at any time during the performance of our studies. This result 
is consistent with previous reports of “incomplete”/”non-classical” lymphoid neogenesis 
of TLS detected in primary human melanoma (179) and oral squamous cell carcinoma 
(37). These TLS are instead defined by the presence of PNAd+ HEV and the proximity 
of DC and B/T cells to the therapeutically-induced HEV (Figure S2.4), based on a 
paradigm established for SLO by Tsuboi et al (167). 
The presence of Tregs in TLS has been recently described by Joshi et al. (270), where 
these suppressive cells were observed to localize proximal to DC, B cells, and other T 
cell subsets within these structures. In our studies, Tregs (i.e. CD4+FoxP3+) were 
notably rare events in MC38 tumors, and the frequency of tumor-infiltrating Tregs was 
statistically equivalent in DC.Tbet/EGFP- versus DC.EGFP-treated tumors (Figure 
S2.8A). In striking contrast, we observed that levels of CD11b+Gr1+ MDSC in MC38 
tumors were reduced after i.t. treatment with DC.Tbet/EGFP versus DC.EGFP (Figure 
S2.8B). When taken in the context of our findings for reduced levels of immune 
checkpoint molecules associated with TIL exhaustion/anergy in our treatment models 
(Figure S2.5C), this may support the general capacity of i.t.-delivered DC.Tbet to 
promote TLS in the context of an “immunologically normalized” TME.  
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In “classic” TLS formation, B cell nucleation/GC formation appears to critically depend 
on the action of Tfh cells (261–263,271) and follicular DCs (37). As such, we would 
hypothesize that B cell nucleation/GC formation may fail after treatment with DC.Tbet or 
DC.IL-36γ based on the absence or dysfunction of Tfh and follicular DC within the TME. 
We will evaluate this supposition in prospective studies in each of our tumor models. In 
this same vein, we also previously reported early infiltration of NK cells into the TME of 
DC.Tbet-treated MCA205 tumors (36). We are prospectively evaluating whether any 
deficiency in Tfh cell numbers/function may be related to the recruitment of NK cells that 
have been reported to inhibit Tfh numbers/function (272) or alternatively to the inability 
of DC.Tbet or DC.IL-36γ cells, or an IL-36γ-rich microenvironment, to sponsor the 
differentiation or survival of Tfh cells in TLS induced within the treated TME. 
An additional major finding in our studies reflects the apparent cooperativity of Tbet and 
IL-36γ in therapeutic DC, with ectopic expression of either gene product promoting the 
robust upregulation of the alternate gene product in transfected DC. Hence, in addition 
to the aforementioned transactivation of IL-36γ by Tbet in DC.Tbet (Figure 2.1A and 
(197)), we also observed strong upregulation of Tbet mRNA/protein expression in 
DC.IL-36γ versus control DC (Figs. 2.6C-E). This is suggestive of a positive feed-back 
loop in their molecular regulation, at least in myeloid DC. Like DC.Tbet, DC.IL-36γ were 
capable of mediating potent anti-tumor effects and promoting TLS formation when 
injected directly into established tumors in wild-type C57BL/6 host animals. We also 
observed that the therapeutic anti-tumor benefits of DC.Tbet were lost when applied to 
tumor-bearing IL-36R-/- mice, and that DC.IL-36γ derived from Tbet-/- bone marrow 
remained effective in suppressing the progressive growth of tumors in wild-type 
C57BL/6 mice. These findings support the cooperativity of Tbet and IL-36γ underlying 
the anti-tumor efficacy observed for this DC-based cellular therapy, with IL-36γ being 
down-stream of Tbet in the underlying operational paradigm. 
While our findings suggest the Tbet- and IL-36γ-dependency of therapeutic efficacy 
(TLS formation and slowed tumor growth in vivo) associated with i.t. delivery of DC.Tbet 
or DC.IL-36γ, it remains unclear as to whether DC provide more than a “vessel” to 
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deliver the key Tbet-/IL-36γ-dependent signals into the therapeutic TME. We are 
currently investigating the comparative treatment benefits associated with mTbet and 
mIL-36γ recombinant protein/gene (rAd)-based therapies applied locoregionally in the 
setting of well-established MCA205 and MC38 murine tumor models. It is also both 
practical and pertinent to ask whether in vitro conditioning of DC (in the absence of 
genetic engineering) is capable of yielding IL-36γ-secreting cells that might be 
competent to recapitulate the therapeutic benefits of DC.Tbet or DC.IL-36γ upon 
delivery into the TME. As shown in Figure 2.6F, DC cultured with agonists for TLR3, 
TLR4 and TLR7 (but not TLR2, TLR9 or CD40) were capable of stimulating increased 
secretion of IL-36γ from DC, albeit to far lower levels than those achieved from DC.Tbet 
or DC.IL-36γ. Nevertheless, it will be important that prospective translational modeling 
includes a comparison of DC.Tbet/DC.IL-36γ versus TLR-agonized DC as therapeutic 
agents. Furthermore, it has also been reported that cathelicidin anti-microbial peptides 
including LL-37 (in humans) and CRAMP (in mice) promote robust production of IL-36γ 
by keratinocytes in the skin (198), with both proteins found prevalently in psoriatic 
plaques (273,274). As a consequence, it will be informative to determine whether local 
application of CRAMP to our tumor models begets IL-36/IL-36R-dependent TLS 
development as well as therapeutic benefit. 
Even though DC.Tbet preferentially produce IL-36γ (over alternate IL-36R agonists IL-
36α and IL-36β), an additional remaining question is whether i.t. administration of IL-
36α or IL-36β, or neutralizing antibodies against the natural IL-36R antagonists (i.e. IL-
1F5/IL-36RA/IL-36RN or IL-1F10/IL-38; (193)), which might be used to agonize IL-36R-
dependent signaling in the TME, would prove therapeutic against well-established 
tumors. In our murine gene array analyses of DC.Tbet and DC.IL-36γ (Figs. 2.1A, 
2.6C), IL-36α transcription is upregulated, albeit to a lesser extent than is IL-36γ (8-20 
fold versus 105-316 fold, respectively), supporting the reported co-regulation of these 
two IL-36R agonists (220) and suggesting that administration of IL-36α might lead to 
effects similar to those observed following IL-36γ-based therapy. Interestingly, a meta-
analysis has recently revealed an association between tumor expression of IL-1F5 and 
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poor clinical prognosis in cancer patients (240), and IL-1F5 (and to a lesser extent IL-38) 
appears to be commonly expressed at the protein level in the TME of a broad range of 
cancer histologies (Figure S2.9). Prospective experiments using i.t. delivery of DC.IL-
36α, DC.IL-36β or (positive control) DC.IL-36γ +/- blocking anti-IL1F5 or anti-IL-1F10 
antibodies will attempt to clarify these issues in our murine tumor models. Future 
studies will also elucidate which tumor stromal/immune cell populations respond to IL-
36R agonism in the therapeutically-effective TME. 
Although not critical to the therapeutic benefits observed in our tumor models (28), it is 
also notable that DC.Tbet and DC.IL-36γ secrete high-levels of IL-12p70 (Figs. 2.1C, 
2.6H and (266)), which is known to be induced by IL-36R-mediated signaling (220). IL-
12 has recently been reported to upregulate IL-36R expression on CD8+ T cells and to 
promote the development of improved Type-1 antigen-specific immunity under 
conditions of aerobic glycolysis (240) (a characteristic of the progressor TME) (193), 
providing further support for the reinforcing nature of Tbet- and IL-36γ-associated 
(immune)biologies within the purview of cancer immunotherapy. Tsurutani et al. (240) 
also suggest that IL-2 and costimulation potently upregulate CD8+ T cell expression of 
IL-36R, which could foreshadow the superior anti-tumor activity of combined 
immunotherapies integrating DC.Tbet or DC.IL-36γ with i.) systemic or locoregional 
administration of rIL-2 and/or ii.) costimulatory agonists or immune checkpoint inhibitors 
(i.e. to improve the ratio of co-stimulatory/co-inhibitory signals into anti-tumor effector 
cells) and/or iii.) adoptive T cell or CAR-T cell-based therapy (to promote extended 
Type-1 polarization and functionality of the transferred anti-tumor effector cells). 
In conclusion, our findings support the utility of Tbet- and IL-36γ-driven, IL-36R-
dependent therapies to recondition the TME by fostering the development of non-
classical TLS and an “immunogically normalized” microenvironment (i.e. fewer MDSC, 
lower expression of immune checkpoint molecules on CD3+ TIL) in association with 
delayed tumor growth in both wild-type and peripheral lymph node-deficient hosts. Such 
approaches would be expected to promote improved cross-priming of anti-tumor T 
effector cells within the TME, as well as to condition the TME to preferentially recruit 
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vaccine-primed or ACT T cells into tumor sites when applied in combination protocols. 
The further inclusion of immune checkpoint blockade or regulatory cell 
depletion/antagonists would also be expected to improve the fate of the TLS-sponsored 
anti-tumor T cell repertoire. Such combination regimens are currently being investigated 
in our pre-clinical models, with the intent to inform future clinical trial designs for the 
treatment of patients with solid forms of cancer. 
 
 
 
2.5 MATERIALS AND METHODS 
 
2.5.1 Study design. 
 
The objectives of these studies were to test the hypothesis that early infiltration of 
immune cells into the TME and formation of TLS correlated with delayed tumor 
progression as a consequence of DC.Tbet-based therapy, and to identify downstream 
mediators of these effects. Once IL-36γ was identified as a potential candidate (Figure 
2.1A), we sought to characterize its role in mediating anti-tumor immunity and immune 
cell recruitment to the TME. The sample sizes and endpoints were determined based on 
previously published work (28,36) and Institutional Animal Care and Use Committee 
(IACUC) guidelines. In all in vivo experiments, cohorts of mice were randomized 7 days 
following tumor inoculation. Experiments were replicated as described in individual 
figure legends. All experiments were performed in an unblinded fashion. 
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2.5.2 Mice. 
 
Female 6-8 week old wild-type C57BL/6 (H-2b) mice, as well as, LTA-/- and Tbet/TBX21-
/- mice (all on the B6 background) were purchased from the Jackson Laboratory (Bar 
Harbor, ME). IL-36R-/- and Tbet-ZsGreen (Tbet-ZsG) reporter mice (275) were kindly 
provided under MTAs from AMGEN and Dr. Jinfang Zhu (NIH/NIAID), respectively, from 
stocks maintained at Taconic. All animals were handled under aseptic conditions per an 
IACUC-approved protocol and in accordance with recommendations for the proper care 
and use of laboratory animals. 
 
2.5.3 Tumor cell lines and culture. 
 
The MCA205 sarcoma and MC38 colon carcinoma (H-2b) cell lines were purchased 
from the American Type Culture Collection (ATCC) These cell lines were free of 
Mycoplasma contamination and were maintained in complete medium (CM: RPMI-1640 
media supplemented with 10% heat-inactivated fetal bovine serum, 100 μg/mL 
streptomycin, 100 U/mL penicillin, and 10 mmol/L L-glutamine, all reagents purchased 
from Invitrogen, at 5% CO2 tension in a 37°C humidified incubator.  
 
2.5.4 Recombinant adenoviruses (rAd). 
 
E1/E3-substituted, replication-defective (Ad5-derived) recombinant adenoviruses 
encoding EGFP (rAd.EGFP), murine Tbet (rAd.mTbet), as well as the empty control 
Ad.ψ5 vector, have been described previously (27). To generate the rAd.mIL36γ vector, 
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the nucleotide sequence encoding a fusion protein composed of the hCD8α signal 
peptide fused to the N-terminus of the bioactive mIL-36γ (G13–S164) protein was 
isolated by PCR amplification from the pcDEF3.hCD8/mIL36γ plasmid (223) using 
specific primers (forward: 5’-AAAGTCGACGCCATGGCCTTACCAGTGAC-3’ and 
reverse: 5’-AAAGGATCCTTAAGACTTTATATCTAA-3’), then ligated into the SalI-
BamHI cloning site in the pAdLox shuttle vector (27), yielding pAdlox.mIL36γ. After 
sequence validation of the plasmid, rAd.mIL36γ was generated by co-transfection of 
pAdLox.mIL36γ and ψ5 helper virus DNA into the adenoviral packaging cell line CRE8 
(27). rAd.mIL36γ was purified from specific CRE8 lysates by cesium chloride density-
gradient centrifugation and subsequent dialysis before storage in 3% threalose at -80°C. 
Titers of viral particles were determined by optical densitometry. As needed, rAd vectors 
were further expanded, qualified and supplied by the University of Pittsburgh Cancer 
Institute’s Vector Core Facility (a Shared Resource). 
 
2.5.5 Generation of BM-derived DC and transduction with adenoviral vectors in 
vitro. 
 
DC were generated from the tibias/femurs of mice, and infected with recombinant 
adenovirus as previously described (27) for 48h to produce control DC (i.e. DC.ψ5 or 
DC.EGFP), DC.Tbet or DC.IL-36γ. In cases where DC.EGFP was used as the control, 
DC.Tbet and DC.IL-36γ were co-transduced with Ad.EGFP to produce DC.Tbet/EGFP 
and DC.IL-36γ/EGFP, respectively. Western blotting and qPCR were used to document 
expression of mTbet in transduced DC as previously reported (27), while the presence 
of IL-36γ in transfected DC was detected by Western blotting using a polyclonal rabbit 
anti-mIL36γ (IL-1F9) antibody (223) or by qPCR using primers described in Table S2.1 . 
For ELISA analyses, cell-free supernatant was harvested 48h following infection. For 
gene array analyses only, DC.Tbet, DC.IL-36γ, or uninfected DC (i.e. DC.null) were 
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activated in vitro for 24h in media containing 10 µg/mL LPS (Sigma-Aldrich, part number 
L4516) and 10 ng/mL rmIFNγ (Peprotech, part number 315-05), or left untreated, prior 
to mRNA isolation. 
 
2.5.6 In vitro stimulation of DC. 
 
In selected experiments as indicated, DC were generated from the tibias/femurs of mice 
as previously described (27) and were then stimulated in vitro using TLR2 agonist 
HKLM (108 cells/mL), TLR3 agonist polyI:C (1 µg/mL), TLR7 agonist CLO97 (1 µg/mL) 
(all from Invitrogen, part number tlrl-kit1hw), TLR4 agonist LPS (10 µg/mL) with or 
without rmIFNγ (10 ng/mL), TLR9 agonist ODN1585 (5 nmol; Invitrogen, part number 
tlrl1585) or anti-CD40 antibody FGK45 (1 µg/mL), in complete media containing 1000 
U/mL granulocyte/macrophage colony-stimulating factor (GMCSF) and 1000 U/mL 
recombinant murine IL-4 (Peprotech). After 24h of stimulation, cell-free supernatant was 
harvested for subsequent analysis by ELISA. 
 
2.5.7 ELISA. 
 
Murine IL-36γ ELISA kit (Aviva Systems Biology Corporation, part number OKEH03002) 
was used per the manufacturer’s instructions. 
 
2.5.8 DC-Based Therapy. 
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Recipient wild-type, mutant or transgenic (H-2b) mice received s.c. injections of 5 x 105 
MCA205 sarcoma cells or 1 x 105 MC38 colon carcinoma cells in the right flank on day 
0. On day 7 post-tumor inoculation, mice were randomized into treatment cohorts of 5 
mice, with each cohort exhibiting comparable mean tumor sizes (approximately 40-50 
mm2). One million DC (i.e. control DC.ψ5, control DC.EGFP, DC.Tbet, or DC.IL-36γ) 
developed from wild-type C57BL/6 or syngenic mutant (IL-36R-/- or Tbet-/-) or transgenic 
Tbet-ZsG mice were then injected i.t. in a total volume of 100 µl (in PBS) on day 7 post-
tumor inoculation, and then again 1 week later. In some experiments, where noted, IL-
36γ function was blocked by i.t. injection of rmIL-1F5 (an IL-36R antagonist also known 
as IL-36RA or IL-36RN; purchased from Life Technologies, part number 50213-MNAE) 
at the time of therapeutic DC delivery (and then daily x 2). In other experiments, where 
noted, LTβR signaling was blocked by i.t. injection of 100 µg LTβR-Ig or control antibody 
(Sigma-Aldrich, part number AG714) 3 hours prior to each delivery of DC. Mean tumor 
size (+ SEM) was monitored every 3-4 days and recorded in mm2 by determining the 
product of the largest orthogonal diameters measured using vernier calipers. Mice were 
euthanized when tumors became ulcerated or if they exceeded a size of 400 mm2, in 
accordance with IACUC guidelines. 
 
2.5.9 In vivo depletion of CD4+ or CD8+ T cells. 
 
In selected experiments, as indicated, mice were injected i.p. with 50 - 100 µg rat 
isotype control Ab (Sigma-Aldrich), 50 µg anti-CD4 mAb GK1.5 (eBioscience, part 
number 16-0041) or 100 µg anti-CD8 mAb53-6.7 (Biolegend, part number 100716) on 
days 6, 13 and 20 after tumor inoculation. Specific cell depletion was > 95% effective in 
vivo based on flow cytometry analysis of peripheral blood mononuclear cells obtained 
by tail venipuncture from treated mice 24-48h after Ab administration (data not shown). 
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2.5.10 Imaging of tumor tissues. 
 
Tumor samples were prepared and sectioned as previously reported.47 Briefly, tumor 
tissues were harvested and fixed in 2% paraformaldehyde (Sigma-Aldrich) at 4°C for 
2h, then cryoprotected in 30% sucrose for 24 hours. Tumor tissues were then frozen in 
liquid nitrogen and 6 micron cryosections prepared. Hematoxylin & Eosin (H&E) stains 
were performed as previously described (276). For immunofluorescence microscopy 
(IFM) analysis of TLS, sections were stained as previously described using primary and 
secondary antibodies as indicated in Table S2.2. In tumors where a biotinylated primary 
antibody was used, the following protocol modification was made: after blocking with 
BSA, slides were treated with Avidin Blocking Buffer for 15 minutes, washed in 0.5% 
BSA in PBS, and treated with Biotin Blocking Buffer (both from R&D Systems, part 
number CTS002) for 15 minutes, before the addition of the primary antibody. Cell nuclei 
were then stained with DAPI as previously described (28). After washing, sections were 
then covered in Gelvatol (Monsanto) and a coverslip applied. Slide images were 
acquired using an Olympus 500 scanning confocal microscope or an Olympus Provis 
AX70 fluorescence microscope (both from Olympus America). Positively stained cells 
were quantified by analyzing images at a final magnification of ×20 using Metamorph 
Imaging software (Molecular Devices) or NIS-Elements software (Nikon Instruments, 
Inc.). 
 
2.5.11 Flow cytometric analyses. 
 
Tumors were isolated from C57BL/6 mice 20 days following initial tumor inoculation, 
mechanically minced, and enzymatically digested with 0.5 mg/mL collagenase IA 
(Sigma-Aldrich, part number C5894), 0.5 mg/mL collagenase II (Sigma-Aldrich, part 
number C1764), 0.5 mg/mL collagenase IV (Sigma-Aldrich, part number C1889), and 
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20 U/mL DNase I (Sigma-Aldrich, part number D5025). The resulting single cell 
suspensions were labeled using fluorescently labeled antibodies as indicated in Table 
S2.2. Cell staining for cell surface markers was performed in PBS in the presence of 
anti-CD16/CD32 (i.e. Mouse BD Fc Block; BD Biosciences, part number 553142). To 
stain for intracellular transcription factors, FoxP3/Transcription factor staining buffer set 
(eBioscience, part number 00-5523-00) was used with the anti-Tbet APC (Biolegend, 
part number 644814). 
 
2.5.12 RNA purification and PCR analyses. 
 
Total RNA was isolated from control or rAd-infected DC using Trizol reagents 
(Invitrogen, part number 15596018) or Buffer RLT (Quiagen, part number 1030963). 
Total RNA was further purified using the RNeasy Plus Micro Kit (Qiagen, part number 
74034) including the gDNA Eliminator spin column. The purity and quantity of the total 
RNA was assessed using Nanodrop ND-1000 (CelBio SpA). For gene array analyses, 
gene expression analyses were performed on total RNA using the mouse Clariom D 
Assay (Affymetrix, part number 902513) according to the manufacturer’s instructions by 
the University of Pittsburgh’s Genomics Research Core (a Shared Resource), and data 
was analyzed using Transcriptome Analysis Console 3.0 (Affymetrix). Otherwise, total 
RNA (1 µg) was reversed transcribed into cDNA using the High-Capacity RNA to cDNA 
Kit (Qiagen, part number 4387406) and the cDNA added to RT2 SYBR Green ROX™ 
qPCR Mastermix (Qiagen, part number 4385612) and used for quantitative PCR using 
specific primer pairs (Table S2.1). Reactions were performed on a StepOnePlusTM Real-
Time PCR thermocycler (Applied Biosystems) using the recommended cycling 
conditions. mRNA expression levels were normalized to expression of control β-Actin or 
HPRT mRNA and analyzed using the 2-∆∆CT method. 
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2.5.13 Statistical analyses. 
 
Comparisons between groups were performed using Student’s t-test or one-way 
Analysis of Variance (ANOVA) with post-hoc analysis, as indicated. All data were 
analyzed using GraphPad software (La Jolla, CA). Differences with a p-value < 0.05 
were considered significant. 
 
 
 
2.6 ADDITIONAL SUPPORTING INFORMATION 
 
2.6.1 Materials and Methods 
 
Female 6-8 week old wild-type C57BL/6 and Rag1-/- mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and maintained under aseptic conditions per an 
IACUC-approved protocol and in accordance with recommendations for the proper care 
and use of laboratory animals. Studies were carried out as described in Section 2.5. In 
some experiments, where noted, mice were treated with intravenous injections of 100 
ug anti-CD62L (clone: MEL-14) or an isotype control antibody (both from Biolegend) on 
d7 and d14 post-tumor inoculation (i.e. 4 hours prior to each intratumoral injection of 
DC). 
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2.6.2 Adaptive immune cells are required for TLS formation 
 
MC38 tumors were established in Rag1-/- mice and treated on d7 and d14 post-tumor 
inoculation with i.t. injections of 106 DC.EGFP, DC.Tbet/EGFP, or DC.IL-36γ/EGFP cells 
and measured 2-3 times per week (Figure 2.8A). On d20, tumors were harvested and 
imaged by immunofluorescence microscopy for the presence of TLS (i.e. based on 
staining patterns for PNAd+, CD3+ and CD11c+ cells; Figure 2.8B). Results indicate that 
despite treatment in these immunodeficient mice, tumors rapidly progress and fail to 
develop intratumoral TLS. 
 
 
 
 
Figure 2.8. The adaptive immune system is required for TLS formation. 
 91 
Rag1-/- animals were inoculated subcutaneously with 105 MC38 adenocarcinoma cells 
on d0. On d7 and d14, mice were treated with i.t. injections of 106 DC.EGFP, 
DC.Tbet/EGFP, or DC.IL-36γ/EGFP cells. Tumor growth was measured approximately 
every 3 days (A). On d20, tumors were harvested and visualized by 
immunofluorescence microscopy for PNAd, CD3, and CD11c to assay for the presence 
of TLS, which were not observed in the TME (B). Bars = 100 microns. 
 
 
2.6.3 Immune cell trafficking via CD62L-PNAd interactions is required for the 
therapeutic efficacy of DC.IL-36γ-based therapy 
 
We next sought to understand the mechanism of recruitment of TIL into the TME, and 
whether PNAd-based recruitment is required for the therapeutic efficacy of DC.IL-36γ-
based treatment. To achieve this, we treated mice as described in Figure 2.7A. 
Additionally, mice treated with DC.IL-36γ were also treated i.v. with 100 µg anti-CD62L 
(MEL-14) or 100 µg isotype control antibody 4 hours prior to each injection of DC, to 
block interaction between CD62L expressed on naïve (and central-memory) T cells and 
PNAd on tumor-associated HEV. While DC.IL-36γ plus isotype-treated tumors exhibited 
delayed tumor growth, DC.IL-36γ plus anti-CD62L-treated tumors progressed at a rate 
similar to that of DC.EGFP-treated tumors (Figure 2.9A). Furthermore, while DC.IL-36γ 
plus isotype-treated tumors upregulated transcript expression of IL36G, Tbet, and 
biomarkers associated with TLS formation including LIGHT, LTA, CCL19, CCL21, 
CCR7, and CHST4, DC.IL-36γ plus anti-CD62L-treated tumors marginally upregulated 
expression of IL36G and failed to upregulate any other TLS-linked transcripts evaluated 
(Figure 2.9B). 
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Figure 2.9. CD62L-PNAd interaction is required for the therapeutic efficacy of DC.IL-36γ 
treatment. 
WT mice were inoculated subcutaneously with 105 MC38 adenocarcinoma cells on d0. 
On d7 and d14, mice were treated with i.t. injections of 106 DC.EGFP or DC.IL-
36γ/EGFP cells. Where indicated, some animals were co-treated with i.v. injections of 
100 ng anti-CD62L antibody 4h prior to DC injection. Tumor growth was measured 
approximately every 3 days (A). On d20, tumors were harvested and analyzed by qPCR 
for the expression of indicated TLS-associated genes (B).  
 
 
 93 
2.6.4 Interpretation 
 
In these studies, we sought to understand the requirements for T/B cells and for 
CD62L+ immune cell recruitment in delaying tumor progression and forming TLS in 
DC.IL-36γ-treated tumors in vivo. Previous work from our group determined that CD8+ T 
cells were required for therapeutic efficacy associated with DC.Tbet-based treatment 
(28). Here, we show that an adaptive immune cell infiltrate is required for the formation 
of TLS. In Rag1-/- mice that lack mature T and B cells, TLS do not form even after i.t. 
injection of DC.Tbet or DC.IL-36γ cells. These results demonstrate that while IL-36 
signaling is required for TLS formation (Figure 2.7D), its local production may not 
directly lead to upregulated expression of PNAd on the tumor vasculature; instead, it 
likely assists in the early recruitment of lymphocytes into the TME by inducing 
expression of T cell chemoattractants such as CCL19 and CCL21 produced by DC/VEC 
within the treated TME; these recruited TIL then drive PNAd upregulation and the 
development of HEV. Next, we showed that blockade of CD62L, the ligand for PNAd, 
abrogates the efficacy of DC.IL-36γ treatment. Other work on the DC.Tbet and DC.IL-
36γ therapies showed that these treatment modalities remain effective even when the 
injected DC (generated from CCR7-/- hosts) are defective in their capacity to traffic to 
lymph nodes (Figure 2.3 and ref. (28)), indicating that while anti-CD62L also blocks 
recirculation of T cells into the lymph nodes, such effects are likely unimportant to the 
underlying therapeutic biology of our model system. Interestingly, while TIL are recruited 
into the TME of DC.Tbet- and DC.IL-36γ-treated tumors at least 72h prior to expression 
of PNAd, these results suggest that sustained local therapeutic immunity in the TME 
requires the presence/function of intratumoral HEV. The mechanism supported by these 
data is detailed in Figure 2.10 (updated from (36)). 
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Figure 2.10. Proposed mechanism for the efficacy of DC.Tbet- and DC.IL-36γ-based 
therapies. 
Following i.t. Injection of DC.Tbet or DC.IL-36γ cells, a rapid (within 4-10 hour) 
infiltration of CD4+ and CD8+ T cells into the TME is observed, likely due to the 
production of chemokines by the injected DC as well as IL-36γ interaction with cells of 
the tumor vasculature to promote further chemokine expression. Within 2 days, NK cell 
infiltrate is observed. Upregulation of chemokines including CCL19, CCL21, LTA, and 
LIGHT is observed in the TME beginning at this timepoint. By 4-5 days following 
treatment, upregulation of PNAd on the vasculature (i.e formation of HEV) is observed, 
concurrent with a tightening of TIL and DC to surround these HEV. These TLS persist 
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for at least 2 weeks post-treatment, at which point a Type-1 T cell response and a 
decrease in T cell expression of exhaustion markers are noted. 
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3.1 ABSTRACT 
 
IL-1 family cytokines play a dual role in the gut, with different family members 
contributing either protective or pathogenic effects. IL-36γ is an IL-1 family cytokine 
involved in polarizing Type-1 immune responses. However, its function in the gut, 
including in colorectal cancer pathogenesis, is not well appreciated. In a murine model 
of colon carcinoma, IL-36γ controls tertiary lymphoid structure formation and promotes a 
Type-1 immune response concurrently with a decrease in expression of immune 
checkpoint molecules in the tumor microenvironment. Here, we demonstrate that IL-36γ 
plays a similar role in driving a pro-inflammatory phenotype in human colorectal cancer. 
We analyzed a cohort of 33 primary colorectal carcinoma tumors using imaging, flow 
cytometry, and transcriptomics to determine the pattern and role of IL-36γ expression in 
this disease. In the colorectal tumor microenvironment, we observed IL-36γ to be 
predominantly expressed by M1 macrophages and cells of the vasculature, including 
smooth muscle cells and HEV. This pattern of IL-36γ expression is associated with a 
CD4+ central memory T cell infiltrate and an increased density of B cells in tertiary 
lymphoid structures, as well as with markers of fibrosis. Conversely, expression of the 
antagonist to IL-36 signaling, IL-1F5, was associated with intratumoral expression of 
checkpoint molecules, including PD-1, PD-L1, and CTLA4, which can suppress the 
immune response. These data support a role for IL-36γ in the physiologic immune 
response to colorectal cancer by sustaining inflammation within the tumor 
microenvironment. 
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3.2 INTRODUCTION 
 
Colorectal cancer is the third most common form of cancer worldwide (277). In 2017, it 
is estimated that over 50,000 Americans will die from the disease (278), and in France, 
approximately 17,500 colorectal cancer-associated deaths are reported each year 
(279). While the rate of mortality from colorectal cancer is currently decreasing in both 
countries, only a subset of patients is likely to respond to therapeutic intervention, with 
most patients having limited or invasive treatment options available (280). 
 
We recently reported the efficacy of an IL-36γ-based therapy in delaying tumor 
progression in the MC38 murine model of colon adenocarcinoma (35). The IL-36 
cytokines are an IL-1 subfamily (191) consisting of three agonists that signal through a 
common heterodimeric receptor, IL-36R (232,281). Signaling through the IL-36R can be 
inhibited by the full receptor antagonist, IL-1F5 (aka IL-36RA), which blocks the 
recruitment of IL-1RAcP, the IL-1 family receptor accessory protein, required for 
signaling through the IL-36R (232). IL-36R is expressed on endothelial cells as well as 
cells of the immune system, including T cells and DCs (220,225,237,282). Through its 
effects on immune cells, IL-36γ is involved in polarizing towards Type-1 immune 
responses (197,222). In particular, it is a downstream target of the Type-1 transactivator 
Tbet (197) and can induce Tbet expression in target cells (35). The therapeutic 
introduction of IL-36γ into the TME using a DC-based vector delayed tumor progression 
in conjunction with a rapid (within 4-10h) recruitment of T cells into the TME and the 
formation of tumor-associated tertiary lymphoid structures (TLS). IL-36γ-overexpressing 
DC displayed elevated levels of TLS-promoting chemokines, including LTβR agonists 
LTA and LIGHT, and CCR7 agonist CCL21. When introduced intratumorally, IL-36γ-
based therapy also decreased the level of PD-1, CTLA4, and TIM-3 on CD3+ TIL (35). 
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It has recently been described that in humans, some colorectal cancers also presents 
with a high immune infiltrate (283), which is sometimes organized into TLS. The 
presence of TLS within the TME is a positive prognostic marker in colorectal carcinoma 
and many other solid tumors (60,177,284). TLS form at sites of persistent inflammation, 
such those found in tissues impacted by chronic viral infections, autoimmune diseases, 
or cancer. These structures are often marked by a germinal center with dense B cell 
infiltrate and follicular DCs (15,285). The principal histologic marker used to identify TLS 
in colorectal cancer is therefore CD20, which identifies these B cells (61,183). In 
addition, TLS contain follicular DCs and DC-LAMP+ mature DCs in a T cell zone, and 
are surrounded by blood and lymphatic vessels (61,183) including HEV (60) that allow 
naïve and central memory lymphocytes to be recruited into TLS. 
  
In this study, we attempt to translate our findings from the mouse model of colon 
carcinoma into human by investigating the pattern of expression of IL-36γ in colorectal 
cancer, and whether IL-36γ expression is associated with TLS components and the 
infiltration of immune cells into the TME. 
 
 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Public transcriptomic data sets 
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Transcriptomic data from colorectal cancer tumors (286) was downloaded from Gene 
Expression Omnibus (accession code GSE39582). The data from Affymetrix Human 
Genome U133 Plus 2.0 Array was normalized using the frozen RMA method with the R 
package frma (287). Normalized sorted cells transcriptomic data was obtained from 
Becht et al. (288) (Gene Expression Omnibus accession code GSE86362). The 
expression fold-change of a gene was computed as the difference between the median 
log2 gene expression for the positive samples (defined as all samples from the 
considered cell population) and all negative samples (defined as all other samples).  
 
3.3.2 Patient cohort 
 
A cohort of 33 primary colorectal tumors was collected between October 2, 2014 and 
March 3, 2016 from patients operated at the Ambroise Paré hospital (Boulogne 
Billancourt, France). This research was conducted in accordance with the 
recommendations outlined in the Helsinki declaration and was approved by the medical 
ethics board of the hospital. Patient characteristics are summarized in Table 3.1. 
 
3.3.3 IHC, immunofluorescence and image quantification 
 
IHC staining was performed as previously described (289). Serial 5-mm formalin-fixed 
paraffin-embedded tissue sections generated from colorectal cancer were stained using 
the Dako Autostainer Plus (Agilent). Antigen retrieval and deparaffinization were carried 
out on a PT-Link (Dako) using the EnVision FLEX Target Retrieval Solutions (Dako). 
The antibodies used are listed in Table S3.1 and negative control staining for the IL-36γ 
antibody is demonstrated in Figure S3.1. Signal intensity was amplified using Envision+ 
System HRP labelled polymers (Dako) or ImmPRESS HRP Polymer Detection Kit 
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(Vector). For IHC staining, peroxidase activity was detected using diaminobenzidine 
(DAB) substrate (Dako), counterstained with hematoxylin (Dako), and mounted with 
Glycergel Mounting Medium (Dako). The degree of smooth muscle actin (SMA) 
expression in the tumor stroma was quantified according to the following grading 
system: (1) scarce fibroblasts; (2) continuous layer of fibroblast between tumor nests 
with overall thickness inferior to three cells; (3) continuous layer of fibroblast between 
tumor nests with overall thickness superior to three cells and fibroblast area <50%of 
tumor area; and (4) continuous layer of fibroblast between tumor nests with overall 
thickness superior to three cells and fibroblast area >50% of tumor area. 
For immunofluorescent staining, signals were detected by Tyramide SuperBoost Signal 
Amplification (Life Technologies) and slides were counterstained and mounted using 
ProLong Gold Antifade reagent with DAPI (Molecular Probes). Slides visualized by IHC 
were digitalized with a NanoZoomer scanner (Hamamatsu) and digitally-quantified with 
Calopix software (Tribvn). Slides visualized by immunofluorescence were digitalized 
with an Axioscan scanner (Zeiss) and digitally-quantified with Visiopharm Integration 
System (VIS) software (Visiopharm). 
 
3.3.4 Tumor processing, surface staining and cell sorting  
 
Flow cytometry staining was performed as previously described (289). Briefly, tumors 
were dilacerated and incubated for 1 hour at 4°C with Cell Recovery Solution (Fisher 
Scientific); mixtures were filtrated and TILs separated with Ficoll-Paque PLUS (GE 
Healthcare Life Science). Cells were then stained with the monoclonal antibodies as 
listed in Table S3.2. Samples were acquired in a FACS Fortessa cytometer with 
FACSDiva software (BD Bioscience) and data analyzed with FlowJo 7.9.4 software 
(Tree Star, Inc.). The fraction of cells co-expressing multiple markers was calculated in 
SPICE 5.3033 (Exon), a data mining software application that normalizes and analyzes 
large FlowJo datasets (290). 
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3.3.5 Gene array analyses 
 
Total RNA was isolated from fresh tumor tissue using Quiashredder columns and the 
RNeasy Mini Kit (both from Qiagen). RNA quality was validated using the RNA 6000 
Nano Chip (Agilent) and read on a 2100 Bioanalyzer (Agilent). Transcript analysis was 
assayed with nCounter (Nanostring). The list of gene targets evaluated in this study is 
listed in Table S3.3. 
 
3.3.6 Statistical analyses 
 
All data was analyzed using R (R Foundation for Statistical Computing). For categorical 
variables, data was analyzed using the Mann-Whitney test in the case of two groups; for 
more than two groups, analyses were carried out using the Kruskal-Wallis test for 
overall comparison and Dunn test for pairwise comparison (with the use of the R 
package dunn.test), with Benjamini-Hochberg (False Discovery Rate) correction method 
for multiple testing. For comparisons of two continuous variables, data were analyzed 
by Pearson correlation. Test results were considered significant when p < 0.05. For 
correlations, data were considered biologically meaningful if the absolute value of the 
correlation value was > 0.5. 
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3.4 RESULTS 
 
3.4.1 IL-36γ is detected in the immune and vascular compartments in the TME 
 
We first used immunohistochemical staining to identify and localize IL-36γ+ cells within 
patient colon carcinoma primary tumors. IL-36γ was detected on a variety of cell types in 
the TME, including immune cells (Figure 3.1A), tumor cells (Figure 3.1B) and 
vascular/perivascular cells (Figure 3.1C and 3.1D). We noted that within the vascular 
compartment, both smooth muscle cells (SMC; Figure 3.1C) and vascular endothelial 
cells (VEC; Figure 3.1D, indicated by an arrow and inset) were IL-36γ positive, though 
coordinate detection in the same vessel was uncommon. Instead, SMC surrounding 
large vessels, and VEC of smaller vessels, were found to be IL-36γ+. We did not 
observe significant differences in IL-36γ expression between tumors with MSI versus 
MSS microsatellite status (data not shown). 
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Figure 3.1. IL-36γ is expressed by a variety of cell populations in the TME. 
FFPE tumor sections were stained for IL-36γ by IHC as described in Materials and 
Methods for expression of IL-36γ. Expression of this protein was observed in immune 
cells (A), tumor cells (B), and cells of the vasculature (C, D). Of note, both smooth 
muscle (C) and endothelial cells (D) of the vasculature were observed to express IL-36γ. 
Bars = 250 microns. 
 
 
To further investigate the distinct subtypes of immune cells expressing IL-36γ in the 
TME, we analyzed transcriptomic data of purified immune cell populations from MCP-
transcriptomes of 81 public data sets (Figure 3.2). IL36G was found to have a higher 
transcription level in activated macrophages, also referred to as classically-activated or 
M1 macrophages, than in all other immune cell types, including “alternatively activated” 
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M2 macrophages (log2-fold change versus other cells 5.35, see Materials and 
Methods). The two other IL-36γ transcript positive cell types - dermal DCs and 
Langerhans cells - are found in other organs than the colon. Immunofluorescence 
imaging showed that CD68+ macrophages are capable of expressing IL-36γ protein 
within the colorectal cancer TME (Figure 3.3A). After quantitation, it was determined 
that 40.4% of CD68+ cells in the TC and 38.7% in the IM of tumors expressed IL-
36γ (Figure 3.3B). 
 
 
 
 
Figure 3.2. M1 macrophages express high levels of IL-36γ. 
Affymetrix microarray data from the Gene Expression Omnibus (GSE39582) was 
analyzed for expression of IL36G in various human immune cell subsets. Data are 
presented on a log2 scale. Results indicate an elevated level of IL36G expression by 
activated M1 macrophages compared to the median expression by all other cell types. 
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Figure 3.3. Intratumoral macrophages are a source of local IL-36γ. 
IL-36γ was visualized by immunofluorescence imaging in conjunction CD68+ 
macrophages (A). Bars = 50 microns. Data were analyzed as described in Materials 
and Methods, and the average frequency of IL-36γ+ macrophages in both the TC and IM 
is presented in B. 
 
 
3.4.2 IL-36γ expression by macrophages is associated with markers of 
inflammation 
 
We next investigated whether a correlation could be made between IL-36γ expression 
by macrophages and other previously established prognostic markers for patients with 
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colon cancer, using a prospective cohort of 33 primary tumors. In particular, we were 
interested in determining whether IL-36γ+ macrophages were linked to a fibroblastic 
signature within the TME and/or to a strong intratumoral Type-1 immune response. 
Alpha-smooth muscle actin (SMA) was used to detect cancer associated fibroblasts by 
IHC grading, as described in Materials and Methods (291). In this cohort, 15% (5/33) of 
tumors were classified as SMA grade 1, 27% (9/33) were grade 2, 42% (14/33) were 
grade 3, and 15% (5/33) were grade 4. As shown in Figure 3.4A, tumor-associated 
macrophages located in the TC were positively correlated with an increase in SMA 
grade. When just the IL-36γ+ macrophage subset was analyzed, this correlation became 
stronger in the TC, with a similar correlation noted in the IM. IFM imaging suggested a 
close contact between (IL-36γ+) macrophages and SMA+ cells in the TME (Figure 
3.4B). TIL subsets were phenotyped by flow cytometric analysis of T cells isolated from 
fresh tissues. We identified four subsets each of CD4+ and CD8+ T cells: naïve (CCR7+ 
CD45RA+), effector memory (TEM; CCR7- CD45RA-), central memory (TCM; CCR7+ 
CD45RA-), and effector memory RA (TEMRA; CCR7- CD45RA+) (Table 3.2) (289). We 
found a positive correlation between CD4+ central memory T cells (Figure S3.2) and 
macrophages in the TC (r = 0.574 and p = 0.000923; Figure 3.4C), but not the IM (data 
not shown). When just the IL-36γ+ macrophage subset in the TC was studied, the 
correlation with CD4+ TCM was improved (r = 0.608 and p = 0.000364; Figure 3.4D). 
We also analyzed the expression of immune genes (Table S3.3) in whole tumor 
samples, and the gene expression studies showing negative correlation between CD4+ 
TCM and the CSF1R transcript, a marker of immunosuppressive M2 macrophages (p = 
0.044; Figure 3.4E) confirmed these data. No significant correlations were found 
between IL-36γ+ macrophages in the TC and any other naïve or memory CD4+ or CD8+ 
TIL subsets (Figure S3.3). Thus, it appears that IL-36γ+ macrophages are associated 
with both an increased fibroblastic signature – a negative prognostic marker – and a 
memory/Type-1 immune response – a positive prognostic marker in the setting of 
colorectal cancer. 
 108 
 
 
Figure 3.4. IL-36γ+ macrophages are associated with a proinflammatory TME.  
FFPE tumor sections were visualized by IHC for expression of alpha-SMA or by 
immunofluorescence for IL-36γ+ CD68+ macrophages. A positive correlation between 
increased alpha-SMA grade and intratumoral density of IL-36γ+ macrophages is shown 
in A. In B, tumors were visualized either by immunofluorescence for CD68 and IL-36γ 
(left panel) or by IHC for alpha-SMA (right panel). CD68+ macrophages and alpha-SMA+ 
cells were observed in close contact with each other within the TME. Bar = 250 microns. 
We also investigated the relationship between macrophages and CD4+ central memory 
T cells in tumors. We report that the overall density of macrophages is positively-
correlated with the presence of CD4+ central memory T cells in tumors (C), but that the 
strength of this correlation is increased when just the IL-36γ+ macrophage subset is 
analyzed (D). Furthermore, the presence of CD4+ central memory T cell infiltrate is 
inversely correlated with the expression of CSF1R, a biomarker of M2 macrophages 
(E). 
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3.4.3 The predominant IL-36γ-expressing cells in TLS are HEV-associated VEC 
 
CD4+ TCM have been reportedly found primarily in TLS (aka tertiary lymphoid organs or 
ectopic lymphoid-like structures) within the confines of human tumors (45). Since IL-36γ 
expression was correlated with CD4+ TCM, we next investigated TLS in the colorectal 
cancer TME, using the B cell marker CD20. Indeed, we found a series of dense CD20+ 
aggregates in tumors from this patient cohort, with most being located in the IM (Figure 
3.5A). TLS can also be marked by the presence of peripheral node addressin (PNAd)+ 
HEV (Figure 3.5B), i.e. specialized CD31+ VEC involved in the recruitment of CD62L/L-
selectin+ naïve or central memory lymphocytes from the peripheral blood circulation. We 
next investigated the expression of IL-36γ within these structures. We found that IL-36γ 
was principally expressed on HEV themselves, with minimal expression by the 
constituent immune cells or by “normal” CD31+ PNAd- VEC (n = 7; Figure 3.5B). Since 
IL-36γ has not been reported by other groups to be expressed by the vasculature, we 
next sought to further investigate this pattern of expression. 
 
3.4.4 IL-36γ expression on the vasculature is associated with maintenance of TLS 
structures 
 
To investigate vascular expression of IL-36γ, we divided our cohort into two groups: 
patients with IL-36γ expression on any vessels in the tumor (i.e., including HEV or 
arteries, n = 21), and those devoid of IL-36γ expression in vascular structures (n = 12). 
Within these cohorts, we then analyzed tissues for correlations between vascular 
expression of IL-36γ and immune cell infiltrate into the tumors. We observed that in the 
IM, the density of CD20+ B cells in the TLS of patients with IL-36γ+ blood vessels was 
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significantly higher than in patients without any IL-36γ+ vessels (p=0.00879; Figure 
3.5C). We did not discern a significant correlation between IL-36γ expression on blood 
vessels and the density of intratumoral B cells outside of TLS (p=0.829; Figure 3.5D) or 
absolute numbers of TLS within tumors (data not shown). These data suggest that IL-
36γ expression on the vasculature may be involved in the maintenance of TLS in the 
TME. A larger cohort of patients presenting with TLS will be required to parse the 
effects of HEV versus vasculature outside of TLS. 
 
 
 
 
Figure 3.5. Expression of CD20 suggests presence of TLS in colorectal tumors. 
FFPE tumors were visualized by IHC for the presence of CD20 (A), a B cell marker 
used to identify TLS. TLS in the IM are annotated with green arrows; TLS in the TC are 
marked by yellow arrows. Tumor sections were probed with antibodies against CD31 
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and PNAd to identify HEV, together with an antibody reactive against IL-36γ (B). Bars = 
5 mm in panel A and 200 microns in panel B. Following the observation that HEV were 
the primary cell type expressing IL-36γ within TLS, we noted that IL-36γ expression on 
the vasculature correlated with an increased density of B cells within TLS (C), but not 
outside of these structures (D) within the TME. 
 
 
3.4.5 IL-1F5 expression in the TME is associated with immunosuppressive 
markers 
 
Tissue expression of IL-1F5 (aka IL-36RA), the natural antagonist to the IL-36 receptor, 
was probed using IHC to investigate whether this negative regulatory member of the IL-
36R signaling pathway might be associated with suppression of either TIL function or 
TLS organization in our cohort. IL-1F5 expression was found on the tumor vasculature 
(Figure 3.6A) as well as vasculature in the tonsil, a secondary lymphoid organ (Figure 
S3.4). The density of B cells in IM-localized TLS was not significantly different in tumors 
whether blood vessels expressed IL-1F5 or not (Figure 3.6B). We next investigated 
whether the presence of intratumoral IL-1F5 correlated with other markers of the TME 
as detected by transcriptome analysis. IL-1F5 (but not IL-36γ) expression in the IM of 
tumors was found to be positively-correlated with local expression of the PDCD1 (i.e. 
PD-1), CTLA4, and CD274 (PD-L1) immune checkpoint markers, but not with 
expression of LAG3, ICOS, or ICOSL (Figure S3.5). 
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Figure 3.6. Presence of the IL-36 receptor antagonist, IL-1F5, is not correlated with the 
density of CD20+ B cells in TLS. 
FFPE tumor sections were visualized by IHC for expression of IL-1F5, the natural 
antagonist to the IL-36 receptor. Like IL-36γ, IL-1F5 was observed to be expressed on 
the tumor vasculature (A). Bars = 250 microns. When the intensity of IL-1F5 expression 
was correlated with the density of B cells in TLS within colon carcinoma lesions, no 
significant relationship was observed (B). 
 
 
 
3.5 DISCUSSION 
 
In this study, we report a link between intratumoral expression of IL-36γ and markers of 
an ongoing anti-tumor immune response in the TME. IL-36γ+ macrophage density was 
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found to correlate with CD4+ TCM frequency in TILs. CD4+ TCM infiltrate was also 
associated with a decreased M2 macrophage marker in the TME. In human lung (45) 
and breast cancer (180) cancers, CD4+ TCM have been reported to be found 
predominantly within tumor-associated TLS. The presence of TLS within the TME has 
been associated with an ongoing local anti-tumor immune response (284). It has 
previously been reported as a positive prognostic marker in colorectal cancer 
(41,177,183), with TLS most commonly identified by dense aggregates of CD20+ B cells 
resembling the germinal centers found in lymph nodes (47). 
Our studies also suggest a link between IL-36γ+ macrophages and SMA grade in our 
tumors. In colorectal cancer, the grade of SMA is associated with poor progression-free 
and overall survival rates (283,291). In the setting of esophageal squamous cell 
carcinoma, expression of fibroblast-associated genes, including SMA, are associated 
with poor overall and progression-free survival (292). In this latter study, the authors 
observed that increased prevalence of tumor-infiltrating macrophages was associated 
with an increased fibroblast signature and poor prognosis. Thus, we would predict that 
SMA grade 4 patients are most likely to also exhibit robust IL-36γ+ macrophage 
infiltrates and Type-1 pro-inflammatory/anti-tumor immune responses. Indeed, it has 
previously been reported in a murine model of atherosclerosis that M1 macrophages 
can act indirectly as lymphoid tissue inducer cells that lead to the formation of TLS by 
the secretion of chemokines and cytokines that act on SMA+ vascular smooth muscle 
cells and convey a lymphoid tissue organizer phenotype onto these cells (293). Further 
studies should investigate a role for IL-36γ+ macrophages in TLS organization in the 
TME, and whether cancer patients with a high IL-36γ+ macrophage or TLS signature 
have a better prognostic outcome than their counterparts lacking these specific immune 
infiltrates. 
Release of IL-36γ in IBD and colitis leads to IL-36R-mediated signaling in colonic 
fibroblasts and to secondary production of chemokines/cytokines (i.e. GMCSF, CCL1, 
CCL2) known to recruit and differentiate monocytes/macrophages (201), and IL-36γ 
treatment has been shown in in vitro models to lead to the secretion of chemokines 
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including CXCL1, CXCL2, and CXCL8 by myofibroblasts (294). Furthermore, IL-36R 
signaling promotes healing of the mucosa following damage. These results are 
consistent with our current findings suggesting a positive correlation between IL-36γ+ 
macrophages and SMA in the TME. Notably, fibrosis is a mechanism involved with the 
healing of damaged tissues (295), and tumors have long been referred to as “wounds 
that do not heal” (296). One might therefore anticipate that signaling through the IL-36R 
on colonic fibroblasts could coordinately promote macrophage recruitment and mucosal 
healing mechanisms that drive local fibrosis. However, in the context of cancer, fibrosis 
is classically viewed as a promoter of disease progression (297). In addition to 
fibroblasts, a common cell type involved with the progression of fibrosis is the 
myofibroblast (298). Interestingly, IL-36γ can be intrinsically expressed by colonic 
myofibroblasts as a consequence of IL-1β-induced signaling (214). Furthermore, IL-1β 
is a key cytokine in the transition of stromal cells including fibroblasts, smooth muscle 
cells, and pericytes to become myofibroblasts (299). Together, these results suggest 
that in addition to the IL-36γ+ SMA+ cells within the tumor that were determined by 
pathologic characterization to be muscle fibers (Figure 3.2C), a portion of the IL-36γ+ 
SMA+ cells may represent mature myofibroblasts. Since myofibroblasts have been 
reported to facilitate metastasis of colorectal cancer (300), future studies should 
investigate the relationship between intratumoral patterns of IL-36γ expression and 
colon carcinoma progression and metastasis. Such studies should also include 
analyses of IL-36α, another agonist of IL-36R, that has been reported to independently 
predict increased overall survival amongst patients with colorectal cancer (301). 
To the best of our knowledge, we are the first to characterize expression of IL-36γ by 
cells of the tumor-associated vasculature, with this cytokine found located on vascular 
endothelial cells in HEV and on SMC surrounding large blood vessels. Signaling 
through the IL-36R on VEC can result in upregulated expression of VCAM-1 and ICAM-
1 and the production of chemokines, such as IL-8, CCL2, and CCL20 (282). Following 
stimulation of with IL-36γ, T cells exhibit increased migratory capability towards VEC 
(282). These data suggest that the vascular endothelial cells of HEV may be able to 
both produce and respond to IL-36γ in an autocrine manner, a phenomenon which has 
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previously been shown to occur in myeloid cells (221,228,302). Thus, a positive 
feedback signaling mechanism may increase the “recruiting” capacity of IL-36γ+ HEV for 
protective/therapeutic immune cell populations into existing TLS, either from the 
periphery or from elsewhere within colorectal cancer lesions. 
In conclusion, our findings support a role for macrophage- and VEC-produced IL-36γ in 
recruiting and maintaining intratumoral immune responses, independent of other factors 
known to promote anti-tumor immunity. The promotion of a memory T cell response and 
the maintenance of TLS are both predictors of a positive prognosis in colorectal cancer 
and are both associated with increased IL-36γ production within the TME. In line with 
these findings, tumors presenting with elevated levels of the IL-36 receptor antagonist, 
IL-1F5, generally express less IL-36γ (data not shown) and were observed to have 
lower levels of central memory T cell infiltrates and lower densities of intratumoral B 
cells. IL-1F5 expression also was associated with elevated levels of the immune 
checkpoint molecules PD-1, PD-L1, and CTLA4 in the TME. In other studies, 
expression of IL-1F5 has been associated with a poor prognosis in colorectal cancer 
(303). Because IL-36γ has a higher binding affinity for the IL-36R than does IL-1F5 
(220), administration of an IL-36γ-based therapy would be expected to at least partially 
reverse the inhibition mediated by endogenous IL-1F5, leading to enhanced tumor 
infiltration by beneficial immune cell populations. Because of the correlation between IL-
1F5 expression and an upregulation of immune checkpoint molecules, the co-
application of an IL-36γ-based therapy with checkpoint blockade would be expected to 
also enhance the anti-tumor efficacy of these treatments. 
Future studies should determine whether the presence of IL-36γ in the TME is predictive 
of superior response to immunotherapeutic intervention. Available data (304) suggests 
that a high level of expression of IL-36γ in the tumor microenvironment of several types 
of human tumors is associated with an increase in overall survival, though this does not 
reach statistical significance (Figure S3.6). Based on the data presented in our studies, 
we predict that analyzing intratumoral cell type-specific expression of IL-36γ will prove to 
be a more robust prognostic marker of survival than expression by bulk tumor. 
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3.6 ADDITIONAL SUPPORTING INFORMATION 
 
3.6.1 Materials and Methods 
 
Bone marrow cells were collected from the tibias/femurs of C57BL/6 mice and cultured 
for 7 days in macrophage complete media (DMEM supplemented with 10% FCS, 10% 
L-929 supernatant (a generous gift from Dr. Bryan Brown, Elizabeth Stahl, and Samuel 
LoPresti, University of Pittsburgh), 2% MEM non-essential amino acids (Gibco), 1% 1M 
Hepes buffer (Gibco), 100 mg/mL streptomycin, 100 U/mL penicillin, 10 mmol/L L-
glutamine (all from Invitrogen), and 0.615 mM β-mercaptoethanol (Sigma)). On d7, 
polarization was induced by the addition of either 20 ng/mL rmIFNγ (Peprotech) + 100 
ng/mL LPS (Sigma-Aldrich) (M1) or 20 ng/mL IL-4 (Peprotech) (M2) for 24h. To confirm 
macrophage derivation from bone marrow, cells were profiled by flow cytometry using 
an antibody against F4/80 (clone: BM8, eBioscience). To check M1 polarization, an IL-
12p70 ELISA (BD Biosciences) was performed using cell-free supernatant collected on 
d8. Additionally, qPCR analysis was performed using primers listed in Tables S2.1 and 
S3.4 to both confirm M2 polarization and determine the expression level of pro-
inflammatory genes by macrophage subsets. 
 
3.6.2 Murine M1 macrophages exhibit a TLS-promoting phenotype 
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Bone marrow precursor cells were cultured in vitro for 7 days in macrophage complete 
medium and then stimulated for 24h to induce polarization to an M1 (LPS + IFNγ) or M2 
(IL-4) phenotype, or left unstimulated to generate M0. On day 8, macrophages were 
profiled by flow cytometry to validate F4/80 upregulated expression (Figure 3.7A). To 
confirm M1 polarization, cell-free supernatant from M0, M1, and M2 was analyzed by 
ELISA for secretion of IL-12p70, and results indicated that M1, but not M0 or M2 
macrophages secreted high levels of the cytokine (Figure 3.7B). The polarization of M1 
macrophages was further supported by qPCR analysis indicating an upregulation of 
iNOS/NOS2 specifically in these cells (>105-fold), while M2 polarization was confirmed 
by qPCR indicating an upregulation of Arg1 (>500-fold), compared to M0 cells (Figure 
3.7C). qPCR results also showed that M1, but not M2 macrophages express pro-
inflammatory and TLS-inducing cytokines IL-1β, TNFα, and LTA (but not LIGHT or 
CCL21, Figure 3.7C; or CCL19, data not shown). Concurrently, M1 macrophages also 
expressed elevated levels of the IL36G transcript (>25-fold; Figure 3.7C). 
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Figure 3.7. M1 macrophages express genes linked to the promotion of tertiary lymphoid 
organogenesis. 
Following 7 days of differentiation and 24h of polarization, M0, M1, and M2 
macrophages were profiled by flow cytometric analysis to check for upregulation of the 
macrophage lineage marker F4/80 (A). In B, M1 polarization was verified using an 
ELISA to measure secretion of IL-12p70 by each of the three subsets. M2 polarization 
was confirmed by qPCR analysis for high expression of Arg1 and low expression of the 
M1 marker iNOS (C). Additionally in C, the expression of IL-36γ, Tbet, and several TLS-
associated genes, including TNFα, LTA, LIGHT, and CCL21 was evaluated to 
determine the potential capacity of M1 versus M2 macrophages to serve as initiators of 
TLS formation. 
 
 
3.6.3 Interpretation 
 
These data provide further support for IL-36γ produced by M1 macrophages as having 
potential to drive inflammation in the TME, as we observed to be the case in human 
colorectal cancer. In an in vitro model, murine M1 (but not M2) macrophages upregulate 
numerous molecules known to be involved in tertiary lymphoid organogenesis and 
immune cell trafficking. Our findings are consistent with a report indicating that M1 
macrophages can exhibit a lymphoid tissue organizer phenotype in atherosclerosis 
(293). Furthermore, these data suggest that therapeutic introduction of M1-polarized 
macrophages into the TME may confer a therapeutic benefit akin to that observed for 
intratumorally administered DC.IL-36γ cells. The attenuation of the M2/tumor-associated 
macrophage (TAM) phenotype through targeting of Arg1 (305) is another interventional 
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strategy by which macrophage skewing towards an M1 phenotype might be achieved 
for clinical benefit in the cancer setting. 
 
While M1 macrophages exhibit a lymphoid tissue organizer-like phenotype, they also 
express high levels of iNOS/NOS2. iNOS is known to be immunosuppressive, and can 
even activate pathways that inhibit further M1 differentiation (306,307). Several groups 
have proposed that antagonizing iNOS in the TME potentiates the efficacy of existing 
cancer immunotherapies (308). In the case of iNOShi macrophages acting as lymphoid 
tissue inducer cells, however, it remains to be seen whether inhibition of iNOS can 
further increase the expression level of TLS-inducing genes or if it would adversely 
impact their expression by negatively affecting M1 polarization. Indeed, one study 
reports that NO prevents the repolarization of an M1 to M2 phenotype, while inhibition of 
nitric oxide production by M1 macrophages allows these cells to repolarize towards an 
M2 phenotype following stimulation with IL-4 (309). 
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4.0 DISCUSSION AND PERSPECTIVES
 
 
 
4.1 FURTHER DEFINING THE LINK BETWEEN IL-36γ AND TBET 
 
Previous studies have established Tbet as a driver of IL-36γ expression in immune cells 
(197). In this study, we determine that in addition, IL-36γ can induce expression of Tbet 
in target cells (Figure 2.6). Both (transduced) DC.IL-36γ cells as well as splenocytes 
cultured in the presence of cell-free supernatant collected from DC.IL-36γ cells 
upregulate expression of Tbet (Figure 2.6). These data indicate a positive feedback 
loop between Tbet and IL-36γ that can potentiate Type-1 immune responses through 
the IL-36R. This is further supported by data from our gene array analyses indicating 
that DC.Tbet cells highly upregulate IL36G >100-fold (Figure 2.1A) and DC.IL-36γ cells 
upregulate Tbet to the same magnitude (Figure 2.6C). Interestingly, IL-36γ was shown 
to be present in the nucleus of DC.IL-36γ cells (Figure 2.6H), similarly observed to 
occur with other IL-1 family members such as IL-1α, IL-33, and IL-37 (200,208,310). 
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4.2 IL-36γ IS A NOVEL DRIVER OF THE ANTI-TUMOR IMMUNE RESPONSE 
 
The major component of this work investigated the function of IL-36γ in the anti-tumor 
immune response. First, we build upon previous work showing the anti-tumor efficacy of 
DC.Tbet-based therapy (28) by identifying two novel but related roles for IL-36γ in 
driving this response (35). IL-36γ was identified as being highly upregulated in DC.Tbet 
cells as compared to mock transduced DC, so we generated DC.IL-36γ cells and 
determined that production of IL-36γ by injected DC is sufficient to drive delayed tumor 
progression, even in the absence of Tbet expression by these cells. Intratumoral 
injection of either DC.Tbet or DC.IL-36γ, but not control DC. ψ5 or DC.EGFP, cells into 
established MCA205 or MC38 tumors leads to the formation of intratumoral tertiary 
lymphoid structures by day 4-5 following treatment. Previous work has shown that the 
efficacy of DC.Tbet therapy is dependent on the presence of CD8+ T cells and NK cells 
(28); here, we elaborate on that requirement by showing that in Rag1-/- animals, not only 
do tumors rapidly progress, but TLS do not form. This is in line with our data showing 
that the initial infiltration of immune cells into the TME occurs as early as 4 hours 
following the injection of DC.Tbet cells into the TME (Figure 2.2; i.e. at least 72 hours 
prior to the upregulation of PNAd on tumor vasculature), supporting a role for this early 
T cell infiltrate in the formation of TLS. These data indicate a previously unreported 
requirement for adaptive immune cells in promoting TLS formation and suggest that the 
immune cells found within these structures is likely to be a mix of lymphoid tissue 
inducer-like cells present in the tissue before the formation of TLS, and cells recruited 
into established after the conversion of the local vasculature to an HEV phenotype. 
Further supporting the importance of TLS in mediating the anti-tumor immune response 
downstream of DC.Tbet- or DC.IL-36γ-based therapy, and building upon previous data 
showing that injected DC.Tbet cells do not need to migrate to lymph nodes in order for 
the treatment to be effective (28), MCA205 tumors established in lymph node-deficient, 
LTA-/- mice and treated with DC.Tbet exhibited delayed tumor progression not 
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significantly different from the rate of tumor growth observed in WT DC.Tbet-treated 
animals (Figure 2.3). 
We also show that the drivers of TLS formation are similar between our model, other 
reports of TLS formation, and lymph node organogenesis. Indeed, LTA and LIGHT are 
highly upregulated in both DC.Tbet and DC.IL-36γ cells and treated tumors, and 
upregulation of the T cell/DC chemoattractants CCL19 and CCL21 is observed in 
treated tumors as well (Figures S2.2, S2.3, S2.6). It appears likely that locally elevated 
concentrations of these molecules is specifically required for treatment efficacy and TLS 
formation, based on the data from tumors established and treated in LTA-/- mice (Figure 
2.3) and those treated with an LTβR-blocking antibody (Figure 2.5B). 
Based on these findings, we have proposed a definition for non-classical TLS, which 
differ from classical TLS due to the lack of a B cell germinal center-like structure. 
Instead, we define TLS based on the close proximity of CD11c+ DC to PNAd+ (CD31+) 
HEV, a phenotype that has also been observed in human tumors (15,37). These 
lymphoid aggregates also contain CD3+ T cells, in line with reports that TLS function as 
local sites of immune priming due to the close contact between antigen presenting cells 
(APC) and lymphocytes at the site of antigen presentation (311). Specifically, we report 
that the distance of T cells, B cells, and DC from HEV in TLS is consistent with that 
distance in lymph nodes (Figure S2.7 and ref. (167)). This further supports the 
similarities between TLS and SLO in both structure and function. We also show that 
injected DC persist within TLS in DC.Tbet- and DC.IL-36γ-treated tumors (Figure 2.7B), 
consistent with the previously reported mechanism of action of DC.Tbet cells requiring 
close contact with T cells to induce Type-1 immunity (266) and further supporting the 
definition of non-classical TLS as utilizing DC as the nucleating event. 
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4.3 ENDOGENOUS EXPRESSION OF IL-36γ IS LINKED TO A PRO-
INFLAMMATORY PROFILE 
 
We next wanted to observe whether the presence of IL-36γ in human colorectal 
carcinoma was linked to any of the same immune phenotypes observed in the MC38 
murine model of colon carcinoma. Using a cohort of 33 primary colorectal carcinoma 
patients, we investigated the pattern of expression of IL-36γ and its relationship to other 
markers of inflammation, including the memory T cell response, TLS, and fibroblast 
deposition. Within the immune compartment, IL-36γ was observed to be primarily 
expressed by classically activated/M1 macrophages (Figure 3.2; something which we 
also confirmed in murine macrophages; Figure 3.7). This pattern of expression was 
positively correlated with an SMA+ fibroblastic signature within the TME as well as the 
infiltration of CD4+ TCM – a cell type linked to TLS presence in human tumors. 
We are the first to report that IL-36γ can also be expressed by cells of the vasculature, 
including vascular associated smooth muscle and endothelial cells, and HEV (Figure 
3.1C, 3.1D, and 3.5B). Indeed, within TLS, IL-36γ is predominantly expressed by the 
endothelial cells of HEV, and not the constituent immune cells or “normal” CD31+ PNAd- 
VEC. The expression of IL-36γ by the vasculature is associated with an increased 
density of TLS-associated B cells. 
These data link IL-36γ to a pro-inflammatory and anti-tumoral response in the 
pathogenesis of human colorectal cancer. Further supporting this, IL-1F5, the 
antagonist to the IL-36R, is associated with markers of immunosuppression in the TME, 
including PD-1, CTLA4, and PD-L1. In our murine model, DC.IL-36γ-based therapy led 
to decreased the expression of PD-1 and CTLA4 on the surface of intratumoral CD3+ T 
cells. These data suggest that IL-36γ is dually important for reversing immune 
suppression in the TME, both by directly downregulating markers of T cell exhaustion 
and preventing IL-1F5 binding to the IL-36R and blocking agonistic signaling events. 
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4.4 PERSPECTIVES
 
 
 
4.4.1 The biologic function of IL-36γ 
 
DC.IL-36γ cells are engineered to express the truncated, bioactive form of IL-36γ (192), 
which is widely thought to be its secreted form. While reports indicate that pyroptotic cell 
death via a Caspase-1 and 3/7-mediated mechanism, neutrophil elastase, and 
proteinase-3 are each capable of cleaving this cytokine (195,312) it remains unclear 
how IL-36γ is either secreted from or trafficked within a cell as like the other IL-1 family 
cytokines, IL-36γ lacks both a defined nuclear localization signal and a canonical 
cleavage site. Therefore, subsequent work should investigate the regulation of IL-36γ 
trafficking and specific roles of intranuclear versus secreted IL-36γ, in order to better 
understand the diverse biologic functions of this cytokine. It has also not been 
investigated whether IL-36γ is capable of trafficking into the nucleus in immune cell 
types other than DC, and if so, whether it is involved in the activation of the same or 
different genes across cell types. 
Data from these studies also indicates that signaling through IL-36R on host cells, likely 
those of the stroma or vasculature, is required for the anti-tumor efficacy of DC.IL-36γ-
based therapy (Figure 2.7). Preliminary data suggests that not only is this signaling 
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event required for therapeutic benefit, but removal of other sources of the IL-36R in the 
TME, that may act as “sinks” for IL-36γ, augments the benefit conferred by i.t. delivery of 
DC.IL-36γ. Specifically, we noted that DC.IL-36γ generated from IL-36R-deficient 
animals and delivered i.t. into MC38 tumor-bearing WT hosts delayed the rate of tumor 
growth to a greater extent than delivery of WT DC.IL-36γ (Figure S4.1). Thus, it 
appears that although a feed-forward loop propagating IL-36γ expression by injected DC 
is likely to occur in the WT system, this interaction may be at minimum unimportant and 
at most detrimental to the therapeutic potential of this therapeutic modality. Future 
studies should specifically investigate which cells in the TME require IL-36R expression 
for the optimal generation of an anti-tumor immune response. 
 
4.4.2 Tertiary lymphoid structures 
 
Tertiary lymphoid structures were first defined a decade ago in non-small cell lung 
cancer (15). Since then, they have emerged as a positive prognostic marker in nearly all 
types of primary human cancer (except for hepatocellular carcinoma; ref. (32)). Several 
groups have also used murine models to begin to better understand the mechanisms 
controlling the formation of TLS. Lymphotoxin signaling is known to be important in 
secondary lymphoid organogenesis; for the formation of TLS, lymphotoxin α3 was 
shown to be the crucial signal of this pathway leading to TLS formation in murine 
models of lung cancer and melanoma (34,313), and this is not contradicted by our data 
showing an upregulation of LTA in DC.Tbet and DC.IL-36γ cells and treated sarcomas 
and colon carcinomas. Subsequent studies should investigate whether there is a 
mechanistic relationship between IL-36γ and LTA and/or LIGHT, the other lymphotoxin 
family member observed to be upregulated in these cells, to determine whether the 
paradigm mediating DC.Tbet- and DC.IL-36γ-based therapeutic efficacy is in line with 
that observed by other groups. This will help to inform the design of future 
immunotherapies by being able to rationally target the downstream effector molecules 
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that are directly responsible for tertiary lymphoid organogenesis in different tumor 
subtypes. Similarly to the advance from using DC.Tbet to using DC.IL-36γ 
therapeutically in order to bypass a transcription/translation step before the production 
of a secreted effector, it may be possible to directly introduce the chemokines/cytokines 
involved in immune cell recruitment and TLS formation, including the lymphotoxins, 
CCR7 agonists, or CXCL13, into the TME. This was previously shown to be effective 
when LIGHT was therapeutically introduced into the TME (94,98,314,315), but has yet 
to be investigated for other lymphoid tissue-inducing signals. 
In human colorectal cancer, we observed that vascular expression of IL-36γ is positively 
correlated with the density of CD20+ B cells in TLS. CXCL13 is the B cell homeostatic 
chemokine that is responsible for the chemotaxis and retention of B cells at lymphoid 
sites (80). While the precise link between IL-36γ and CXCL13 has yet to be elucidated, 
it is possible that in human colorectal cancer, IL-36γ is driving expression of CXCL13, 
which is in turn responsible for the observed density of intra-TLS B cells. In the murine 
MC38 model, ectopic overexpression of IL-36γ in the TME is associated with a delayed 
(5 days) but >30-fold upregulation of intratumoral CXCL13 expression (Figure S2.6). In 
several other disease models, signaling via the CXCR5-CXCL13 axis is required for 
classical tertiary lymphoid organogenesis (316,317), such as what is observed in human 
colorectal cancer. Alternatively, LPS has been shown to drive expression of both IL-36γ 
(e.g. Figure 2.6F) and CXCL13 (318); in the colon microenvironment, it is possible that 
bacterial LPS is stimulating the expression of these two molecules in parallel. However, 
LPS stimulation in colorectal cancer appears to drive a metastatic phenotype (319,320), 
and expression of CXCL13 has been associated with a poor prognosis and metastatic 
disease (136,321). The apparent dual functions of CXCL13 in colorectal cancer, and 
their link to IL-36γ, should be reconciled in future studies. 
 
4.4.3 Combination immunotherapy 
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Because of the relationship between signaling through the IL-36R and a decrease in 
immunosuppressive markers in the TME, there is also the potential for IL-36γ-based 
therapy to be used in combination with established immunotherapies for cancer that 
also block the PD-1/PD-L1 and CTLA4 signaling pathways. Checkpoint blockade 
immunotherapies have shown clinical success over the past decade, with FDA approval 
for several of these drugs being awarded in recent years (322,323). In colorectal 
cancer, a subset of patients that bears a high mutational burden responds favorably to 
this kind of therapy (324), and several clinical trials are in progress to test the efficacy of 
anti-PD-(L)1 therapies in this disease (325); however, CRC overall remains extremely 
difficult to treat with checkpoint blockade therapies (326). The combination of an anti-
PD-1, anti-PD-L1, or anti-CTLA4 antibody with an IL-36γ-based therapy could confer a 
benefit to patients that currently do not respond to checkpoint blockade, as the addition 
of exogenous IL-36γ should decrease the expression of immunosuppressive receptors 
on TIL while increasing the overall number of TIL within the TME (i.e. Figure S2.5) and 
promoting the formation of TLS. Conversely, one can think of combining an IL-36γ-
based therapy with checkpoint blockade immunotherapy as a means of shifting from a 
delay in the rate of tumor progression, as observed following treatment with DC.IL-36γ 
(Figure 2.7A), to tumor regression by changing the phenotype of TIL recruited into the 
TME following the therapeutic introduction of IL-36γ to a more effector-like and less 
exhausted phenotype. 
However, in several immunotherapy trials, the prevalence of immune-related adverse 
events affecting the colon, as well as a lack of efficacy of checkpoint blockade 
immunotherapies in colon cancer, have been reported. One meta-analysis indicated 
that while the incidence of death following immune checkpoint blockade therapy across 
a variety of tumor types was low, colon-associated adverse events, including colitis, 
diarrhea, and bowel perforation, were often linked to mortality (327). In a Phase II study 
of the anti-CTLA4 antibody tremelimumab in colorectal cancer, the study results 
indicated no significant improvement of patient outcome following treatment, with 11% 
of patients presenting with grade 3/4 diarrhea, and 2% with grade 3/4 ulcerative colitis 
(328). Anti-PD-1 therapy has, as well, not conferred an objective response to colorectal 
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cancer patients in the clinic, despite the expression of PD-L1 by tumor cells (329). Thus, 
it will remain important to strike a balance between developing combinatorial strategies 
to improve the efficacy of checkpoint blockade therapies and preventing serious 
immune-related adverse events, especially when treating disease burden in the colon. 
 
4.4.4 Alternative means of therapeutically introducing IL-36γ into the TME 
 
In these studies, we therapeutically introduce IL-36γ into the TME using DC engineered 
to ectopically overexpress IL-36γ. While this model has some advantages, including the 
delivery of additional DC into the TME which can then serve as the nucleating event 
leading to the formation of TLS, other delivery mechanisms may be more advantageous 
for clinical use. Indeed, we have observed that introducing IL-36γ into the TME of 
established MC38 tumors either via direct injection of IL-36γ protein into tumor lesions 
(data not shown) or by transducing the tumor cells themselves to ectopically 
overexpress IL-36γ can also delay the growth of the tumor (223). Thus, cell-free delivery 
of IL-36γ into the TME is a mechanism that warrants further investigation. 
Additionally, several signaling pathways can induce IL-36γ expression by APC. The 
most well-characterized signals leading to IL-36γ expression are the agonists to TLR3, 
TLR4, TLR7, and TLR9 (213,330–332); in our studies, the highest level of IL-36γ 
secretion was observed following TLR7 stimulation (Figure 2.6F). Several TLR agonists 
have been tested therapeutically in animal models of tumors. Imiquimod, a TLR7/8 
agonist that has been shown to induce IL-36γ expression by keratinocytes (229), can 
also activate plasmacytoid DC to destroy melanoma tumors (333,334). A TLR2/4 
agonist has been shown in a murine model of lymphoma to polarize DC towards a 
Type-1 phenotype and function as an adjuvant in combination with autologous DC and 
antigen to delay tumor progression (335). 
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STING agonism also leads to IL-36γ expression by target cells. Ongoing work in our 
laboratory seeks to investigate whether therapeutic introduction of STING agonists (e.g. 
dsDNA or analogues) into the TME causes tumor regression by the same TLS-inducing 
mechanism as does DC.IL-36γ treatment. Our preliminary data suggests that treatment 
of BMDC with STING agonists leads to production of IL-36γ by target cells that is 
comparable to DC.IL-36γ cells (data not shown). Therapeutic STING agonsim has been 
shown in the preclinical MC38 and B16 models to cause the regression of established 
tumors (336,337). Tumors themselves can also agonize STING in the local milieu via 
the release of dsDNA that activates DC in the TME, and this is required for the control 
of tumor growth (338).  
Multiple TLR and STING agonists are currently in clinical trials (reviewed in (339,340)). 
In the context of the data presented in our studies, it would be beneficial to evaluate 
whether IL-36γ is upregulated in tumors treated with these therapies, as well as whether 
TLS formation might serve as a prognostic biomarker for the therapeutic efficacy of 
these agents. 
Expression of IL-36γ can also be induced by the cathelicidins LL-37 (in humans) and 
CRAMP (in mice) (198). In cancer, LL-37 appears to play a dual role as it can support 
tumor progression, metastasis, or apoptosis depending on the tissue type and 
magnitude of expression (341). In colon cancer, LL-37 may play an anti-tumorigenic 
role, by targeting cancer-associated fibroblasts and interrupting epithelial to 
mesenchymal transition (342), or a pro-tumorigenic role by activating the Wnt/β-catenin 
pathway in tumor cells (343). While no clinical trials are currently in progress evaluating 
cathelicidin treatment in colon cancer, it is being studied in melanoma (344,345) Of note 
to this study, colonic fibroblasts can be IL-36R+, and signaling through the IL-36R 
promotes intestinal inflammation in a mouse model (201), suggesting that a possible 
secondary method of action for the anti-tumoral properties of cathelicidin treatment in 
colon cancer warrants further investigation. 
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4.4.5 Clinically relevant murine models 
 
The murine studies described in this work used transplantable models of sarcoma and 
colon adenocarcinoma to evaluate the efficacy of DC.Tbet- and DC.IL-36γ-based 
therapies. Using inducible or spontaneous tumor models can provide a more 
translational understanding of the benefit of (immuno)therapeutic interventions. These 
models can more closely mimic characteristics of human disease than transplantable 
models that take less time to establish (346), and the immunosuppressive 
microenvironment that develops over time in inducible or spontaneous models may be a 
useful trait for predicting the clinical efficacy of novel therapeutics; for example, in vitro 
studies of anti-CTLA4 antibodies show that this intervention appears to act at least in 
part by blocking the function of Tregs (347). Proteins expressed by tumors can also 
impact the immune microenvironment; for example, the addition of transgenic MUC1 
expression to a spontaneous murine model of adenocarcinoma is associated with 
fibrosis and an increased CD4+ T cell infiltrate in the TME – more closely mimicking the 
phenotype of human adenocarcinomas – compared to MUC1- models (348). 
Modeling primary versus metastatic tumors in mice is another facet in better 
recapitulating the biology of progressive human tumors. In this regard, the success rate 
for anti-angiogenic therapies differs dramatically when comparing treatments applied to 
spontaneous versus experimental lung metastases of breast and colon cancers in 
murine models (349). Notably, bilateral tumor models or tumor rechallenge models 
following initial treatment can also be used to evaluate the ability of a therapeutic 
intervention to generate robust systemic effects that are durable (27,55). 
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APPENDIX A
 
 
 
SUPPLEMENTARY FIGURES 
 
 
 
Figure S2.1. Human DC.Tbet cells upregulate expression of IL-36γ. 
DC were isolated from human PBMC by lymphocyte depletion and infected for 48h with 
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rAd.hTbet or empty (control) vector rAd.ψ5 for 48h. Transduced DC (i.e. DC.ψ5 or 
DC.Tbet) were treated with 250 ng/mL IFN-γ and 10 μg/mL LPS, or left untreated, for an 
additional 24h. DC.ψ5 and DC.Tbet were then analyzed as described in Supplemental 
Methods. In A, a hierarchical clustering analysis of the 903 genes differentially 
expressed (p<0.01) between DC.Tbet and DC.ψ5 depicted. In B, transcripts up-
regulated > 5 fold in DC.Tbet versus DC.ψ5 are reported.  
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Figure S2.2. DC.mTbet express TLS-associated cytokines/chemokines and further 
potentiate their expression in the therapeutic TME. 
In A, mRNA was extracted from DC.Tbet or control DC.ψ5 (48h after DC infection with 
rAd) and analyzed by real-time PCR for the indicated TLS-associated transcripts. In B, 
DC.Tbet or control DC.ψ5 were injected i.t. into established day 7 s.c. MCA205 
sarcomas. At various time points after treatment, animals were euthanized and tumors 
isolated, with total mRNA extracted for subsequent real-time PCR analyses of TLS-
associated transcript levels. Data are presented as the ratio of mRNA transcript levels 
between the DC.Tbet and control treated cohorts for each time point analyzed.  
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Figure S2.3. LTA and CCL21 are upregulated in DC.Tbet/EGFP- vs. DC.EGFP-treated 
tumors. 
DC.Tbet/EGFP or control DC.EGFP were injected i.t. into established day 7 s.c. MC38 
carcinomas. At various time points after treatment, animals were euthanized and tumors 
isolated, with total mRNA extracted for subsequent real-time PCR analyses of LTA and 
CCL21 transcript levels. Data are representative of those obtained in 2 independent 
experiments performed.  
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Figure S2.4. Lymphocytes in TLS functionally resemble HEV in SLO. 
105 MC38 colon carcinoma cells were injected into the flanks of syngenic wild-type 
C57BL/6 mice and allowed to establish. Tumor-bearing mice were randomized into 
groups of 5 animals/cohort on day 7 post-implantation, with all cohorts exhibiting 
comparable mean tumor sizes. These animals were then treated on days 7 and 14 by 
i.t. injection of 106 control DC.EGFP or DC.Tbet/EGFP (n = 5 mice/group). Tumors 
were isolated on day 20 (i.e. 6 days post-2nd injection of DC) and analyzed for PNAd 
and T cells, DC, (A) or B cells (A, B). In A, the distance between each lymphocyte and 
the nearest PNAd+ HEV was measured using Euclidian distance analysis. In B, a 
representative immunofluorescence microscopy image showing B cells (B220) and HEV 
(PNAd) is shown.  
 
 136 
 
 
Figure S2.5. Phenotype of TIL from DC.Tbet/EGFP- versus DC.EGFP-treated tumors 
shows increased Type-1 functional polarity and decreased expression of 
exhaustion/anergic markers. 
105 MC38 colon carcinoma cells were injected into the flanks of syngenic wild-type 
C57BL/6 mice and allowed to establish. Tumor-bearing mice were randomized into 
groups of 5 animals/cohort on day 7 post-implantation, with all cohorts exhibiting 
comparable mean tumor size. These animals were then treated on days 7 and 14 by i.t. 
injection of 106 control DC.EGFP or DC.Tbet/EGFP (n = 5 mice/group). On day 5 post-
2nd injection of DC, tumors were isolated and subject to collagenase and DNAse 
digestion, with single-cells analyzed by flow cytometry for expression of the indicated 
markers. In A, tumors were gated by FSC, SSC-A, SSC-H, and SSC-W, as shown. In B 
and C, plots were additionally gated on CD3+ T cells, as represented in A. 
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Figure S2.6. DC.IL-36γ express TLS-associated cytokines/chemokines and further 
potentiate their expression in the therapeutic TME. 
In A, mRNA was extracted from DC.IL-36γ/EGFP or control DC.EGFP (48h after DC 
infection with rAd) and analyzed by real-time PCR for the indicated TLS-associated 
transcripts. In B, DC.IL-36γ/EGFP or control DC.EGFP were injected i.t. into established 
day 7 s.c. MC38 colon carcinomas. At various time points after treatment, animals were 
euthanized and tumors isolated, with total mRNA extracted for subsequent real-time 
PCR analyses of TLS-associated transcript levels. Data are presented as the ratio of 
mRNA transcript levels between the DC.Tbet and control treated cohorts for each time 
point analyzed.  
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Figure S2.7. Lymphocytes in TLS functionally resemble HEV in SLO. 
105 MC38 colon carcinoma cells were injected into the flanks of syngenic wild-type 
C57BL/6 mice and allowed to establish. Tumor-bearing mice were randomized into 
groups of 5 animals/cohort on day 7 post-implantation, with all cohorts exhibiting 
comparable mean tumor sizes. These animals were then treated on days 7 and 14 by 
i.t. injection of 106 control DC.EGFP or DC.IL-36γ/EGFP (n = 5 mice/group). Tumors 
were isolated on day 20 (i.e. 6 days post-2nd injection of DC) and analyzed for PNAd 
and T cells (left) or B cells (right). The distance between each lymphocyte and the 
nearest PNAd+ HEV was measured using Euclidian distance analysis.  
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Figure S2.8. MDSC, but not Tregs, are reduced in the TME after treatment with 
DC.Tbet/EGFP versus DC.EGFP. 
105 MC38 colon carcinoma cells were injected into the flanks of syngenic wild-type 
C57BL/6 mice and allowed to establish. Tumor-bearing mice were randomized into 
groups of 5 animals/cohort on day 7 post-implantation, with all cohorts exhibiting 
comparable mean tumor sizes. These animals were then treated on days 7 and 14 by 
i.t. injection of 106 control DC.EGFP or DC.Tbet/EGFP (n = 5 mice/group). Tumors 
were isolated on day 20 (i.e. 6 days post-2nd injection of DC) and analyzed for Tregs 
(CD4+ FoxP3+; A) or MDSC (CD11b+ Gr1+; B) by immunofluorescence microscopy. 
Data were digitally-quantitated and are reported as mean +/- SEM; *p < 0.05 (t-test). 
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Figure S2.9. Expression of IL-1F5/IL-36RN and IL-1F10/IL-38 across human cancer 
types. 
Representative images of specific IHC-stained tissues from human breast carcinoma, 
colon carcinoma, glioma, melanoma and prostate carcinoma were downloaded from the 
Human Protein Atlas (http://www.proteinatlas.org/). Consensus staining for IL-1F5 is 
summarized as: “Most of the malignant tissues exhibited moderate to strong 
cytoplasmic positivity” (http://www.proteinatlas.org/ENSG00000136695-IL36RN/cancer). 
Consensus staining for IL-1F10/IL-38 is summarized as “a single case of glioma 
exhibited moderate cytoplasmic staining. Fraction of cells in rare squamous cell 
carcinomas of cervix showed moderate, granular staining. Remaining cancer tissues 
were negative” (http://www.proteinatlas.org/ENSG00000136697-IL1F10/cancer). 
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Figure S3.1. Negative control staining. 
Colon sections were stained as described in Materials and Methods with a rabbit 
polyclonal anti-human IL-36γ antibody (A and B, right). To confirm antibody specificity, 
staining on serial sections was performed using either a rabbit IgG isotype control 
antibody (A) or by a mixture of the rabbit polyclonal anti-human IL-36γ antibody with 5-
times molar excess recombinant human IL-36γ protein (R&D Systems). Scale bars = 
250 microns. 
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Figure S3.2. Representative gating strategy to identify T cells. 
After digestion and staining as described in Materials and Methods, cells were gated by 
size and by expression of CD3 T cells were then gated on expression of CD4 and CD8. 
To identify memory and naïve subsets, central memory T cells were considered 
CD45RA- CCR7+; effector memory RA (EMRA) T cells were CD45RA+ CCR7-; effector 
memory T cells were CD45RA- CCR7-; and naïve T cells were CD45RA+ CCR7+. 
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Figure S3.3. IL-36γ+ macrophages are not strongly correlated with most naïve and 
memory TIL subsets. 
FFPE tumor sections were visualized by immunofluorescence for CD68 and IL-36γ or 
fresh tumor lysate was analyzed by flow cytometry for naïve and memory TIL 
populations. The correlation between IL-36γ+ macrophages and all CD4+ and CD8+ 
naïve and memory cell populations (including naïve, central memory, effector memory, 
and EMRA, except for CD4+ TCM as shown in Fig. 4) was either not statistically 
significant or did not meet our threshold for correlation value of 0.5. 
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Figure S3.4. Vasculature of secondary lymphoid organs express IL-1F5. 
FFPE sections of tonsil (a secondary lymphoid organ used as a control in this set of 
experiments) were visualized by IHC for expression of IL-1F5, which was observed to 
be expressed on the vasculature, especially surrounding germinal centers. Bar = 250 
microns. 
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Figure S3.5. IL-1F5 expression positively-correlates with expression of 
immunosuppressive genes in the TME. 
IL-1F5 expression was visualized by IHC as described in Fig. 7, and transcript 
expression of PDCD1 (PD1), CTLA4, CD274 (PD-L1), LAG3, ICOS, and ICOSL was 
quantified by nCounter (Nanostring). Only expression of PDCD1 (PD1), CTLA4, and 
CD274 (PD-L1) was directly correlated with IL-1F5 expression in the IM of tumors. 
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Figure S3.6. Intratumoral expression of IL-36γ is associated with a trend towards 
increased overall survival in several human cancers. 
Kaplan-Meier plots showing the association of intratumoral IL36G expression and 
overall survival were retrieved from PrognoScan (http://www.abren.net/PrognoScan-
cgi/PrognoScan.cgi). Results indicate a trend towards an increase in overall survival of 
patients expressing high versus low levels of IL-36γ, though the data did not reach 
statistical significance. 
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Figure S4.1. IL-36R-deficient DC.IL-36γ confer superior therapeutic benefit versus WT 
DC.IL-36γ. 
 
105 MC38 colon carcinoma cells were injected into the flanks of syngenic wild-type 
C57BL/6 mice and allowed to establish. Tumor-bearing mice were randomized into 
groups of 5 animals/cohort on day 7 post-implantation, with all cohorts exhibiting 
comparable mean tumor sizes. These animals were then treated on days 7 and 14 by 
i.t. injection of 106 control DC.EGFP, WT DC.IL-36γ/EGFP, or DC.IL-36γ/EGFP 
generated from IL-36R-deficient cells. Tumor growth was measured every 3-4 days. 
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SUPPLEMENTARY TABLES 
 
 
Table S2.1. Real-time PCR primers used in this study. 
 
Target Primer direction 5'  3' Sequence 
mCCL19 
Forward  TGTTCACCACACTAAGGGGC 
Reverse  TGTTGCCTTTGTTCTTGGCAG 
mCCL21 
Forward  AGGCAGTGATGGAGGGGGA 
Reverse  GCTTAGAGTGCTTCCGGGGTA 
mCXCL13 
Forward  TCTCCAGGCCACGGTATTCT 
Reverse  GGGGCGTAACTTGAATCCGA 
mIL36γ 
Forward  ACTCCTGACTTTGGGGAGGT 
Reverse  CACGCTGACTGGGGTTACTC 
mLIGHT 
Forward  ATCTTACAGGAGCCAACGCC 
Reverse  ACGTCAAGCCCCTCAAGAAG 
mLTα 
Forward  GCCCATCCACTCCCTCAGAA 
Reverse  TGCTGGGGTACCCAACAAGG 
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Table S2.2. Antibodies used in this study. 
 
Primary-Secondary Antibody Pairs 
Primary Antibody Secondary Antibody Assay 
Target Host Clone Company Host Conjugate Company  
β-Actin rabbit polyclonal Abcam goat HRP Santa Cruz Biotechnology WB 
Tbet rabbit polyclonal Santa Cruz Biotechnology goat HRP Santa Cruz Biotechnology WB 
IL-36γ rabbit polyclonal Denning laboratory goat HRP Santa Cruz Biotechnology WB 
IL-36γ rabbit polyclonal Denning laboratory donkey Cy3 Jackson ImmunoResearch IFM 
CD4 rat RM4-5 BD Pharmingen goat Cy3 Jackson ImmunoResearch IFM 
CD4 rat RM4-5 eBioscience  N/A Streptavidin Jackson ImmunoResearch IFM 
CD8a rat 53-6.7 BD Pharmingen goat Cy3 Jackson ImmunoResearch IFM 
CD19 rat 1D3 BD Pharmingen goat Cy3 Jackson ImmunoResearch IFM 
PNAd rat MECA-79 BD Pharmingen goat Cy3 Jackson ImmunoResearch IFM 
CD11c hamster N418 eBioscience donkey AF-488 Life Technologies IFM 
CD11c hamster N418 eBioscience goat Cy3 Jackson ImmunoResearch IFM 
CD11c hamster N418 eBioscience goat Cy5 Jackson ImmunoResearch IFM 
CD45R/B220 rat RA3-6B2 BD Pharmingen goat AF-647 Life Technologies IFM 
CD3 rat 17A2 BD Pharmingen goat AF-647 Life Technologies IFM 
rat IgG2a (Control) rat KLH/G2a-1-1 eBioscience  N/A  N/A  N/A blocking 
CD11b rat M1/70 Biolegend N/A Streptavidin Jackson ImmunoResearch IFM 
Gr1 rat RB6-8C5 BD Pharmingen goat AF-647 Life Technologies IFM 
CD4 rat RM4-5 BD Pharmingen goat AF-647 Life Technologies IFM 
FoxP3 rat FJK-16s eBioscience N/A Streptavidin Jackson ImmunoResearch IFM 
CD16/CD32 rat 2.4G2 BD Biosciences N/A N/A N/A blocking 
Fluorescently Conjugated Primary Antibodies 
Target Host Clone Company Conjugate Assay 
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CD3 hamster 145-2C11 BD Pharmingen BUV395 FC 
Tbet mouse 4B10 Biolegend APC FC 
PD-1 hamster J43 eBioscience FITC FC 
Tim3 rat B8.2C12 Biolegend APC FC 
CTLA4 hamster UC10-4B9 eBioscience PE FC 
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Table S3.1. Antibodies used for immunohistochemical and immunofluorescent imaging. 
 
Target Company Clone 
αSMA Dako 1A4 
CD20 Dako L26 
CD31 Leica 1A10 
CD68 Dako PG-M1 
DC-LAMP Dendritics 1010E1.01 
IL-1F5 Novus polyclonal 
IL-36γ Novus polyclonal 
PNAd BD MECA-79 
Rabbit IgG isotype Jackson Immunoresearch polyclonal 
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Table S3.2. Antibodies used for flow cytometric analyses. 
 
Target Company Clone Conjugate 
CCR7 Biolegend G043H7 PE-Cy7 
CD3 BD UCHT1 AF700 
CD4 Biolegend OKT4 BV 605 
CD45RA Beckman Coulter 2H4 ECD 
CD8 Biolegend RPA-T8 BV 650 
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Table S3.3. mRNA expression analysis of immune genes. 
 
Gene target 
CCL19 IL12A 
CCL2 IL17A 
CCL20 IL23 
CCL21 IL6 
CD19 LAG3 
CD274 PDCD1 
CD68 PDCD1LG2 
CSF1R TGFB1 
CTLA4 TGFB2 
CXCL10 TGFB3 
CXCL13 TIE1 
EOMES TNF 
FLT3 VEGFA 
ICOS VEGFB 
ICOSLG VEGFC 
IFNG 
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Table S3.4. Additional real-time PCR primers used in this study. 
 
Target Primer direction 5'  3' Sequence 
mArg1 
Forward  TTGGGTGGATGCTCACACTG 
Reverse  TTGCCCATGCAGATTCCC 
mArg2 
Forward  GGGCCCTGAAGGCTGTAG 
Reverse  AATGGAGCCACTGCCATC 
miNOS 
Forward  CAGGACCACACCCCCTCGGA 
Reverse  CCTGACCATCTCGGGTGCGG 
mIL36β 
Forward  TGCATGGATCCTCACAATCTCC 
Reverse  TCAGTCAGGACCCATACCA 
mTbet 
Forward  GTTCCCATTCCTGTCCTTC 
Reverse  CCTTGTTGTTGGTGAGCTT 
mIL1β 
Forward  GGAGAACCAAGCAACGACAAAATA 
Reverse  TGGGGAACTCTGCAGACTCAAAC 
mTNFα 
Forward  CATCTTCTCAAAATTCGAGTGACAA 
Reverse  TGGGAGTAGACAAGGTACAACCC 
mCXCL12 
Forward  GCCCTTCAGATTGTTGCACGGC 
Reverse  GCGCCCCTTGTTTAAAGCTTTCTC 
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